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SCN11A Sodium channel, voltage-gated, type XI, alpha subunit 
SF-36  Generic short-form SF-36 health survey 
SFN  Small fiber neuropathy 
SFN-SIQ SFN Symptom Inventory Questionnaire 
SNRI  Serotonin-Noradrenalin reuptake inhibitors 
TCA  Tricylic antidepressants 
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Small fiber neuropathy 
Anatomy 
Small fiber neuropathy (SFN) is a condition in which the small peripheral nerve fibers are 
affected. The peripheral nervous system includes the somatic and autonomic nervous system, 
which both consist of myelinated and unmyelinated nerve fibers with a variation in diameter, 
each having their own function. In SFN the thinly myelinated Aδ- and unmyelinated C-fibers 
are damaged. These fibers serve as noci- and thermoceptors in the skin. After activation, 
signals are conducted via the dorsal root ganglion (DRG) neurons to the central nervous 
system.1 In the autonomic nervous system the Aδ-fibers have a preganglionic, and the C-fibers 
a postganglionic sympathetic and parasympathetic function.2, 3  
In peripheral nerves, voltage-gated sodium channels (VGSC) are essential for the generation 
and conduction of action potentials. VGSCs Nav1.7, Nav1.8, and Nav1.9, respectively encoded 
by SCN9A, SCN10A, and SCN11A, are preferentially expressed in the small diameter DRGs and 
axons. Besides, Nav1.7 is also present in sympathetic ganglion neurons (SGN), and along with 
Nav1.9 in trigeminal ganglion neurons.4 
 
Large nerve fiber- versus small fiber neuropathy 
In general, polyneuropathy is considered as a condition of axonal degeneration of the large 
diameter peripheral nerves, with diabetic neuropathy being most prevalent. However, 
demyelinating neuropathies, such as the immune-mediated Guillain-Barré syndrome and 
various types of the hereditary Charcot-Marie Tooth neuropathy, are also forms of 
polyneuropathy. All these conditions have in common that patients may have muscle 
weakness, sensory disturbances (e.g. diminished vibration sense) and reduced tendon reflexes 
at neurological examination. The diagnosis can be supported by abnormalities in nerve 
conduction studies (NCS).5 In some conditions, such as diabetic neuropathy, the clinical picture 
can show additional symptoms like spontaneous neuropathic pain and autonomic dysfunction, 
which cannot solely be explained by large nerve fiber damage. Four decades ago, the first 
pathological studies that investigated the role of other nerve fibers, showed additional 
myelinated and unmyelinated small nerve fiber degeneration of sural nerves and post mortem 
removed splanchnic nerves.6, 7 However, isolated damage to small nerve fibers can also occur. 
This condition is called pure SFN. 
 
Pure small fiber neuropathy 
One of the main symptoms of pure SFN is excruciating neuropathic pain, which is most often 
described as burning, shooting and/or prickling. Other sensory symptoms include an altered 
pain sensation and thermal perception. Autonomic symptoms may also be present, like hot 
flashes, palpitations, orthostatic dizziness, dry eyes or mouth, accommodation problems, 
micturation and bowel disturbances, sexual dysfunction, and hyper- or hypohidrosis.8, 9 The 
clinical picture is suspect for having SFN when a patient reports two or more of these SFN-
specific symptoms, which can be assessed by using the validated SFN-Symptom Inventory 
Questionnaire (SFN-SIQ).10 Sensory symptoms usually start distally in the feet and hands 
because the nerve endings are the most vulnerable.8 This is called a length-dependent pattern. 
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The complaints can expand to proximal over time. Also, a patchier or non-length dependent 
pattern of complaints is described in patients with SFN.11, 12 In SFN, neurological examination 
does not generally show any abnormalities in motor and large sensory nerve fiber functions 
(muscle strength, vibration sensation). Hyperalgesia and/or allodynia, as well as reduced 
pinprick and temperature sensation can be found.13 
 
Diagnostics  
One of the most applied and studied methods to examine small nerve fiber function is 
temperature threshold testing (TTT). This is a non-invasive test that measures warm and cold 
sensation in hands and feet. The values obtained by the method of levels are compared to age- 
and gender specific normative values.14, 15 Besides this qualitative test, small nerve fibers in the 
epidermis can be determined quantitatively in a skin biopsy, which is taken from the lower leg. 
In skin biopsy, the intra-epidermal nerve fiber density (IENFD) is determined as a measure of 
small nerve fiber degeneration. Worldwide normative values are available to evaluate the 
IENFD.16 Unfortunately, TTT has a low specificity and depends on the degree of collaboration 
of the patient. On the other hand, skin biopsy has a high specificity and a moderate sensitivity, 
and is an invasive time-consuming method.16, 17 Therefore, in the absence of a golden standard, 
at the moment the diagnosis of pure SFN is based on typical symptoms in combination with an 
abnormal TTT and/or abnormal IENFD in skin biopsy, without signs of involvement of the large 
nerve fibers (neurological examination and NCS).8, 18  
 
Epidemiology 
SFN is not a rare condition, with an incidence of at least 12 per 100,000 persons per year and 
a prevalence of at least 53 per 100,000 persons in the southern part of the Netherlands.19 This 
is probably an underestimation, because of the unfamiliarity of the condition in patients, 
general practitioners, and even medical specialists, including neurologists.  
 
Impact 
SFN causes a significantly reduction of the quality of life,20 even substantially lower compared 
to patient populations like patients after myocardial infarction. 
The prognosis of SFN is not very well known. In one study, the complaints of SFN remained 
stable over time in almost half of the patients, were progressive in about 30%, and improved 
in 10%, whereas in 13% the disease progressed to the involvement of large nerve fibers.21 
Progression of SFN can lead to worsening of pain or to extension of the complaints to other 
parts of the body. The severe reduction in quality of life and the long-term prognosis urge the 
need for development of more effective treatments.20 
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Figure 1. The pathophysiology of SFN and development of (targeted) treatment 
 
Legend to figure 1. The figure represents diagnostic testing for possible associated conditions in patients with SFN. 
If the diagnosis SFN is made in a patient, several diagnostic tests are usually performed to search for underlying 
conditions. Further scientific research may provide new insights into pathophysiology. This may eventually result 
in the development of more targeted treatments.  
 
Associated conditions 
The pathophysiology of SFN is still largely unsolved. In literature, various conditions are 
mentioned to contribute to the development of SFN. However, a clear causal relationship is 
often not proven. Moreover, many conditions are only reported in case reports, and large 
prevalence studies are lacking. It is important to gain knowledge about the conditions that are 
associated with SFN, as some of these are treatable, and adequate treatment might slow down 
the course of SFN, or may even lead to regeneration of nerve fibers.22, 23 Besides, it can 
contribute to a better understanding of the pathophysiology of SFN, which is necessary to 
develop targeted treatments (Figure 1).  
The different associated conditions can be classified in the following groups: metabolic 
diseases (e.g. diabetes mellitus18 or kidney failure24), neurotoxic exposure (e.g. 
chemotherapy25 or alcohol abuse26), vitamin deficiencies or intoxications (e.g. vitamin B12 
deficiency27 or vitamin B6 toxicity28), infectious diseases (e.g. HIV29 or Lyme’s disease30), 
immunological diseases (e.g. sarcoidosis31 or coeliac disease32), and hereditary causes (e.g. 
sodium channel gene mutations33-35 or haemochromatosis36).8, 17 Despite thorough workup, no 
associated conditions can be found in 30-50% of patients with SFN. This is called idiopathic 
SFN.19, 20, 37  
One of the most studied diseases in SFN is diabetes mellitus.18 It is thought that this metabolic 
disease causes damage to the nerve fibers in various ways, for example by the enhanced polyol 
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pathway activity caused by hyperglycemia or because of vascular ischemia.38, 39 However, it 
remains unclear why some patients develop neuropathy, while others do not, and why only a 
subset of patients with diabetic neuropathy develop pain.40 Recently, a genetic link has been 
found in some patients with SFN and pathogenic sodium channel variants.40  
 
Voltage-gated sodium channel mutations  
Gain-of-function SCN9A-mutations were first found in patients with primary erythromelalgia 
(IEM), a condition characterized by recurrent burning pain and redness of the extremities, 
induced by warm temperature and exercise.41, 42 Subsequently, these mutations were also 
found in paroxysmal extreme pain disorder (PEPD), in which patients suffer from sudden 
attacks of severe pain in the mandibular, ocular and rectal areas, accompanied by 
erythematous color changes (flushes).43, 44 Loss-of-function SCN9A-mutations were found in 
patients with pain insensitivity and autonomic deficits, called congenital insensitivity to pain 
(CIP).45, 46 Gain-of-function mutations can cause a shift in hyperpolarization, whereby the 
channels are activated by smaller depolarization than in wild-type channels. Besides, the 
channels can show impaired deactivation.47 Both these changes may lead to increased firing of 
the neurons, called hyperexcitability, which in turn might lead to axonal degeneration.48 
Because the clinical picture of IEM and PEPD shows similarities with SFN, this triggered the 
interest to investigate the role of SCN9A-muations in SFN. In a cohort of 28 biopsy-confirmed 
SFN patients gain-of-function mutations of the SCN9A-gene were found in 28% of the 
patients.33 After this discovery mutations in the SCN10A- and SCN11A-gene were also found to 
be present in SFN patients.34, 35 These findings have driven the search for targeted 
treatments.49  
 
Treatment 
When an underlying condition is found, treatment will start with specific therapy for this 
condition. However, a large proportion of patients suffer from idiopathic SFN, or patients will 
still require neuropathic pain treatment even though the underlying condition is treated well.50 
At the moment, SFN is not a curable condition, where current treatment possibilities can only 
diminish the complaints, instead of recovering the nerve fiber degeneration. Current 
treatment of SFN consists of different classes of neuropathic pain medication, including 
antidepressants, anticonvulsants, opioids, and topical agents, as shown in table 1.51-53 
In general, the efficacy of neuropathic pain treatment is disappointing, with only 50% pain 
reduction in around 50% of the patients.51, 52, 54 Furthermore, Table 1 shows that current drugs 
frequently produce bothersome side effects, partly because the medication is not specifically 
acting on peripheral nerves. Consequently, there is significant interest in the development of 
targeted treatments, like selective sodium channel blockers. Selective sodium channel blockers 
might not only be effective in patients with a gain-of-function sodium channel gene mutation, 
but also in other patients with chronic neuropathic pain, because the sodium channels play an 
important role in the generation of action potentials, leading to pain perception. Moreover, 
chronic pain states may also result in a higher expression of sodium channels.55 Selective 
sodium channel blockers can block the hyperexcitable channels and thereby may reduce the 
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excessive firing of the neurons, as shown in figure 2. The advantage of these selective sodium 
channel blockers is that they are expected to cause fewer side effects. 
 
Furthermore, it is conceivable that immunological mechanisms play a role in a subset of 
patients with SFN, since several immune-mediated diseases, such as sarcoidosis, Sjogren’s 
disease and systemic lupus erythematosis may cause SFN.56-61 Besides, auto-antibodies,62-64 
inflammatory changes in nerves,65, 66 and elevated pro-inflammatory cytokines67 have been 
found in patients in SFN. In other immune-mediated neuropathies, such as chronic 
inflammatory demyelinating polyneuropathy68, 69 and Guillain-Barré syndrome70 treatment 
with intravenous immunoglobulin (IVIg) has proven to be efficacious. Moreover, some case 
studies in patients with SFN and chronic pain have also reported effect of immunomodulating 
therapy.57, 59, 71-73 Pain reduction with IVIg treatment has also been summarized recently.72 
Therefore, treatment with IVIg in patients with SFN is hypothesized to be effective. 
 
Figure 2. Schematic display of the mechanism of action of sodium channel blockers.  
 
 
Legend to figure 2. This figure shows the voltage-gated sodium channel (VGSC): the VGSC in resting state (A), will 
open upon depolarization, caused by an external stimulus (B). After depolarization there are two mechanisms for 
closure: fast inactivation (C), which will take only milliseconds. A second way of closing is the slow inactivation (D), 
which can take seconds to minutes. Finally, the sodium channel will enter the resting state again (A) (Figure  
adapted from, Janneke G.J. Hoeijmakers. Small fiber neuropathy and sodium channel gene mutations – a 
paradigm shift. Thesis Maastricht University 2014). 
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General aim of this thesis. 
The general aim of this thesis is to investigate the prevalence of associated conditions in SFN 
and to evaluate the efficacy, safety and tolerability of specific neuropathic pain treatment 
options in patients with SFN. 
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In literature it has been described that SFN could be the first symptom of a metabolic disorder, 
called Fabry disease. Chapter 2 shows the prevalence of Fabry disease in patients with SFN 
without other Fabry specific symptoms.  
 
Based on the results of the previous chapter, chapter 3 describes the prevalence of other 
associated conditions in SFN that are mentioned earlier in literature. Also recommendations 
for diagnostics profile will be made. 
 
The treatment of neuropathic pain in patients with SFN is challenging. In chapter 4 the different 
therapeutic options currently used, are discussed and possible pitfalls are highlighted, with 
special interest for the elder patients. Eventually, a therapeutic algorithm is provided. 
 
In chapter 5 the protocol of the Lacosamide-Efficacy-‘N’-Safety in Small fiber neuropathy 
(LENSS) study is described. In this randomized, double-blinded, placebo-controlled, crossover 
study Lacosamide is compared to placebo in a group of patients with an SCN9A-associated SFN. 
 
Chapter 6 shows the results of the LENSS study that is extensively described in the previous 
chapter. It discusses the efficacy, safety, and tolerability of lacosamide compared to placebo. 
 
In a large proportion of the patients with SFN, no underlying condition can be found, which 
makes targeted treatment difficult. An immunological cause is suspected in at least part of the 
patients. The study protocol of a randomized, double-blinded study with intravenous 
immunoglobulin, as a new and different treatment possibility will be discussed in chapter 7. 
 
For the overview, in chapter 8 and 9 the findings of this thesis are summarized and the future 
perspectives will be discussed. 
 
Finally, chapter 10 will discuss the importance, influence, and practical implementation of the 
findings of this thesis. 
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Abstract 
Objective: Screening for Fabry disease in patients with small fiber neuropathy has been 
suggested, especially since Fabry disease is potentially treatable. However, the diagnostic yield 
of testing for Fabry disease in small fiber neuropathy patients has never been systematically 
investigated. Our aim is to determine the presence of Fabry disease in patients with small fiber 
neuropathy.  
Methods: Patients referred to our institute, who met the criteria for isolated small fiber 
neuropathy were tested for Fabry disease by measurement of alpha-Galactosidase A activity 
in blood, lysosomal globotriaosylsphingosine in urine and analysis on possible GLA gene 
mutations.  
Results: 725 patients diagnosed with small fiber neuropathy were screened for Fabry disease. 
No skin abnormalities were seen except for redness of the hands or feet in 30.9% of the 
patients. Alfa-Galactosidase A activity was tested in all 725 patients and showed diminished 
activity in eight patients. Lysosomal globotriaosylsphingosine was examined in 509 patients 
and was normal in all tested individuals. Screening of GLA for mutations was performed for 
440 patients, including those with diminished α-Galactosidase A activity. Thirteen patients 
showed a GLA gene variant. One likely pathogenic variant was found in a female patient. The 
diagnosis Fabry disease could not be confirmed over time in this patient. Eventually none of 
the patients were diagnosed with Fabry disease.  
Conclusions: In patients with isolated small fiber neuropathy, and no other signs compatible 
with Fabry disease, the diagnostic yield of testing for Fabry disease is extremely low. Testing 
for Fabry disease should be considered only in cases with additional characteristics, such as 
childhood onset, cardiovascular disease, renal failure or typical skin lesions.   
2No Fabry disease in SFN 
37 
Introduction 
Small fiber neuropathy (SFN) is a disorder of the thinly myelinated Aδ-fibers and unmyelinated 
C-fibers. These fibers are responsible for the sensation of temperature and pain and regulate 
a great deal of the autonomic nervous system. As a result, SFN is clinically characterized by 
neuropathic pain and autonomic symptoms.1, 2 Patients with SFN experience different types of 
pain mainly described as a burning sensation, itching, prickling, or shooting pains. These 
symptoms usually occur in a symmetrical length-dependent pattern,3 but non-length 
dependent patterns have been described.4 SFN is not a rare condition; a recent study showed 
a minimum prevalence of 53/100.000.5 Many diseases can underlie small nerve fiber damage, 
such as diabetes or impaired glucose tolerance, HIV infection, immune-mediated disorders 
(e.g. Sjögren syndrome and sarcoidosis),2 and hereditary disorders (e.g. sodium channel gene 
mutations).6-8 Diabetes mellitus is considered one of the most common causes of SFN. Despite 
thorough investigations, an underlying cause cannot be identified in 38-48% of the patients.5, 
9  
One of the possible causes of SFN is Fabry disease (FD).10-12 FD is an X-linked glycolipid storage 
disease due to a mutation in the GLA gene. This causes an absent or diminished activity of the 
lysosomal enzyme alpha-Galactosidase A (α-Gal A), leading to accumulation of 
globotriaosylceramide (lyso-GB3) in different cell types and subsequently to severe multi-
system disease.13, 14 The involvement of different cell types leads to various clinical 
manifestations, such as cardiovascular disease, renal failure, and skin lesions. The 
accumulation of lyso-GB3 also occurs in neurons, which causes neurological symptoms. The 
symptoms may develop in different periods of the patient’s life. Shooting pain and discomfort 
in the hands and feet, which are triggered by heat, exercise, and stress, are considered the 
most common symptoms that patient experience in early childhood and adolescence. About 
70% of children and adolescents with classical FD develop pain in hands and feet.15 These 
neuropathic pain symptoms can become more generalized over time.16 However, it is not clear 
how often FD is the underlying cause in patients presenting with SFN.  
The relationship between FD and small nerve fiber dysfunction has been described before.10-
14 The prevalence of SFN cases that are caused by FD is not well known. However, it is important 
to identify patients with FD, because it is a treatable disorder. Treatment with enzyme 
replacement therapy (ERT) may improve the quality of life and prevent serious and potential 
life-threatening complications.17-20 Early ERT has been suggested to improve small nerve fiber 
function,14, 21, 22 although these findings could be not validated by others.23 
The aim of our study is to investigate the prevalence of FD in a well-defined cohort of patients 
diagnosed with SFN and related costs to this diagnostic testing.  
 
Methods 
Patients 
We included all consecutive patients referred for possible SFN to the Maastricht University 
Medical Center (Maastricht UMC+) between August 2006 and April 2015. The diagnosis SFN 
was made if patients fulfilled the criteria for SFN as described earlier.2, 24 These criteria include 
the presence of ≥ 2 typical symptoms for SFN not otherwise explained, no signs of large fiber 
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involvement, and reduced intraepidermal nerve fiber density25 and/or abnormal temperature 
thresholds in quantitative sensory testing.26, 27 Screening for FD was performed in all patients 
with SFN as described in the following. 
 
Biochemical assessments and DNA analysis for FD 
Presence of FD was examined through measurement of α-Gal A activity in leukocytes,28 lyso-
GB3 excretion in urine,29 and screening of the GLA gene for mutations. α-Gal A enzyme activity 
is considered normal between 30 and 180 mmol/L and diminished <30 mmol/L.  
Lyso-GB3 excretion is considered abnormal >0 nmol/mmol creatinine.29 The measurement of 
lyso-GB3 excretion in urine was incorporated in our workflow for SFN patients from April 2012. 
Variants in the coding and intermediate flanking regions of the GLA gene were classified 
according to the Practice Guidelines for the Evaluation of Pathogenicity and the Reporting of 
Sequence Variant in clinical Molecular Genetics.30 Class 1 and 2 variants are considered non-
pathogenic. Class 3 variants have an uncertain pathogenicity. Class 4 variants are likely to be 
pathogenic and class 5 variants are certain pathogenic.30 
In men, a normal α-Gal A activity and lyso-GB3 excretion excludes FD.14 However, if the enzyme 
activity is reduced or the lyso-GB3 is increased, screening of the GLA gene for mutations is 
required to confirm FD (Figure 1A).14, 31 In women, a normal α-Gal A enzyme activity15 and 
normal lyso-GB3 excretion does not rule out FD. Due to skewed X-inactivation,32 it is known 
that the clinical manifestations in heterozygous females may range from asymptomatic to 
severely affected subjects. As GLA is the only gene in which mutations are known to cause FD,33 
screening of the GLA gene for mutations is the most reliable method of diagnosing the carrier 
state in females. Biochemical findings of α-Gal A and lyso-GB3 could serve as biomarkers of 
disease severity.29 Therefore, α-Gal A activity, lyso-GB3 excretion, screening of the GLA gene 
for mutations were performed simultaneously in women (Figure 1B).14, 34 
 
Standard protocol approvals, registrations, and patient consents 
The Maastricht UMC’s Medical Ethics Committee and Board of Directors approved this study. 
According to the Code of Conduct for the use of data in Health Research,35 for this type of 
retrospective study, informed consent does not need to be obtained if the data are used 
anonymously and patients are given the opportunity to object against the use of their medical 
and personal data for research (which is the case in the Maastricht UMC+). All data were 
obtained from medical records. Patient records were anonymized and de-identified prior to 
analysis. The individuals described in this manuscript have given written informed consent for 
publication of their case details. 
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Figure 1. Diagnostic algorithm for confirming Fabry disease in SFN patients. 
 
Legend to figure 1: (A) Diagnostic algorithm for men. (B) Diagnostic algorithm for women. α-Gal A: α-galactosidase 
A, FD: Fabry disease, Lyso-GB3: lysosomal globotriaosylceramide. 
a Abnormal findings of the GLA gene include class 3 variants (uncertain to be pathogenic), class 4 variants (likely 
to be pathogenic), and class 5 variants (certain pathogenic). 
b The diagnosis FD is confirmed in women when the abnormal findings of the GLA gene complemented with 
abnormal findings in the biochemical assessment (α-Gal A and Lyso-GB3). 
 
Results 
Patient selection and general characteristics 
A total of 1040 patients were referred to the Maastricht UMC+ for possible SFN. In 771 patients 
(74%) the diagnosis SFN was confirmed. Forty-six patients with SFN were excluded from the 
study based on non-available or incomplete FD diagnostic data. Eventually, a total of 725 
patients with SFN were screened for FD (305 (42.1%) men, 420 (57.9%) women). All patients 
except seven were adults (99%). The median age of onset of the complaints was 47, with a 
standard deviation of 14.3. 
Possible underlying causes in our patient cohort were diabetes mellitus (n=35; 4.8%; 4 type 1 
diabetes (0.6%), 31 type 2 diabetes (4.3%)), sarcoidosis (n=23; 3.2%), morbus Sjögren (n=11, 
1.5%), monoclonal gammopathy of undetermined significance (n=5; 0.7%), and 
hypothyreoidism (n=3; 0.4%). 
Besides redness of the hands or feet in 30.9% of the 725 patients, no other skin abnormalities 
were seen. None of the patients had a history of cardiomyopathy of renal failure. 
 
Diagnostics for Fabry disease  
The three tests for FD, α-Gal A activity in blood, lyso-GB3 excretion in urine, and GLA gene 
sequencing, were applied to the study population as presented in Figure 2.  
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Figure 2. Small fiber neuropathy patients analyzed for Fabry disease (FD) in the Maastricht University Medical 
Center. 
 
Legend to figure 2: Illustration of the outcome of investigations to confirm the diagnosis of Fabry disease. α-Gal 
A: α-galactosidase A, Lyso-GB3: lysosomal globotriaosylceramide, FD: Fabry disease, SFN: small fiber neuropathy. 
a Missing data.  
b The measurement of lyso-GB3 excretion in urine was incorporated in our workflow for SFN patients from April 
2012.  
c GLA gene sequencing was performed in all women, and in males in case of reduced α-Gal A enzyme activity. 
d These includes the class 2 variants (unlikely to be pathogenic) and the class 3 variants (uncertain to be 
pathogenic). 
 
α-Gal A enzyme activity 
α-Gal A enzyme activity was determined in leukocytes of all 725 eligible patients. In eight 
patients (1.1%) a reduced α-Gal A enzyme activity was found, ranging from 2.8 to 26.9 mmol/L. 
The α-Gal A enzyme activity was normal in the other 718 patients (30.3-191.9 (mean 81.2) 
mmol/L).   
 
Lyso-GB3 excretion in the urine 
Five hundred nine of the 725 SFN patients were tested for lyso-GB3 excretion in the urine. All 
results were normal (100%). Five of these 509 patients with a normal lyso-GB3 excretion had 
a diminished α-Gal A enzyme activity (7.1-26.9 mmol/L).  
 
GLA gene screening for possible mutations 
A total of 440 patients underwent screening of the GLA gene for mutations. Thirteen SFN 
patients (3.0%) carried a variant in the GLA gene (Table 1).  
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Table 1: GLA gene variants and results of biochemical testing in a population of SFN patients (n=725). 
Patient c.position variant p.position 
variant 
Class α-Gal A 
(mmol/L) 
Lyso-GB3 
(nmol/mmol 
creatinine ) 
1 F c.-40G>C - 2 57.4 NA 
2 F c.-8C>G - 2 68.8 NA 
3 F c.48T>G p.Leu16Leu 2 69.7 NA 
4 F c.123C>T p.Thr41Thr 2 72.9 NA 
5 F c.352C>T p.Arg118Cys 4 59.2 0 
6 F c.376A>G p.Ser126Gly 2 52.6 0 
7 F c.801+21T>C - 2 43.2 0 
8 F c.937G>T p.Asp313Tyr 3 62.4 NA 
9 F c.937G>T p.Asp313Tyr 3 60.6 NA 
10 M c.937G>T p.Asp313Tyr  3 30.3 0 
11 F c.937G>T p.Asp313Tyr 3 51.5 0 
12 F c.937G>T p.Asp313Tyr 3 62.5 0 
13 F c.999+11_12ins11+999+16_20del5 - 2 78.9 NA 
Legend to table 1: α-Gal A: α-galactosidase A enzyme activity, F: female, Lyso-GB3: lysosomal 
globotriaosylceramide, M: male, NA: not available. 
 
Of the nine variants identified [c.-40G>C; c.-8C>G; c.48T>G (p.Leu16Leu); c.123C>T 
(p.Thr41Thr); c.352C>T (p.Arg118Cys); c.376A>G (p.Ser126Gly); c.801+21T>C; c.937G>T 
(p.Asp313Tyr) (n=5); c.999+11_12ins11+999+16_20del5], only one variant (c.352C>T 
(p.Arg118Cys) was classified as a likely pathogenic. The other eight variants were classified as 
a class 2 or class 3 variant. The eight patients with a reduced α-Gal A enzyme activity were also 
part of this cohort and showed no abnormalities.   
 
The patient carrying the c.352C>T variant heterozygous was a 33-year old female. Her α-Gal A 
enzyme activity was normal (59.2 mmol/L). The patient was referred to a tertiary referral and 
treatment center for FD in the Netherlands, where a detailed work-up of potential FD-
pathologies and biomarkers was performed. The α-Gal A enzyme activity was retested and 
normal (53.0 mmol/L). For this patient no excretion of lyso-GB3 was detected in urine. During 
three years of follow-up, the patient did not develop symptoms or signs of FD (skin lesions, 
cornea verticillata, cardiac or renal involvement). Therefore the diagnosis of FD could not be 
confirmed. All patients with a class 2 or 3 variant had a α-Gal A enzyme activity >30 mmol/L, 
and if tested, normal lyso-GB3. 
In total, 725 patients underwent testing for FD, and the diagnosis FD was not confirmed in any 
of these patients. 
 
Diagnostics for FD costs  
In our center, the costs per person for testing α-Gal A enzyme activity in leukocytes are $ 1,186, 
for Lyso-GB3 in urine $ 883, and for GLA gene sequencing $ 1,017, which is a total of $ 2,069 
(for men) and $ 3,086 (for women) per patient. In this cohort of 725 patients the costs for FD 
diagnostics were $ 1,756,777.  
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Discussion 
In a large cohort of patients diagnosed with isolated SFN who were tested for FD (n=725), we 
did not find any patients with FD. In only one patient a possible pathogenic variant was 
identified, but after thorough investigations and years of follow-up, the diagnosis FD could not 
be established. Because FD is a treatable disease, early diagnosis can prevent further 
complications of the disease and may improve the quality of life.17-20 However, little is known 
about the prevalence of SFN as first symptom of FD. Previously, only two small cohort studies 
examined the presence of GLA gene mutations in idiopathic SFN. The first study identified one 
GLA gene mutation in a cohort of 24 patients diagnosed with idiopathic SFN.36 In a second 
study, in one out of 29 patients with idiopathic SFN, a variant of the GLA gene was shown. As 
in our study, the diagnosis FD could not be made in any of these patients.37 However, our study 
is the first that systematically examined the prevalence of FD in a large clinically well-defined 
cohort of patients diagnosed with isolated SFN. 
Our results show isolated SFN not being the first and certainly not the only symptom of FD. 
Patients with FD probably also have other symptoms, like skin lesions or hearing loss, cardiac 
or renal involvement leading to the diagnosis of FD.17 These symptoms could be accompanied 
with neuropathic pain, but the neuropathic pain alone does not seem typical for adult FD 
patients. A previous study showed that only 12 patients, out of a cohort of 366 patients with 
FD, had neurological signs or symptoms, without the involvement of any other organs.15 The 
general view at our center is that patients with potential SFN related complaints are being 
referred and examined, often without an underlying etiology. Possible referral bias is 
conceivable in cases having other symptoms indicative for FD being referred to a tertiary center 
for FD.  
Neuropathic pain has been addressed as one of the first symptoms of FD in some cases.11-13, 16 
However, most of these studies concerned children, adolescents and young adults.17, 38 These 
observations were not confirmed by the current study in adults with SFN. In contrast with 
literature,13, 15 none of the children in our study cohort were diagnosed having FD. However, 
some caution is warranted since only 7 children were part of the study population.   
From the current results, it is clear that the suspicion of FD is extremely low, if not absent in 
adult patients presenting with SFN without concomitant symptoms or signs compatible with 
FD (skin lesions, hearing loss, cardiac or renal involvement). In addition, genetic and 
biochemical testing for FD is expensive, more than 1.7 million US dollars in the cohort (n=725) 
examined in the current study with no patient being diagnosed having FD. Therefore, in adult 
patients with isolated SFN, routine screening for FD does not seem warranted.   
In case testing for FD is warranted, we would recommend to start with the GLA gene 
sequencing as the first test.14, 39, 40 If this test turned out to be normal, the patient is diagnosed 
not having FD. Whenever a variant of the GLA gene is found, the diagnostics could be 
complemented with the α-Gal A enzyme activity, and other biochemical assessments 
necessary, to confirm the diagnosis FD. This strategy would largely reduce the costs of 
diagnostic testing for FD.  
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Abstract 
Background and purpose: Small fiber neuropathy (SFN) is a common disorder, leading to 
neuropathic pain and autonomic symptoms. The objective of this study was to investigate 
associated conditions in a large cohort of SFN patients and compare the prevalence to healthy 
individuals.  
Methods :A total of 921 patients with pure SFN were screened according to a standardized 
comprehensive diagnostic algorithm and compared with literature findings. 
Results: No associated condition could be found in 53% of the patients. Autoimmune diseases, 
sodium channel gene mutations, diabetes mellitus including glucose intolerance, and vitamin 
B12 deficiencies were more prevalent than reported literature findings, followed by alcohol 
abuse, chemotherapy, monoclonal gammopathy of undetermined significance, and 
haemochromatosis. In patients who were already known with a possible underlying condition 
at screening, additional underlying conditions were still found in another 26.7% of patients. 
Conclusions: Based on these results, it is recommended that patients with pure SFN are 
screened at least for autoimmune diseases, sodium channel gene mutations, diabetes mellitus 
including glucose intolerance, and vitamin B12 deficiency, even when they already have a 
potential underlying condition at referral.  
  
3Associated conditions in SFN 
49 
Introduction 
Small fiber neuropathy (SFN) affects the thinly myelinated Aδ-fibers and the unmyelinated C-
fibers and leads to excruciating neuropathic pain and autonomic symptoms1 with a negative 
impact on quality of life expectations.2 The diagnosis of pure SFN is based on typical complaints, 
combined with abnormal intraepidermal nerve fiber density in skin biopsy and/or abnormal 
temperature threshold testing levels, without signs of large nerve fiber involvement.1, 3 SFN 
has been described in several conditions, such as diabetes mellitus and sodium channel gene 
mutations.1, 4 Management is mostly based on symptomatic treatment. Knowing which 
conditions are associated with SFN is important, since some conditions are potentially 
treatable. Most patients diagnosed with SFN undergo many diagnostic tests to find an 
underlying cause, leading to high burden for patients and high health-related costs.5 
Illustratively, it was shown that Fabry disease was not found in 725 patients with isolated SFN, 
even though it has been mentioned in the literature as a potential underlying illness.6 This may 
also apply to other conditions. A better selection of associated conditions may result in a more 
targeted diagnostic work-up with lower costs. 
The aims of this study were to investigate associated conditions in a large cohort of patients 
with pure SFN and to compare the prevalence with literature reports on these conditions in 
healthy persons. Finally, recommendations are provided for a more targeted diagnostic work-
up in patients with pure SFN. 
 
Methods 
Patients 
From January 2010 to December 2015, all consecutive patients fulfilling the diagnosis criteria 
for SFN at our SFN Center, Maastricht University Medical Center+ (Maastricht UMC+), were 
included in this study. Maastricht UMC+ serves as a tertiary referral center for SFN in the 
Netherlands. Records on complaints and medical history were collected in a standardized 
fashion as described earlier.7 To confirm the diagnosis of SFN, patients needed to have the 
typical complaints of SFN combined with a reduced intraepidermal nerve fiber density in skin 
biopsy8 and/or abnormal temperature threshold testing9 without large nerve fiber involvement 
based on neurological examination (normal muscle strength, vibration sense, and tendon 
reflexes) and nerve conduction studies. 
To find possible underlying conditions, blood and urine analyses, and a chest X-ray were 
performed (table 1). The selection of these additional investigations was based on literature 
review1, 10-12 and on corresponding diagnostic guidelines (see below). 
 
Underlying conditions 
The following underlying conditions were screened for: alcohol abuse, diabetes mellitus 
including glucose intolerance, haemochromatosis, autoimmune diseases, monoclonal 
gammopathy of undetermined significance, sodium channel gene mutations, and vitamin B12 
deficiency. The definitions of these underlying conditions are summarized in the supporting 
information 1. 
  
Chapter 3 
50 
Table 1: Diagnostic tests performed in patients referred to the SFN Center 
Kind of test  Disease investigated Abnormal values 
X-ray  Chest X-ray Sarcoidosis  
Blood samples 
 
Glucose  Diabetes Mellitus Two sober plasma levels of ≥ 
7.0 mmol/l or the 
combination of a sober 
plasma glucose level of ≥ 7.0 
mmol/l, a random plasma 
glucose level of ≥ 11.1 mmol/l 
with complaints of 
hyperglycemia, or a level of ≥ 
11.1 mmol/l after 120 min 
Glucose tolerance test Impaired glucose tolerance Sober level of < 7.0 mmol/l 
and a level of ≥ 7.8 and < 11.1 
mmol/l after 120 min 
Cholesterol Hypercholesterolemia Low density lipoprotein value 
above 3.1 mmol/l, high 
density lipoprotein value 
lower than 0.9 mmol/l, and 
triglyceride value above 2.1 
mmol/l 
Liver function Hepatic impairment  Increased liver functions 
Kidney function Renal insufficiency Glomerular filtration rate < 30 
Thyroid function Hypothyroid or 
hyperthyroid function 
Increased or decreased 
thyroid stimulating hormone / 
thyroxin 
Vitamin B1 Vitamin B1 deficiency <100 nmol/l 
Vitamin B6 Vitamin B6 toxicity >200 nmol/l 
Vitamin B12 Vitamin B12 deficiency <148 pmol/l 
Anti-tissue transglutaminase Coeliac disease Present 
Anti extractable nuclear 
antigen antibodies 
Sjogren’s disease Present 
Antinuclear antibodies, anti-
neutrophil cytoplasmic 
antibodies, and soluble 
Interleukin-2 receptor 
Other auto-immune 
diseases 
Present or soluble IL-2 
receptor above 700 U/l 
Monoclonal gammopathy Monoclonal gammopathy 
of undetermined 
significance 
Present 
Borrelia burgdorferi 
(immunoglobulin I and M) 
Lyme’s disease Present 
Anti-human 
immunodeficiency virus 1 
and 2 
Human immunodeficiency 
virus 
Present 
Alfa-galactosidase A activity 
and alpha-galactosidase A 
gene 
Fabry disease < 30 mmol/l and variants class 
3, 4 or 5. 
SCN9A-, SCN10A-, and 
SCN11A-gene 
Sodium channel gene 
mutations 
Variants with uncertain 
clinical significance, possibly 
pathogenic, probably 
pathogenic or pathogenic 
variants 
Urine sample lysosomal 
globotriaosylceramide 
Fabry disease >0 nmol/mmol creatinine 
Legend to table 1: SCN, sodium voltage-gated channels.  
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Supporting information 1. Definitions of underlying conditions. 
 
Literature comparison 
Literature research on potential conditions related to SFN was performed in PubMed database 
using the following keywords “small fiber neuropathy”, “small fibre neuropathy”, 
“neuropathy”, “painful neuropathy”, “etiology”, in combination with the different known 
conditions. Also Dutch guidelines were searched for prevalence of the conditions in healthy 
controls. 
Underlying conditions 
Alcohol abuse was defined as an alcohol consumption of >5 international unit (IU) per day.1 The 
diagnosis DM was based on two fasting plasma glucose levels of ≥7.0 mmol/l (measured on two 
different days), the combination of a fasting plasma glucose level of ≥ 7.0 mmol/l, a random plasma 
glucose level of ≥ 11.1 mmol/l with complaints of hyperglycemia or a level of ≥ 11.1 mmol/l after 
120 minutes at the glucose tolerance test.2 Impaired glucose tolerance was defined as a glucose 
level of ≥ 7.8 and < 11.1 mmol/l after 120 minutes at a sober level of < 7.0 mmol/l.2 
Haemochromatosis was suspected when there was an increase in the transferrin saturation and 
the serum ferritin. If there was a high level of iron, the blood was tested for a mutation in the HFE 
gene (High iron Fe).3 An experienced internal medicine physician confirmed the diagnosis of 
hemochromatosis.  
Patients were referred to an immunologist for additional investigations, when an underlying 
immunological disease was suspected, such as sarcoidosis (e.g. abnormalities on chest X-ray),4 
Sjogren’s disease (positive anti-ENA antibodies, antinuclear antibodies (ANA)),5 or increased 
soluble Interleukin-2 receptor, a non-specific marker for autoimmune diseases. Coeliac disease was 
suspected when anti-tissue transglutaminase (anti-TTG) was found;6 these patients were referred 
to a gastroenterologist. Potential treatments in these cases were led to the interpretation of these 
experts to execute. 
Monoclonal gammopathy of undetermined significance (MGUS) was diagnosed when monoclonal 
gammopathy was present without evidence for malignancies as a cause after investigation by a 
hematologist.7 
Variants in the coding and intermediate flanking regions of the sodium channel genes SCN9A, 
SCN10A and SCN11A were interpreted in the context of functional assessment, or family 
segregation analysis of phenotype and genotype.8 
Vitamin B12 deficiency was defined as a serum concentration of vitamin B12 lower than 148 
pmol/l.9 
 
1. Koike H, Mori K, Misu K, et al. Painful alcoholic polyneuropathy with predominant small-fiber loss and normal 
thiamine status. Neurology. 2001;56(12):1727-32. 
2. Dutch College of General Practitioners - standard Diabetes Mellitus type 2 2013. Available from: 
https://www.nhg.org/standaarden/volledig/nhg-standaard-diabetes-mellitus-type-2. 
3. Sood R, Bakashi R, Hegade VS, Kelly SM. Diagnosis and management of hereditary haemochromatosis. Br J 
Gen Pract. 2013;63(611):331-2. 
4. National Heart LaBi. Sarcoidosis. How is Sarcoidosis diagnosed? 2013. Available from: 
https://www.nhlbi.nih.gov/health/health-topics/topics/sarc/diagnosis. 
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Statistics 
Patients’ characteristics were expressed as mean with standard deviation, when data were 
normally distributed. When not normally distributed, the median and the interquartile range 
were calculated. Frequencies between two groups were compared by using the chi-squared 
test. A stepwise approach was conducted: the prevalence of conditions potentially related to 
SFN was measured and subsequently compared with reported prevalence in healthy controls. 
Analyses were performed using SPSS (Version 23.0, SPSS Inc., Chicago, IL, USA). 
 
Standard protocol approvals, registrations, and patient consents 
The Maastricht UMC+’s Medical Ethics Committee and Board of Directors approved this study. 
According to the Code of Conduct for the use of data in Health Research,13 for this type of 
retrospective study, informed consent does not need to be obtained if the data are used 
anonymously and patients are given the opportunity to object against the use of their medical 
and personal data for research (which is the case in the Maastricht UMC+). 
 
Results 
Of 1275 patients screened, the diagnosis pure SFN could be established in 72% (n=921; figure 
1). The characteristics of SFN patients included in the study are shown in table 2. After the 
diagnostic workup, no underlying condition was found in 488 patients (53%). 
 
Results of the total cohort of patients with pure SFN. 
In the total cohort, 696 patients (75.6%) did not have known SFN-related comorbidities before 
the diagnostic workup.  
The diagnostic workup (n=921) showed immunological conditions in 175 patients (19%), 
including sarcoidosis (3.0%), Sjogren’s disease (1.3%), coeliac disease (0.5%), other 
autoimmune diseases (8.8%) and non-specific abnormal immunological laboratory findings 
(6.1%). Eight patients had two or more of these conditions. The other most frequently found 
associated conditions with available prevalence numbers in the general population were 
variants in SCN9A (8.5%), SCN10A (4.8%), and SCN11A (3.4%), diabetes mellitus (7.7%), vitamin 
B12 deficiency (4.7%), alcohol abuse (3.0%), chemotherapy (2.2%), monoclonal gammopathy 
of undetermined significance (MGUS) (1.4%) and haemochromatosis (0.3%) (figure 2). The 
MGUS subtypes included IgG-MGUS (62%), IgM-MGUS (15%), IgA-MGUS (15%), and a biclonal-
MGUS (8%, IgG and IgA). The glucose intolerance test was performed in 493 of these patients. 
In total, 48 patients were found with glucose intolerance (9.7%). The prevalence of the other 
conditions screened for are shown in supporting information 2. In 488 patients (53%), no 
underlying conditions were found despite extensive laboratory testing (idiopathic SFN). Of the 
above-mentioned conditions, only variants in the SCN9A-gene were found significantly more 
often in patients with a non-length-dependent pattern of SFN compared to patients with 
length-dependent complaints (12.4% versus 6.9%, p-value: 0.014), whereas all other 
conditions showed no differences. 
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Figure 1 Flowchart of inclusion/exclusion 
 
Legend to figure 1: IENFD, intraepidermal nerve fiber density; SFN, small fiber neuropathy; TTT, temperature 
threshold testing. 
 
Table 2: Characteristics of patients with confirmed diagnosis of SFN 
 Total, n=921 
Female (%)  532 (57.8) 
Age at visit, median (IQR) 53 (44-61.5) 
Age at onset, median (IQR) 47 (38-57) 
Duration of complaints, median (IQR) 3 (2-7) 
Diagnosis SFN  
   Abnormal TTT (%) 614 (66.7) 
   Abnormal Skin biopsy (%) 68 (7.4) 
   Abnormal TTT & Skin biopsy (%) 239 (26) 
Legend to table 2: IQR, interquartile range; SFN, small fiber neuropathy; TTT, temperature threshold testing. 
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Supporting information 2. Prevalence of other conditions. 
Kind of 
test 
 Disease investigated Abnormal values Results in study 
population 
 Kidney function Renal insufficiency Glomerular filtration 
rate < 30 
Prior to screening: 
n=4 (0.4%) 
New cases: n=0 (0%)  
Vitamin B1 Vitamin B1 
deficiency 
<100 nmol/l Prior to screening: 
n=0 (0%) 
New cases: n=22 
(2.4%) 
Vitamin B6 Vitamin B6 toxicity >200 nmol/l Prior to screening: 
n=1 (0.1%) 
New cases: n=47 
(5.1%) 
Anti-human 
immunodeficiency 
virus 1 and 2 
human 
immunodeficiency 
virus 
Present Prior to screening: 
n=0 (0%) 
New cases: n=0 (0%) 
Alfa-galactosidase A 
activity and alpha-
galactosidase A gene 
Fabry disease < 30 mmol/l and 
variants class 3, 4, or 5. 
Prior to screening: 
n=0 (0%) 
New cases: n=0 (0%) 
Urine 
sample 
Lysosomal 
globotriaosylceramide 
Fabry disease >0 nmol/mmol 
creatinine 
Prior to screening: 
n=0 (0%) 
New cases: n=0 (0%) 
Legend to supporting information 2: Results of different laboratory tests in study population, which are not 
mentioned in the manuscript. 
 
Results for the group of SFN patients without known associated conditions at 
presentation.  
Of the patients without comorbidity at presentation (n=696), abnormal immunological 
laboratory findings were present in 5.9%, variants in SCN9A in 9.6%, SCN10A in 4.5%, SCN11A 
in 3.4%, diabetes mellitus in 3%, vitamin B12 deficiency in 0.75%, and MGUS in 0.6%. In 379 of 
these patients, glucose intolerance was tested and this was diagnosed in 35 patients (9.2%). In 
total, associated conditions were found in 208 of these patients (29.9%) with additional 
diagnostic tests.  
 
Results for the group with known comorbidities at presentation. 
In the group of patients that were already known to have one or more comorbidities (n=225) 
at presentation, also new abnormalities were found: abnormal immunological laboratory 
findings (5.8%), variants in SCN9A (4.9%), SCN10A (5.8%), and SCN11A (3.1%), and diabetes 
mellitus (2.7%). In 114 of these patients, glucose intolerance was tested and was diagnosed in 
13 patients (11.4%). In total, additional associated conditions were found in 60 patients (26.7%) 
with our diagnostic panel.  
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Figure 2. Prevalence of possible underlying causes in patients with SFN (n=921).
Legend to figure 2: * Glucose intolerance was only tested in 493 patients instead of 921.
Immunology; Sarcoidosis, Sjogren’s disease, coeliac disease, other autoimmune diseases, and abnormal 
immunological laboratory findings (antinuclear antibodies, anti-neutrophil cytoplasmic antibodies, monoclonal 
gammopathy, soluble interleukin-2 receptor, anti-tissue transglutaminase, and anti-extractable nuclear antigen 
antibodies), MGUS; monoclonal gammopathy of undetermined significance, SCN; sodium voltage-gated channels.
Discussion
In our cohort of 921 patients with pure SFN, an underlying condition was found in 433 patients 
(47%). The most prevalent conditions were immunological conditions, sodium channel gene 
mutations, diabetes mellitus including glucose intolerance, and vitamin B12 deficiency and at 
least these entities are suggested to be tested in the diagnostic workup of potential SFN. Even 
if comorbidity was present at presentation, still other associated conditions were found in 
26.7% after diagnostic testing. After thorough workup, 53% of patients had no underlying 
cause (idiopathic pure SFN), which is in conformity with literature.11, 14 A recent study also 
described high prevalence of immunological abnormalities, but no association with diabetes 
mellitus or vitamin B12 deficiency, possibly due to smaller sample size and different criteria for 
diagnosis of SFN.15
Immunological abnormalities
Immunological conditions may affect nerve fibers,16 and were found in 12.9% (n=119) of 
patients, whereas another 6.1% of patients had one or more abnormal immunological 
laboratory findings. The overall prevalence of autoimmune diseases in the Netherlands is 
around 3%-6%,17 which is much lower than in our cohort.
Also the prevalence of sarcoidosis is higher in our cohort than in the general European 
population (3.0% versus 0.005%-0.03%).18 However, the prevalence of sarcoidosis in our 
cohort might be an overestimation, because until 5 years ago Maastricht UMC+ was a tertiary 
referral center for patients with sarcoidosis.
Sjogren’s disease was present in 1.3% of our SFN patients compared to a prevalence in the 
general population of 0.1%-4.8%, thus within the reported limits in the general population.19
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Of our patients, 0.5% had coeliac disease, with a prevalence of recognized coeliac disease of 
0.016% and non-recognized coeliac disease around 0.35% in the Netherlands.20 
 
Sodium channel gene mutations 
In 16.7% of SFN patients a sodium channel gene variant was found. The sodium channels 
Nav1.7, Nav1.8, and Nav1.9, coded by SCN9A, SCN10A, and SCN11A respectively, are all 
preferentially expressed in peripheral nerves.21 Mutations in the SCN9A-, SCN10A-, and 
SCN11A-gene, showing electrophysiological changes in the corresponding channel, have been 
described by others and us in patients with SFN.7, 22, 23 Although the exact mechanism for 
axonal degeneration is not completely clear, it is plausible that DRG neuron hyperexcitability 
results in neuropathic pain.24 The results in this cohort are comparable to the results that are 
published earlier in a smaller cohort (n=393),4 although prevalence is lower than the results of 
SCN9A-variants in a small cohort of patients with biopsy-confirmed idiopathic SFN.7 SCN9A-
variants were more frequently found in the patients with a non-length dependent pattern; 
which is in line with the description of different clinical patterns in patients with SCN9A-
mutations and SFN.25 
 
Diabetes mellitus 
Diabetes mellitus was found in 7.7%, of which most (90.1%) were type 2 diabetes. Peripheral 
neuropathy is the most common complication of diabetes mellitus with lifetime prevalence up 
to 50%.26 The prevalence of diabetes is around 6% in the Netherlands.27 Our proportion found 
in SFN (7.7%) is higher than the prevalence of patients in the Netherlands. The prevalence in 
our cohort probably is an underestimation, as most patients with painful diabetic neuropathy 
will not be referred to our center, because painful neuropathy is a well-known complication of 
diabetes mellitus.  
In addition, as has been suggested by literature, the glucose tolerance test was also abnormal 
in 9.7% of the patients, adding to the underlying conditions of SFN.28, 29 
 
Vitamin B12 deficiency 
Vitamin B12 deficiency was present in 4.7% of SFN patients. The prevalence of vitamin B12 
deficiency is less than 3% in the general population aged between 20 and 39 years, and 
increases gradually up to 10% or higher in people of 70 years or older. The prevalence of 
vitamin B12 deficiency in our SFN population was higher than in the general population. 
According to general guidelines, vitamin B12 deficiency was diagnosed when serum vitamin 
B12 was below 148 pmol/l or when there was a history of vitamin B12 deficiency for which 
patients were treated. Homocystein or methylmalonic acid was not assessed, which may have 
led to underestimation of functional vitamin B12 in patients with serum vitamin B12 of 148-
258 pmol/l. 
 
Alcohol abuse 
In our cohort 3.0% of the patients (n=28) reported an alcohol consumption of >5 IU/day. As 
people tend to underreport their alcohol intake, this may be an underestimation as well.30 The 
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typical presentation of alcohol-related peripheral neuropathy is a painful, burning neuropathy 
and autonomic instability.31 In the Netherlands, the estimated prevalence of alcohol abuse is 
0.75% of adults between 18 and 65 years old.30 The prevalence of alcohol abuse is higher in 
our cohort of patients with pure SFN suggesting an association. 
 
Chemotherapy 
Chemotherapy-induced peripheral neuropathy is a well-known adverse event of several 
chemotherapeutic agents, and was present in 2.2% (n=20) of our patients with pure SFN. 
Different prevalence are mentioned, between 17% and 88%, for different ages, different 
grades of neuropathies and different agents.32 The prevalence of chemotherapy found in our 
cohort is probably underestimated, as these patients are usually not referred because the 
neuropathy is considered an expected adverse event of the treatment.  
 
Monoclonal gammopathy of undetermined significance 
In our cohort, 1.4% patients were known with MGUS. The etiology of MGUS in peripheral 
neuropathy is not very well understood.33 In healthy subjects (above 45-50 years old) the 
prevalence of MGUS is found in 3.2%-3.5%.34, 35 The prevalence of monoclonal gammopathy 
increases with age.36 The prevalence of MGUS in our population is lower than the prevalence 
found in the general population. However, the overall prevalence is based on subjects between 
45 and 50 years old, and in our population we have patients ranging from 11 to 85 years. 
 
Haemochromatosis 
Three patients (0.3%) had haemochromatosis. In north-European countries, 0.4% of the people 
are homozygote for the C282Y allele.37 This means that the prevalence in the whole population 
is equal to the prevalence in patients with SFN, which makes the association between SFN and 
haemochromatosis less likely.  
 
Patients with associated conditions at presentation 
Despite having an associated condition at presentation, additional associated conditions were 
found in 26.7% in our SFN cohort. Finding other diseases might lead to new treatment 
possibilities for these patients, and possibly relieve of complaints or prevention of disease 
progression. 
 
Pathophysiology 
This study shows that some of the associated conditions are more prevalent in patients with 
pure SFN compared to healthy persons. However, the underlying pathophysiology is still 
unclear in most of these conditions. It would be of interest to investigate these specific 
conditions in detail in animal models, to search for underlying mechanisms. This knowledge 
would also stimulate the development of targeted therapy. Better treatments would lead to 
reduction of pain, and therefore to lower health costs.5 
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Conclusion. 
Autoimmune diseases, sodium channel gene mutations, diabetes mellitus including glucose 
intolerance, and vitamin B12 deficiency are the most common underlying conditions in 
patients with pure SFN; despite a thorough workup no underlying condition could be found in 
53% of the SFN patients. The prevalence of alcohol abuse, autoimmune diseases, diabetes 
mellitus including glucose intolerance, and vitamin B12 deficiencies seems higher in our 
population of patients with pure SFN than found in the general population. Moreover, the 
prevalence of SFN is much higher in patients which received chemotherapy compared to the 
prevalence of SFN in the Netherlands. For these conditions a causal relationship with small 
nerve fiber damage is suspected. Further research is needed to explore the exact 
pathophysiological mechanisms. Although some patients are already known with an underlying 
condition at presentation, it is still recommended that all patients with pure SFN are tested for 
diabetes mellitus including glucose intolerance, autoimmune diseases, sodium channel gene 
mutations, and vitamin B12 deficiency. Testing for rarer underlying conditions can be 
considered in SFN, based on specific signs or symptoms. 
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Abstract 
Over the last 10 years, the diagnosis small fiber neuropathy (SFN) has gained recognition 
worldwide. Patients often suffer from severe neuropathic pain that may be difficult to treat. A 
substantial subset of patients with SFN is aged 65 years or older, and these patients often 
exhibit comorbidities and usage of multiple drugs, making neuropathic pain treatment more 
challenging. In this review, we highlight relevant pathophysiological aspects and discuss 
currently used therapeutic strategies for neuropathic pain. Possible pitfalls in neuropathic pain 
treatment in the elderly will be underlined. 
  
4Neuropathic pain due to SFN in aging 
67 
Introduction 
Small fiber neuropathy (SFN) is a peripheral neuropathy in which predominantly the 
unmyelinated C-fibers and thinly myelinated Aδ-fibers are affected.1 The diagnosis is based on 
clinical symptoms, reduced intra-epidermal nerve fiber density in skin biopsy, and/or abnormal 
temperature threshold tests,2-4 and no large nerve fiber involvement at physical examination 
or nerve conduction tests. The prevalence is at least 53 cases per 100,000 inhabitants, and the 
rates are higher in elderly patients.5 Many conditions have been associated with small fiber 
neuropathy, such as diabetes mellitus, hyperlipidemia, amyloidosis, Fabry syndrome, celiac 
disease, sarcoidosis and other systemic illnesses, human immunodeficiency virus (HIV) 
infection, and hereditary sensory and autonomic neuropathies.3 Recently, also pathogenic 
mutations in sodium channels (Nav1.7, Nav1.8 and Nav1.9) were reported in patients with 
painful neuropathy.6 Despite a comprehensive work-up of patients with SFN, in a substantial 
proportion (ranging from 24% to 93% in different series) no underlying cause can be 
identified.3 
SFN patients often suffer from devastating pain, and have a severely reduced quality of life.7 In 
addition to the typical SFN-related complaints (neuropathic pain and autonomic symptoms 
such as dry mouth, dry eyes, micturation problems or bowel dysfunction), anxiety, depression, 
sleeping problems and fatigue may also influence quality-of-life expectations.8-10 Pain severity 
is associated with a high use of medication, frequent physician consultations and substantial 
health care costs.10 
For the symptomatic treatment of neuropathic pain in SFN, mostly general guidelines are 
used.11-15 Pharmacological treatment options mainly are antidepressants,16 anticonvulsants,17 
and opioids18 with generally disappointing results.14 
 
Pathways in neuropathic pain 
Understanding pathways and mechanisms involved in the development of neuropathic pain is 
important to define possible therapeutic targets. Pain is defined as an unpleasant sensory and 
emotional experience associated with actual or potential tissue damage.19 As the definition 
suggests, pain is a subjective phenomenon, and is difficult to catch in an objective outcome 
measure.20-23 In humans, pain represents a final integrative package, consisting of 
neurophysiological processes as well as contextual, psychological, and sociocultural factors.   
Neuropathic pain is caused by a lesion or disease that affects the somatosensory nervous 
system.19 The thinly myelinated Aδ-fibers and unmyelinated C-fibers, predominantly involved 
in SFN,1-3 arise in the skin where they serve for the detection of cold, heat and, as nociceptors, 
for detection of painful stimuli.24-26 In addition, they fulfill an efferent function as part of the 
peripheral autonomic nervous system.3, 27 Generally, nociceptors are electrically silent; after 
activation by noxious stimuli an action potential is initiated and transported via peripheral 
axons to the cell bodies located in the trigeminal ganglia and in the dorsal root ganglia 
alongside the spinal column and medulla oblongata.6 Via central axons, the signal is 
transmitted onward to synapse on second order neurons in the central nervous system.24, 26 
Voltage-gated sodium, potassium and calcium channels, transient receptor potential channels 
and acid-sensing ion channels all contribute to the regulation of nociceptor excitability.24, 26, 28-
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30 Recently, painful peripheral neuropathy has been linked to three different types of voltage-
gated sodium channel (VGSC) mutations.6, 31-34  
Animal models and human studies have shown that nerve damage, such as in painful 
peripheral neuropathy, can result in pathologic sensitization and ectopic impulse generation 
in primary afferent nociceptors with subsequent secondary changes in central processing.35 
Central sensitization is largely mediated by the N-methyl-D-aspartate (NMDA) receptor.36 
Activation of descending pathways (spinal norepinephrine pathway and the descending spinal 
serotonergic (5-HT) pathway) in the periaqueductal grey-rostral ventromedial medulla 
oblongata may also reduce pain transmission.37 However, the system may also facilitate pain 
transmission, thereby contributing to chronic pain states.38-40 
 
Small fiber neuropathy in the elderly 
A substantial number of patients with SFN is 65 years or older. In our cohort of 598 patients 
diagnosed with SFN, diagnosed according to international criteria, at the Maastricht University 
Medical Center+,2, 3 19% was 65 years or older (n=117). Most of these elderly patients had 
several comorbidities at first presentation (Figure 1A). Only 11% (n=13) had no comorbidity 
(compared to 46% in patients < 65 years (X2 test: p<0.001). The most frequent concomitant 
disorders were hypertension (60%), cardiovascular disease (44%), immune-mediated diseases 
(20%), malignancy (16%) and diabetes mellitus (9%). As a consequence, most patients used 
several drugs, on average four (Figure 1B). Only 6% did not use any medication (compared to 
26% in patients < 65 years (X2 test: p<0.001). 
The most frequently prescribed pain drugs in this group of elderly patients were 
anticonvulsants (pregabalin, gabapentine, carbamazepine; 16%), antidepressants 
(amitriptyline, duloxetine, nortriptyline, venlafaxine; 14%), opioids (weak and strong opioids; 
14%), cyclooxygenase (COX) inhibitors (11%) and acetaminophen (12%). 
The presence of comorbidity, polypharmacy and physiological changes (e.g. increased body 
fat, reduced muscle mass, reduction body’s fluid balance, decrease in renal and hepatic 
function) in older people increases the risk of side effects and poses a challenge on 
symptomatic drug treatment of neuropathic pain.41, 42  
 
Pharmacological management of neuropathic pain 
Several therapeutic strategies are commonly used for the treatment of neuropathic pain. Most 
pharmacological treatment regimens exist in three groups: antidepressants, anticonvulsants 
and opioids.  However, less than 50% of patients achieve 50% of pain relief with currently 
available drugs.12, 14 Most of the available analgesics act at different levels (e.g. sodium 
channels, noradrenergic system, opioidergic system) and are prescribed without any selection 
in terms of pathogenesis and etiology. Unfortunately, none of the new drugs have proven to 
be more effective than amitriptyline,12 an old antidepressant. Additional treatment strategies 
are topical treatments, such as capsaicin and lidocaine,14, 41 and transcutaneous electrical 
nerve stimulation (TENS).43 
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Figure 1. Comorbidities and use of drugs in the elderly.
Legend to figure 1: A) Number of comorbidities at initial presentation. B) Number of drugs used at initial 
presentation in patients with SFN aged 65 years or older (n = 117). Concomitant disorders were hypertension 
(60%), cardiovascular disease (44%), immune-mediated diseases (20%), malignancy (16%) and diabetes mellitus 
(9%). SFN: small fiber neuropathy
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Antidepressants 
Since the 1960s antidepressants have been used for pain relief,44 and nowadays mainly for 
neuropathic pain treatment. Tricyclic antidepressants (TCAs) and serotonin-noradrenalin 
reuptake inhibitor (SNRIs) are generally considered first-line treatments for neuropathic 
pain.12, 14, 15 
 
Tricyclic antidepressants (TCAs) 
TCAs were initially synthesized as antipsychotic drugs, but appeared to have an antidepressive 
trait.45, 46 They are widely used for neuropathic pain and have a number needed to treat (NNT) 
of 3.6.14 TCAs are also known as dirty drugs because of their actions on multiple 
neurotransmitter receptors: they block reuptake of norepinephrine, VGSCc, and are 
antagonists of H1-histaminic, muscarinic cholinergic and α1-adrenergic receptors. Some TCAs 
inhibit serotonin reuptake or are antagonists of serotonin 2A and 2C receptors.47-53 Other 
presumed effects are anti-inflammatory, increasing and decreasing cytokine production, and 
potentiation of opioid analgesia.54-56 TCAs may improve sleep disturbances and in higher dose 
have an antidepressive effect. The choice of a specific TCA is often influenced by the side effect 
profile. Secondary amine TCAs (nortriptyline and desipramine) are preferred because they are 
better tolerated than tertiary amine TCAs (amitriptyline and imipramine) with comparable 
analgesic efficacy.15, 57, 58  
 
Serotonin-Noradrenalin reuptake inhibitors (SNRIs) 
As the name already suggests, SNRIs have a dual monoamine mechanism that should lead to 
better efficacy, however for neuropathic pain SNRIs have an NNT of 6.4.14 SNRIs indirectly also 
lead to an increase of dopamine in the prefrontal cortex by blocking the norepinephrine 
transporters, which may modulate pain.59, 60 Venlafaxine and duloxetine are well-studied drugs 
for neuropathic pain.14 Duloxetine has a lower incidence of side effects than venlafaxine (such 
as hypertension, nausea and sexual dysfunction).15, 61 Precautions are needed in liver 
dysfunction, severe kidney dysfunction, uncontrolled hypertension, and with venlafaxine in 
significant cardiac disease. Simultaneous use of other antidepressants and tramadol should be 
avoided. 
 
Antidepressants and elderly 
Age-associated morbidity can complicate the treatment with antidepressants. Antidepressants 
are metabolized more slowly in elderly, which can lead to a higher plasma drug level. The 
American Geriatrics Society (AGS) strongly recommends that TCAs should be avoided in older 
adults, because of the risk of adverse events, such as cardiac arrhythmia, somnolence, 
hypotension with increased risk of falls and injury, cognitive impairment, and anticholinergic 
side-effects.62 TCAs should certainly be dosed below 75 mg/day in adults aged 65 years.14 
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Anticonvulsants 
Anticonvulsant drugs have been used since the 1960s for pain management. They exhibit 
different mechanisms of action. Gabapentin and pregabalin are considered first-line treatment 
for neuropathic pain.12, 14, 15 
 
Gabapentin and pregabalin 
Gabapentin was initially designed in 1994 as an analogue of GABA (as an anti-epileptic drug), 
which could penetrate the blood-brain-barrier. In 1996, it became clear that Gabapentin had 
a therapeutic effect on pain. Pregabalin, a chemically related amino-acid drug, was developed 
a few years later.  
Though gabapentin initially was assumed to have a GABA-mimetic effect, it turned out that 
gabapentin does not interact with GABA-A or B-receptors and does not influence GABA 
uptake.63 Gabapentin and pregabalin both bind to voltage gated α2δ-calcium channel of N-type 
and P/Q type in the dorsal horn, but also on the level of the thalamus, periaqueductal gray and 
cortex.64 These presynaptic voltage-sensitive calcium channels are involved in regulation of 
neurotransmitter release by firing synaptic vesicles into the synapse. Binding gabapentin or 
pregabalin blocks calcium influx and influences the release of presynaptic neurotransmitters, 
such as GABA, glutamate, acetylcholine, substance P and monoamines.65-68 
Gabapentin has a NNT of 7.2 for neuropathic pain and pregabalin of 7.7.14 Gabapentin and 
pregabalin both have no clinically important drug-drug interactions. Gabapentin dose titration 
may take several weeks, whereas the starting dose of pregabalin of 75 mg is already 
efficacious.15 The potential for twice daily dosing and the linear pharmacokinetics leading to a 
predictable dose-response relationship of pregabalin may be an advantage in the ease of use 
of pregabalin.  
Side effects of gabapentin and pregabalin are somnolence, dizziness, ataxia, edema and 
tremor. Pregabalin increases slow wave sleep and total sleep duration in patients with pain,69 
and can also be used for generalized anxiety disorders. Both drugs require dosage reduction in 
patients with renal impairment.70 
 
Other antiepileptic drugs 
Several other anti-epileptic drugs, such as topiramate, zonisamide, and oxcarbazepine or 
carbamazepine, have been studied for neuropathic pain, though most studies were negative,14 
and therefore these drugs are not recommended as first-line treatment.  
 
Anticonvulsants and elderly  
Gabapentin or pregabalin are usually well tolerated if titrated appropriately. Treatment should 
start with the lowest possible dose and be increased very slowly based on response and side 
effects, such as somnolence, dizziness, ataxia and peripheral edema.71 Gabapentin can cause 
or exacerbate cognitive or gait impairment. Dose reduction in patients with renal dysfunction 
is needed.70 Furthermore, antiepileptic drugs may lead to an increased risk of falling.71 
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Opioids 
Opioids refer to all substances that produce morphine-like effects that are blocked by 
antagonists such as naloxone, and can be produced synthetically or endogenous. Opioids have 
a well-defined role in the treatment of cancer pain, however, their role in the long-term 
treatment of non-malignant pain is controversial due to concerns about tolerability, the 
development of tolerance to the analgesic effect, and addiction.72 Furthermore, side effects 
occurred in about 50% of patients treated for chronic non-malignant pain, and more than 20% 
discontinued treatment because of adverse events.73, 74 Opioids can be effective in neuropathic 
pain with numbers NNT of 4.7 for tramadol and 4.3 for strong opioids,14, 75 and are considered 
second- and third-line treatments.12, 14, 15 
Opioids produce analgesia by acting on opioid receptors in peripheral afferent neurons, dorsal 
horn of the spinal cord, brainstem and the brain. The opioid receptors are G-protein coupled 
receptors (GPCRs) and are classified as mu (MOP), delta (DOP) and kappa (KOP) and a fourth 
non-classical opioid receptor for nociception/orhanin GQ (NOP).76, 77 The receptor 
pharmacology is complex; the cellular response is not only depending on the ligand and the 
type of receptor, but also on the cellular environment of the receptor.78, 79 After activation of 
the receptor, a portion of the G-protein is released, and leads to inhibition of cyclic AMP, with 
consequently alteration of protein phosphorylation. Cyclic AMP acts as a second messenger 
within the cell resulting in the activation of protein kinases (short term effects) and gene 
transcription proteins and/or gene transcription (long term effects).80 Opioid receptors located 
on the presynaptic terminals of the nociceptive C- and A- fibers can be activated by an opioid 
agonist, which will indirectly inhibit voltage-gated calcium channels, decreasing cAMP levels 
and blocking the release of pain neurotransmitters such as glutamate, substance P, and 
calcitonin gene-related peptide.80 Furthermore, opioids activate presynaptic receptors on 
GABA neurons, which inhibit the release of GABA in the ventral tegmental area, indirectly 
leading to an increase in dopamine. The latter plays a role in the development of addiction.  
One of the most common side effects is constipation, which requires prophylaxis.72 Other side 
effects are pruritus, dizziness, nausea and vomiting, sedation, impaired concentration, and 
ataxia. The risk of respiratory depression should be weighed in patients with underlying 
pulmonary condition or receiving concomitant central nervous system drugs associated with 
hypoventilation. Not all opioids show equal effects on respiratory depression. Long-term use 
of opioids can lead to hypogonadism and immunological changes. Prolonged opioid use may 
lead to tolerance (the need to increase the dose to maintain pain relief) and opioid-induced 
hyperalgesia.81, 82 Rotation from one strong opioid to another can restore not only analgesia, 
but also cause other side effects.83, 84 
One of the biggest concerns is addiction due to prolonged opioid use, with high health and 
economic costs and potential fatal consequences.85, 86  
Increasing opioid doses are strongly related to large increases in risk of overdose morbidity and 
mortality, with a substantially increased risk associated with doses at or above 100–120 mg 
morphine equivalent dose per day.86 Moreover, disordered breathing during non-REM sleep 
increases with dose. Therefore opioid therapy should be part of a multifaceted approach to 
pain management,86 and clinicians should be alert for behavior suggestive of addiction, such 
as frequent change of doctors, non-compliance, and reports of lost prescriptions.85 
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Weak opioids  
Tramadol 
Tramadol, a second line treatment, is a weak opioid receptor agonist and a norepinephrine-
(NE) and serotonin (5HT)-reuptake inhibitor and has a number needed to treat of 4.7.14 Special 
precautions should be taken with patients with asthma, epilepsy, and severe liver and renal 
impairment. It has interactions with most antidepressant drugs. 
 
Strong opioids  
Strong opioids are considered third-line treatment, and have a NNT of 4.3.14  
 
Transdermal Buprenorphine 
Buprenorphine is a semisynthetic non-selective mixed opioid agonist-antagonist and can bind 
to the three classical and the non-classical opioid receptors. The anti-nociceptive effect is 
primarily exerted via the mu-receptor and is attenuated by the nociception receptor. No 
specific adjustments have to be made in kidney impairment. Excretion is mainly by the liver, 
and liver impairment can prolong the half-life, however without clinical relevance because of 
low activity metabolites. Precautions should be taken in patients with asthma or COPD. When 
rotating from a pure agonist, withdrawal symptoms can occur because Buprenorphine is a 
partial Mu-agonist.87   
 
Oxycodone sustained-release 
Oxycodone is an agonist for the mu- and kappa-receptor. Oxycodone has similar efficacy to 
morphine and is usually well tolerated. It frequently causes constipation. Oxycodone has 
multiple active metabolites that may accumulate in renal dysfunction.87 
 
Fentanyl patch 
Fentanyl is an opioid agonist. The vast majority of the metabolites—around 75%—are 
eliminated in the urine. In cases of renal impairment, the clearance of fentanyl is reduced and 
the terminal half-life of the drug is prolonged. The clinical significance of this is not known.87 In 
liver impairment, adjustment of dose may be required, though no specific guideline is available. 
 
Methadone 
Methadone is a synthetic opioid (mu agonist) a weak NMDA receptor antagonist and a 
serotonin-reuptake inhibitor. No adjustments have to be made in kidney impairment. In 
serious liver failure, the use of methadone is contraindicated. Methadone can have a long and 
variable half-life time. Variation of half-life is 8-80 hours, with a risk of accumulation. It has 
potential interactions with multiple drugs. Furthermore, it may cause prolongation of the QT-
time interval,88 and ECG screening or monitoring may be considered.  
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Opioids and elderly 
Although older people tend to require lower doses than younger individuals, opioid effects do 
not appear to vary with age.89 Though short-term efficacy of opioid use (≤ 12 weeks) among 
older adults has been established, almost half of the patients discontinued the medication, 
mostly because of intolerable side effects.90 There is limited evidence in support of long-term 
opioid treatment.86, 91 In the elderly, the half-life time of the active drug and its metabolites is 
increased, but not in buprenorphine making it a relative safe choice in elderly.87 Furthermore, 
buprenorphine does not have a dose-dependent decrease in respiration.92, 93 In elderly 
patients with impaired hepatic and renal function, there is the risk of accumulation of 
metabolites from certain opioids, such as morphine.  
Given the established risks associated with opioid use, such as hospital admission, mortality 
and fractures,94 the potential negative effects must be carefully weighed and be used as part 
of an integrated treatment program, including functional and psychosocial modalities.87, 94 
Methadone should only be prescribed by clinicians who have considerable experience with the 
drug, or in closely monitored settings because of difficulty in titration.62 
 
Topical analgesic agents 
Topical administration may be better tolerated than other routes of administration. However, 
the efficacy of topical lidocaine and capsaicin in the management of localized neuropathic pain 
is limited, and therefore these drugs are considered second-line treatment.14, 41 
 
Capsaicin 
Capsaicin is the primary component in hot peppers that gives the highly strong spicy flavor. 
Topical capsaicin is available in cream with low concentrations capsaicin (0.025-0.075%) and 
transdermal patches with high concentration capsaicin (8%). Capsaicin can only be used when 
the skin is intact and has no interaction with other medication. There are minimal systemic side 
effects (hypertension, first degree atrioventricular block, coughing, nausea). Local side effects 
are erythema, burning pain and itch. Topical treatment with capsaicin can cause reversible 
degeneration of epidermal nerve fibers. The long-term safety of repeated applications of high-
concentration capsaicin patches, particularly with respect to this epidermal nerve fiber 
degeneration is unknown.14  
 
Lidocaine 5% medicated plaster 
Topical lidocaine has been used for both acute and chronic pain treatments. The effect of the 
lidocaine plaster is based on two actions. The plaster itself provides a cooling perception and 
mechanical protection.95-97 Additionally, lidocaine is a VGSC inhibitor, which stabilizes the 
neuronal membrane potential of Aδ- and C-fibers. This pharmacological action results in a 
reduction of pain and allodynia.98 The 5% lidocaine-medicated plaster has minimal systemic 
absorption of the active substance,99 with low risk of toxicity and lack of drug-drug 
interactions.100 Although the absorption of the skin is extremely low, caution is needed in 
patients with class 1 antiarrhythmic drugs or other local anesthetics.  
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Topical agents and elderly 
Lidocaine patch and high-concentration capsaicin patches are considered second-line 
treatment because of low effect sizes. However, lidocaine patches may be considered as first-
line drug in case of side-effects or safety of other first-line treatments, particularly in elderly 
patients.14  
  
Complementary therapies 
Transcutaneous electrical nerve stimulation (TENS) 
TENS is the application of electrical stimulation of varying frequency, intensity and pulse 
duration to the skin for pain relief.101 TENS is generally believed to be a safe non-invasive 
intervention. However, the effectiveness of TENS in chronic pain has not been established with 
certainty.43 
 
TENS and elderly 
Age does not have a significant impact on pain or TENS comfort, though age-related changes 
might limit the use of TENS among the older population.41, 102 
 
Table 1. Practical tips for the best treatment strategy of small fiber neuropathy in the elderly 
Practical tips for the clinician 
Always make the best choice considering safety and tolerability, strive for tailored made therapy and 
individualization of care in clinical practice 
 
Local treatment In case of focal pain distribution or systemic contra-indications 
Medication Take a careful medication history 
Ask for previous adverse effects, inadequate effects, inadequate dose 
Check for comorbidity such as liver and kidney impairment 
Check potential interactions with other drugs, herbs, caffeine, smoking, grapefruit  
Adjust dose if necessary  
Consider genetic testing in patients with a history of many side effects 
Make patient also responsibility for medication history by handing out a form for 
medication 
Opioids Avoid instant release opioids 
Start strong opioids only as third line treatment 
Be aware of the potential risks 
Social context Ask for impact on sleep, work, daily functioning, relationship, anxiety and treat when 
possible 
Age Avoid polypharmacy as much as possible 
Strive for treatment with the least side effects 
Always start low, go slow! 
AND if nothing works consider multi-targeting! 
 
Multifaceted neuropathic pain management in elderly 
Managing neuropathic pain in elderly is often complex due to its multifactorial facets. The 
neurobiology of aging, its relation to pain, changes in pharmacokinetics, drug metabolism, and 
body composition, polypharmacy and cognitive and affective factors may influence pain 
expression and pain management in elderly.103 
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Individual drugs have 50% of pain relief with a NNT of 4-10, meaning that the outcome of drug 
treatment is, at best, moderate.14, 104 Multifaceted therapy is often needed to address the 
various pain conditions, whereas older people may be particularly susceptible to side effects 
and drug interactions. A practical approach is presented in table 1, and figure 2 and 3.
In general, medication should be started in a low dose and titrated slowly. TCAs should be 
avoided in elderly if possible, or at least not be prescribed above 75 mg/day. A therapeutic trial 
should be of adequate length to assess efficacy, and the dose needs to be adjusted if side 
effects become burdensome, with a slower titration curve to attain therapeutic levels if 
needed.62, 103 It is important to optimize one regimen first, and then gradually add agents, if 
needed. Therapies which have overlapping pharmacodynamics or that may have an adverse 
pharmacokinetic interaction, such as metabolic inhibitors, should not be combined. Especially 
in older patients, attention is needed in agents acting within the central nervous system.
Therapy should be tapered down over time, if possible, to attain the lowest effective 
maintenance dose.
Figure 2. Treatment Algorithm for SFN in the elderly
Legend to figure 2 In addition to physical factors, psychological, neurophysiological, socio-economic and cultural 
aspects may influence the experience and maintain pain; a multidisciplinary approach in line with the 
biopsychosocial model is required in optimizing treatment for the individual patient.41 *see also Figure 3 (contra-
indication algorithm for drugs prescription) and Table 1 (Practical tips for the best treatment strategy of SFN in 
elderly), #in contrast with first line neuropathic pain treatment in adults <65 years, TCAs should be avoided in 
older adults, because of the risk of adverse events, such as cardiac arrhythmia, somnolence, hypotension with 
increased risk of falls and injury, cognitive impairment, and anticholinergic side-effects.62 SFN: small fiber 
neuropathy, SNRI: serotonin-noradrenalin reuptake inhibitor, TCA: tricyclic antidepressant.
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Figure 3 Contra-indication algorithm for drugs prescription
Legend to figure 3: For every drug considered, it is advisable to go through these steps to make a deliberate 
decision. Be aware of comorbidity such as kidney and liver impairment or cardiac disease. Yrs: years.
Discussion and future perspectives
In general the treatment of chronic neuropathic pain is complicated and multidimensional. The 
mechanisms underlying its occurrence and chronification, as well as the inter-individual 
variability, remain poorly understood. As a consequence, symptomatic and unspecific 
treatments are frequently the only available therapeutic options. Indeed, all the clinical trials 
carried out in the last 20 years provided similar results, accounting for 50% of pain relief in 50% 
of patients at best.12, 14 Efficacious and tailored treatments for neuropathic pain are the 
ultimate target both for patients and scientists. The discovery of gain-of-function Nav1.7, 
Nav1.8 and Nav1.9 mutations in painful peripheral neuropathy has expanded the spectrum of 
painful sodium channelopathies.6, 34 It provides a better understanding of the pathogenetic 
mechanisms and may provide targets for potential treatment with the expectation of fewer 
side-effects.105-107 Genetics may also play a role in drugs respons. For some drugs, 
pharmacogenetics can predict the efficacy and toxicity of treatment at individual level.108-110
As pain is a complex symptom, in which not only physical factors but also psychological, 
neurophysiological, socio-economic and cultural aspects may influence the experience and 
maintaining of pain, a multidisciplinary approach in line with the biopsychosocial model is 
required in optimizing treatment for the individual patient (Figure 2).41 Psychological
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techniques may be helpful, not just when pharmacological therapy is ineffective, but as an 
adjunct to medication or as a first-line therapy if the patient prefers. Moreover, chronic pain 
often has coexisting symptoms, such as depression, anxiety and sleep deprivation, and focusing 
on relief of these symptoms may be crucial for patients.  
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Abstract 
Background: Small fiber neuropathy generally leads to considerable pain and autonomic 
symptoms. Gain-of-function mutations in the SCN9A-gene, which codes for the Nav1.7 voltage-
gated sodium channel, have been reported in small fiber neuropathy, suggesting an underlying 
genetic basis in a subset of patients. Currently available sodium channel blockers lack 
selectivity, leading to cardiac and central nervous system side effects. Lacosamide is an 
anticonvulsant, which blocks Nav1.3, Nav1.7, and Nav1.8, and stabilizes channels in the slow-
inactivation state. Since multiple Nav1.7 mutations in small fiber neuropathy showed impaired 
slow-inactivation, lacosamide might be effective. 
Methods/Design: The lacosamide-Efficacy-‘N’-Safety in Small fiber neuropathy (LENSS) study is 
a randomized, double-blind, placebo-controlled, crossover trial in patients with SCN9A-
associated small fiber neuropathy, with the primary objective to evaluate the efficacy of 
lacosamide versus placebo. Eligible patients (the aim is to recruit 25) fulfilling the inclusion and 
exclusion criteria will be randomized to receive lacosamide (200 mg BID) or placebo during the 
first double-blinded treatment period (8 weeks), which is preceded by a titration period (3 
weeks). The first treatment period will be followed by a tapering period (2 weeks). After a 2-
week washout period, patients will crossover to the alternate arm for the second period 
consisting of an equal titration phase, treatment period, and tapering period. The primary 
efficacy endpoint will be the proportion of patients demonstrating a 1-point average pain score 
reduction compared to baseline using the Pain Intensity Numerical Rating Scale. We assume a 
response rate of approximately 60% based on the criteria composed by the Initiative on 
Methods, Measurement, and Pain Assessment in Clinical Trials (IMMPACT) group for 
measurement of pain. Patients withdrawing from the study will be considered as non-
responders. Secondary outcomes will include changes in maximum pain score, the Small Fiber 
Neuropathy-Symptoms Inventory Questionnaire, sleep quality and quality of life assessment, 
patients’ global impression of change, and safety and tolerability measurements. Sensitivity 
analysis will include assessing the proportion of patients having ≥2 points average pain 
improvement compared to baseline Pain Intensity Numerical Rating Scale scores. 
Discussion: This is the first study that will be evaluating the efficacy, safety, and tolerability of 
lacosamide in patients with SCN9A-associated small fiber neuropathy versus placebo. The 
findings may increase the knowledge on lacosamide as a potential treatment option in patients 
with painful neuropathies, considering the central role of Nav1.7 in pain. 
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Background 
Neuropathic pain is described as ‘pain caused by a lesion or disease of the somatosensory 
system.1 The prevalence of neuropathic pain in the general population is around 7% to 10%.2, 
3 Neuropathic pain is one of the main symptoms of small fiber neuropathy (SFN), a condition 
that affects the thinly myelinated Aδ-fibers and the unmyelinated C-fibers. Pain in SFN is mostly 
described as a stitching, burning sensation, usually occurring in a length-dependent pattern, 
starting in the feet and hands.4 Body pain is a major contributor to the reduction of quality of 
life in patients with SFN.5 In addition to the neuropathic pain, patients with SFN may suffer 
from autonomic symptoms.6, 7  
Voltage-gated sodium channels have been described to play an important role in neuropathic 
pain.8 In approximately 15% of patients with SFN, gain-of-function mutations in the SCN9A-, 
SCN10A- and SCN11A-gene have been reported.9-12 The SCN9A-gene codes for the voltage-
gated sodium channel Nav1.7, which is predominantly expressed in the small nociceptive and 
autonomic neurons. In addition to being associated with SFN, gain-of-function mutations in the 
SCN9A-gene have been described in the following human pain disorders: inherited 
erythromelalgia (IEM) and paroxysmal extreme pain disorder (PEPD).13, 14 Gain-of-function 
mutations of the SCN9A-gene were found in 28% of patients with SFN proven by skin-biopsy.9 
In a larger cohort (n=393), the prevalence of SCN9A-gene mutations in patients diagnosed with 
SFN based on an abnormal skin biopsy and/or abnormal temperature threshold testing was 
approximately 9%.12 Therefore, Nav1.7 appears to be an appropriate target for treatment of 
different human neuropathic pain conditions, including SCN9A-associated SFN.  
Current treatments for pain in patients with SFN are far from satisfactory.15 Less than 50% of 
the patients achieve a pain reduction of 50%.16, 17 This is possibly due to drugs acting on target 
sites for which no strong evidence of pathogenicity exists. In addition, commercially available 
sodium channel blockers are not selective for Nav1.7, thereby frequently causing intolerable 
side effects involving the heart and central nervous system.  
Lacosamide is a functionalized amino acid molecule that selectively enhances the slow 
inactivation of voltage-gated sodium channels and interacts with the collapsin-response 
mediator protein-2.18 Lacosamide differs from other sodium channel blockers because of its 
unique mechanism of action. It inhibits the currents of hyperexcitable neurons of the voltage-
gated sodium channels Nav1.3, Nav1.7, and Nav1.8 by targeting the slow-inactivation state and 
sparing channels with normal activity.19, 20 In patients with SCN9A-associated SFN, multiple 
mutations in the SCN9A-gene have shown an impaired slow-inactivation,9 which might 
potentially be considered a target mechanism of action of lacosamide. Therefore, a positive 
effect on pain reduction in these patients might be expected.  
To date, no studies with lacosamide have been performed in patients with SFN. Some evidence 
exists of lacosamide reducing neuropathic pain and being well tolerated in patients with a 
painful diabetic neuropathy.21, 22 The same results were seen in one study with patients with 
fibromyalgia.23 However, no robust underlying mechanism has been presented in these 
studies. 
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Methods/Design 
Objective 
The primary objective of this study is to determine the efficacy and safety of lacosamide versus 
placebo in patients with SCN9A-associated SFN. 
 
Study design 
The Lacosamide-Efficacy-‘N’-Safety in SFN (LENSS) study is a randomized, placebo-controlled, 
double blind, crossover-design study (figure 1). The study consists of 2 periods. Before the first 
period, the screening and baseline measurements takes place. Subjects fulfilling the inclusion 
and exclusion criteria are subsequently randomized to receive lacosamide or placebo.  
 
Figure 1 Schematic diagram of study 
 
The first period starts with the first titration period of 3 weeks, in which study medication 
(lacosamide or equivalent placebo) will be gradually increased. Subsequently, patients enter 
the first treatment period of 8 weeks. This period is followed by a 2-week tapering period. After 
a 2-week washout period, the second period, which is executed in the same manner as the 
first period, begins. Subjects cross over to the alternate arm and undergo the second 3-week 
titration period, followed by the second treatment period (8 weeks) and a tapering period (2 
weeks). In both treatment periods, subjects receive lacosamide 200 mg BID or placebo. 
Patients are examined at the study outpatient site at the entry and at the end of both 
treatment periods (maximum of eight site visits). In addition, subjects are contacted and 
interviewed in a standardized manner by phone every 2 weeks to determine clinical condition 
and well-being, and collect data on safety and side effects. A follow-up visit is performed 
approximately 4 weeks after the last dose of study medication. 
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The use of drugs such as lamotrigine, carbamazapine, oxcarbazapine, mexiletine, amitriptyline, 
topical analgesics (e.g., lidocaine patches, capsaicin patches and oral/injectable 
corticosteroids) that act on sodium channels is not allowed during the study period. 
Participants using these drugs require a washout period of at least 5 half-lives (90 days for 
capsaicin patches, which have the longest elimination period of the prohibited medications) 
prior to the screening visit. Other pain medications can be continued provided the dose and 
frequency of dosing have been stable over the previous 30 days prior to screening and remains 
unchanged during the study period. Additional medication is recorded.  
 
Study medication 
Each treatment phase is preceded by a titration phase. The dose of lacosamide is increased 
weakly, starting with 50 mg BID in the first week, followed by 100 mg BID in the second week, 
concluding with 150 mg BID in the third week. After these 3 weeks, the treatment phase begins 
for 8 weeks. Based on previous studies and on the dose-related side effects, a dose of 200 mg 
BID (or equivalent placebo) has been chosen as maintenance dose.24 The subjects start with 
the maintenance dose (200mg BID) at the first day of the treatment phase, therefore this dose 
is not included in the titration phase. After the treatment phase, the tapering phase begins, 
with study medication (lacosamide or placebo) dosage being reduced at once to 100 mg BID in 
the first week of the tapering period and then to 50 mg BID in the second week of the tapering 
period. 
A convenient treatment period of 8 weeks was chosen based on literature findings and 
assuming that a positive effect of lacosamide should be seen within this period, thereby 
limiting the burden for patients.23 
 
Participants 
A total of 25 subjects with genetically proven SCN9A-associated SFN are recruited into the trial. 
SCN9A-mutations classified as certainly, probably, or potentially pathogenic are eligible for 
inclusion.25 Subjects are recruited at the Maastricht University Medical Center+ (Maastricht 
UMC+), the Netherlands.  
Informed consent is obtained from all participants, before any of the study procedures (e.g. 
questionnaires or neurological examination) is performed. 
 
Inclusion criteria 
Subjects must fulfill the following inclusion criteria to be eligible:  
1. Male and/or female subjects between 18 and 80 years. 
2. Presence of a clinical diagnosis of Small Fiber Neuropathy (SFN), with at least 2 of the 
following clinical symptoms not otherwise explained: 
• Burning feet. 
• Allodynia. 
• Diminished pain and/or temperature sensation. 
• Dry eyes or mouth. 
• Orthostatic dizziness. 
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• Bowel disturbances (constipation, diarrhea, gastroparesis). 
• Urinary disturbances. 
• Sweat changes (hyperhidrosis/hypohidrosis). 
• Visual accommodation problems and/or blurred vision. 
• Hot flashes/palpitations. 
• Impotence, diminished ejaculation or lubrication. 
3. In addition to the clinical diagnosis of SFN, presence of confirmed abnormality on intra-
epidermal nerve fiber density evaluation (IENFD) and/or Quantitative Sensory Testing 
(QST)6, 7 and a mutation in the SCN9A gene, confirmed by sequencing.  Where possible, in 
vitro confirmation of the functionality of the mutation should have been performed and 
documented as has been demonstrated previously.6, 9 
4. Presence of pain due to SFN for at least 3 months prior to screening and an average self-
reported pain score of at least 3 during this time. 
5. If on analgesic medication, subject must have a stable analgesic medication regimen for a 
minimum of 30 days before the start of the study and should continue with the same 
unchanged regimen throughout the study. 
6. Evidence of a personally signed and dated informed consent document indicating that the 
subject (or a legal representative) has been informed of all pertinent aspects of the study. 
7. Subjects who are willing and able to comply with scheduled visits, treatment plan, 
laboratory tests, and other study procedures. 
 
Exclusion criteria: 
Subjects presenting with any of the following cannot be included in the study:  
1. Subjects with predominantly signs of large nerve fiber involvement (muscle weakness, loss 
of vibration sense, hyporeflexia/areflexia), or clinically significant abnormal nerve 
conduction studies (NCS). 
2. History or presence of illnesses known to cause SFN (excluding diabetes mellitus), including 
liver, kidney, or thyroid dysfunction, monoclonal gammopathy, connective tissue disorders, 
sarcoidosis, Sjögren syndrome, amyloidosis, Fabry disease, celiac disease, HIV and 
neurotoxic drugs (e.g., chemotherapy). 
3. Subjects with other severe pain conditions, which may impair the self-assessment of pain 
due to SFN. 
4. Any condition possibly affecting drug intake and absorption (e.g., difficulty in swallowing, 
gastrectomy and /or bowel resection). 
5. History of known alcohol, analgesic or illicit drug abuse within 12 months of screening. 
6. Subjects taking medications with potential effect on sodium channels function, e.g., 
lamotrigine, carbamazapine, oxcarbazapine, mexiletine, amitriptyline, topical analgesics 
e.g., lidocaine patches, capsaicin patches and oral/injectable corticosteroids. These 
medications are prohibited until the end of the study period and require a washout period 
of at least 5 half-lives (90 days for capsaicin patches, which is the longest elimination period 
of the prohibited medications) prior to the screening visit.  
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7. 12-lead ECG demonstrating QTcF (Fridericia’s correction) >450 or a QRS interval >120 msec 
at screening.  If QTcF exceeds 450 msec, or QRS exceeds 120 msec, the ECG should be 
repeated 2 more times and the average of the three QTcF values should be used to 
determine the subject’s eligibility. 
8. Severe renal impairment (creatinine clearance ≤ 30 mL/min).  
9. Treatment with an investigational drug within 30 days (or as determined by the local 
requirement, whichever is longer) or 5 half-lives preceding the first dose of study 
medication.  
10. Participation in other studies during the period of current study participation, or has 
planned surgery during the course of the study. 
11. Pregnant females; breastfeeding females; females of childbearing potential not using 
effective and medically reliable contraception or not agreeing to continue effective 
contraception for at least 28 days after the last dose of investigational product. 
12. Other clinically significant or unstable, or severe acute or chronic medical or 
psychiatric/psychological condition or laboratory abnormality that may increase the risk 
associated with study participation or investigational product administration or may 
interfere with the interpretation of study results and, in the judgment of the Investigator, 
would make the subject inappropriate for entry into this study. 
13. In the case of incidental findings the patient and his/her treating physician will be informed 
and asked to undertake action if necessary. If a patient does not want to be informed about 
possible incidental findings, nor wants his treating physician to be informed, he or she 
cannot participate in this study.  
 
Randomization 
After the screening period, patients return to our center. To ensure that eligible subjects are 
compliant, it will be checked that at least 5 of the last 7 days of the pain diary are filled in. This 
is important because the pain diary of the screening period is used as the baseline 
measurement of the primary outcome. Randomization is performed by using ALEA data 
management. This software is provided by the Trans European Network for Clinical Trials 
Services (http://www.tenalea.com/). The randomization is computer-controlled based on the 
electronic case report form that is used. A blinded message is send to the investigator and an 
unblinded message is send to the pharmacy. Patients are stratified based on the type of SCN9A-
variant (1. genetic variant and 2. genetically and functionally confirmed) and on the clinical 
diagnosis of SFN (1. abnormal skin biopsy, 2. abnormal temperature threshold testing, and 3. 
abnormal skin biopsy and abnormal temperature threshold).  
 
Blinding 
The study is subject- and investigator-blinded until the end of the study. Blinding codes are 
only broken in emergency situations for reasons of subject safety.  
Lacosamide and matching placebo is provided as 50 mg tablets for oral administration. Tablets 
are provided in containers. Rescue medication (acetaminophen) is provided in its approved 
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marketed product dress. All medication dispensed to subjects are to be returned to the 
investigator and double-checked by monitor to assure study compliance. 
 
Compliance 
The following compliance calculation are applied:  
 
        % Compliance =  number of tablets taken/number of    
    tablets expected to have taken ×100. 
 
Subjects are coded as being a non-compliant if the percentage compliance according to the 
above formula is less than 80% or greater than 120% study drug compliance.   
 
Efficacy measurements 
The daily Pain Intensity Numerical Rating Scale (PI-NRS) consists of an 11-point numerical scale 
ranging from 0 to 10, were 0 represents no pain and 10 the worst pain possible. The subjects 
are asked to complete the PI-NRS twice daily, in the morning and evening, preferably at fixed 
time points. In addition, the Daily Sleep Interference Scale (DSIS) is completed every day on 
awakening in the morning. The DSIS consists of an 11-point numerical scale ranging from 0 
(pain does not interfere with sleep) to 10 (pain completely interferes with sleep) and is used 
to determine sleep quality. At each assessment, the following additional questionnaires are 
completed: the Neuropathic Pain Scale (NPS), Small Fiber Neuropathy-Symptom Inventory 
Questionnaire (SFN-SIQ), Patients’ Global Impression of Change (PGIC), and the generic short-
form SF-36 health survey (SF-36). 
 
Outcome measurements 
The chosen outcomes are largely based on the international criteria advised by the IMMPACT 
group for measurement of pain.26 
 
Primary outcome 
The primary efficacy endpoint is defined as the proportion of patients demonstrating a 1-point 
average pain score reduction compared to baseline using the PI-NRS. A 1-point change on the 
PI-NRS is considered the minimum clinically important difference (MCID), according to unified 
rule of ½ x standard deviation (SD) and recommendations given by the IMMPACT group.26, 27 
 
Secondary outcome 
Secondary outcomes include changes seen in the maximum pain score on the PI-NRS, the NPS, 
DSIS, PGIC, SFN-SIQ, SF-36, adverse events, laboratory safety tests (e.g. hematology, clinical 
chemistry), blood pressure (BP), pulse rate (PR), and electrocardiogram (ECG). 
Sensitivity analyses include assessing the proportion of patients having ≥ 2 points average pain 
improvement compared to baseline PI-NRS scores. 
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Data management 
An electronic case report file (eCRF) is used for each patient to collect all data. To host the 
eCRF, MACRO electronic data capture is used, powered by InferMed Ltd, London. It has been 
designed to support compliance with the requirements of relevant regulatory bodies including 
ICH Good Clinical Practice (www.infermed.com). Assessments start at the screening visit. In 
addition, assessments at site visits and by phone are performed according to the scheme 
presented in figure 1, and include a standardized interview to determine patient’s clinical 
condition and well-being, assessment of various questionnaires, determining compliance, 
laboratory assessment, and at predefined moments performing ECG. During each contact (visit 
or by phone), adverse events and concomitant medication are discussed. At each visit, the 
diary and residual medications are collected. An overview of the assessments at visits and 
telephone calls are summarized in table 1.   
Privacy of the patients is guaranteed; stored data and materials are only identifiable to the 
person by a sequential assigned subject number. The handling of personal data complies with 
the Dutch Personal Data Protection Act (De Wet Bescherming Persoonsgegevens, WBP). The 
figure for the study protocol is shown in supporting information 1. 
 
Safety reporting 
Adverse events are recorded and monitored. The principal investigator is to be informed 
immediately in case of any serious adverse event (SAE). Every SAE is reported to the Ethics 
Committee. Suspected unexpected serious adverse reactions (SUSAR) are also reported. And 
all SUSARs are expedited to the competent authorities in other Member States, according to 
the requirements of the Member States.  
 
Statistical analysis 
Sample size 
A 1-point change on the average PI-NRS compared to baseline is considered as the MCID.26, 27  
We assume a response rate of approximately 20% in the placebo-treated group, based on a 
meta-analysis of the placebo effect in pain studies in which the effect varied from 7-37% with 
a 50% pain reduction in 16%. In the lacosamide-treated group, we assume a response rate of 
approximately 60% based on the IMMPACT criteria in which the clinical relevant pain reduction 
may be less than 50%. Fixing a two-sided alpha at 5%, a sample size of 22 patients is required 
per treatment group to show efficacy with 80% power between the 2 groups (chi-square test). 
Assuming a dropout rate of  approximately 10% (two to three patients), a total of 25 subjects 
will be needed per treatment group (in a parallel study). Since the number of patients with 
SCN9A-associated SFN is limited, a crossover design was chosen to fulfill sample size 
requirements with the inclusion of 25 subjects. 
 
Type of analysis 
The analyses are performed on the intention-to-treat (ITT) population, defined as all patients 
who received at least one dose of randomized study medication and had at least one post-
baseline assessment. Patients withdrawing from the study are considered as non-responders. 
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The comparison of the proportion of patients in both groups (lacosamide vs. placebo) reaching 
the predefined cut-off is estimated using Kaplan-Meijer serial time series graphs with a log-
rank test.  
 
For secondary efficacy endpoints, the treatment differences for change from baseline in 
selected outcome measures, according to the pre-defined inquiries, are analyzed using non-
parametric tests. Statistical tests used depend on the type of data. Analyses of safety 
parameters are performed on the safety set (SS), which includes all randomized patients who 
took at least 1 dose of trial medication. Individual missing data are assigned using a last 
observation carried forward approach. Other missing-data treatment methods are performed 
(for example single and multiple imputation), to test which of these methods is the best based 
on sensitivity analyses. 
 
Discussion 
In this study, the efficacy, safety, and tolerability of lacosamide in patients with pain due to 
SCN9A-associated SFN is studied. Despite earlier studies performed with lacosamide in painful 
conditions, no study to date has been done in patients with SCN9A-associated SFN.  This is 
interesting because most of them harbor an electrophysiological mechanism of pain induction 
through impaired slow-inactivation of the voltage-gated sodium channel Nav1.7,28 which might 
be a potential target for lacosamide, taking into account its unique mechanism of targeting the 
slow-inactivation.19 Therefore, a positive effect on pain reduction in these patients might be 
expected.  
With lacosamide, we hope to find a new treatment option for the excruciating pain often 
reported by patients with SFN. This is the first pilot study that aims to show the efficacy, 
tolerability, and safety of lacosamide in this specific cohort of patients with SCN9A-associated 
SFN.  
If lacosamide proves to be effective in SFN patients with a Nav1.7 mutation, this might be a 
viable option for patients with painful neuropathies or with neuropathic pain in general, 
considering the central role of Nav1.7 in pain. The first results of the study are expected mid 
2017. 
 
Trial status 
Participant recruitment for this trial is ongoing. Recruitment began in November 2014 and is 
expected to end mid-2016. 
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Abstract 
Background: Symptomatic treatment of neuropathic pain in small fiber neuropathy (SFN) is 
often disappointing. The finding of voltage-gated sodium channel mutations in SFN, with 
mutations in SCN9A, encoding for Nav1.7, being most frequently reported, suggest a specific 
target for therapy. The anticonvulsant lacosamide acts on Nav1.3, Nav1.7, and Nav1.8. The aim 
of this study was to evaluate the efficacy, safety, and tolerability of lacosamide as a potential 
treatment for pain in Nav1.7-related SFN.  
Methods: The LENSS study was a randomized, placebo-controlled, double-blind, crossover-
design study. Subjects were recruited in the Netherlands between November 2014 and July 
2016. Patients with Nav1.7-related SFN were randomized to start with lacosamide followed by 
placebo or vice versa. In both eight-week treatment phases, patients received 200mg BID, 
preceded by a titration period, and ended by a tapering period. The primary outcome was 
efficacy, defined as the proportion of patients with 1-point average pain score reduction 
compared to baseline using the Pain Intensity Numerical Rating Scale. The trial is registered 
with ClinicalTrials.gov, number NCT01911975. 
Findings: Twenty-four subjects received lacosamide, and 23 received placebo. In 58.3% of 
patients receiving lacosamide, mean average pain decreased by at least 1 point, compared to 
21.7% in the placebo group (sensitivity analyses, OR 5.65 (95% CI: 1.83;17.41); p=0.0045). In 
the lacosamide group, 33.3% reported that their general condition improved versus 4.3% in 
the placebo group (p-value 0.0156). Additionally, a significant decrease in daily sleep 
interference, and in surface pain intensity was demonstrated. No significant changes in quality 
of life or autonomic symptoms were found. Lacosamide was well-tolerated and safe in use. 
Interpretation: This study shows that lacosamide has a significant effect on pain, general well-
being, and sleep quality. Lacosamide was well-tolerated and safe, suggesting that it can be 
used for pain treatment in Nav1.7-related SFN. 
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Introduction 
Small fiber neuropathy (SFN) is a peripheral neuropathy of the thinly myelinated Aδ-fibers and 
unmyelinated C-fibers, and is associated with multiple underlying conditions.1-3 Patients suffer 
from excruciating pain and autonomic symptoms, leading to a significant negative impact on 
quality of life.4   
In cases where an underlying condition is present, initial treatment usually focuses on this, but 
additional symptomatic therapy is generally needed. First-line treatment of neuropathic pain 
consists of tricyclic antidepressants, serotonin-noradrenaline reuptake inhibitors, pregabalin 
and gabapentin.5-7 However, the efficacy of these drugs is often unsatisfactory.5, 6 Therefore 
new treatment options are of great importance. 
Voltage-gated sodium channels (VGSC; Navs) underlie the initiation and propagation of action 
potentials in excitable membranes. Animal studies have shown that Navs that are expressed in 
peripheral sensory neurons play important roles in neuropathic and inflammatory pain.8 
Nav1.7, Nav1.8 and Nav1.9, encoded by the genes SCN9A, SCN10A, and SCN11A, respectively, 
are preferentially expressed in dorsal root ganglion (DRG) neurons and their peripheral axons. 
Genetic and functional studies have shown that gain-of-function mutations in these genes 
cause human pain disorders.9 Gain-of-function mutations in Navs have been reported in around 
15% of patients with SFN,3, 10 with SCN9A mutations being the most frequent. Taken together, 
inhibition of Navs is expected to be therapeutically beneficial for pain patients.8 
Lacosamide is a functionalized amino acid which was thought to bind to the slow-inactivated 
state of Navs.11-16 Recent data suggests that lacosamide binds to fast-inactivated Nav1.7 with 
slower kinetics than classical sodium channel blockers.17 Since pain in SFN is produced by 
inappropriate firing of DRG neurons,3, 10 the Nav channels in these neurons would be expected 
to be in at least a partially inactivated state, so that lacosamide would be expected to bind with 
and inhibit these channels, thus attenuating the firing of DRG neurons. In addition, lacosamide 
has also been shown to modulate Nav1.7 via regulation of collapsing response mediator protein 
2 (CRMP2),18 which acts on multiple pathways involved in pain.19 The multi-modal action of 
lacosamide suggests that it might be effective in treating patients with Nav1.7-related SFN. 
To date, no studies with lacosamide in patients with SFN have been published. In studies with 
lacosamide in painful diabetic neuropathy a reduction in neuropathic pain was found, and the 
drug was well tolerated,20-23 but the small number of patients in these cohorts, and the small 
numbers of patients and events for most outcomes led to the conclusion that lacosamide is 
not useful in treating neuropathic pain. The aim of our study was to evaluate the effect on pain, 
safety, and tolerability of lacosamide in painful peripheral neuropathy, with a specific focus on 
a well-defined group of patients with Nav1.7-related SFN.  
 
Methods 
Study design and participants 
The Lacosamide-Efficacy-‘N’-Safety in SFN (LENSS) study was a randomized, placebo-
controlled, double-blind, crossover-design study. A detailed description of the study design 
was published previously;24 a summary is given below. 
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All subjects were recruited at the Maastricht University Medical Center+ (Maastricht UMC+), 
the Netherlands, between November 2014 and July 2016, and data collection continued until 
May 2017. Patients were eligible if they had been diagnosed with pure SFN in combination with 
an SCN9A-variant. According to the international guidelines, the diagnosis of pure SFN was 
based on typical clinical symptoms in combination with a diminished intraepidermal nerve fiber 
density in skin biopsy and/or abnormal temperature threshold testing (TTT) without signs of 
large fiber involvement.1, 2 Patients with a history of associated conditions of SFN (except 
diabetes mellitus) were excluded for this study. Variants of the SCN9A-gene were classified 
according to the Practice Guidelines for the Evaluation of Pathogenicity and the Reporting of 
Sequence Variants in clinical Molecular Genetics.25 SFN patients with an SCN9A-variant that 
was classified as class 3, 4, or 5 (respectively variants of uncertain pathogenicity, variants likely 
to be pathogenic, and clearly pathogenic variants) were included.25 Where possible, in vitro 
confirmation of the functional effect of the mutation was performed and documented.10, 14 All 
participants signed an informed consent form before entering the study. A detailed description 
of the inclusion and exclusion criteria was published elsewhere.24 
The study was conducted in accordance with the Declaration of Helsinki and International 
Conference on Harmonization Good Clinical Practice Guidelines. The institutional Medical 
Ethics Committee approved the study protocol. The trial was registered under 
http://www.clinicaltrials.gov/, NCT01911975, as well as EudraCT, number 2013-001511-70.  
 
Randomization and masking 
From subjects who fulfilled the inclusion- and exclusion criteria, baseline measurements were 
recorded. Randomization was performed by computer software called ALEA. Patients were 
stratified based on the type of the SCN9A-variant (genetically confirmed variant or genetically 
and functionally confirmed variant) and on the clinical diagnosis of SFN (abnormal skin biopsy, 
abnormal TTT, and abnormal skin biopsy in combination with an abnormal TTT). Patients were 
randomized into one of the two treatment arms, starting with lacosamide followed by placebo 
or starting with placebo followed by lacosamide. Because of the crossover-design, patients 
completed two identical study periods, but in different arms. For subjects and investigators, 
the order in which patients received lacosamide and placebo, was blinded. Lacosamide and 
matching placebo were provided as 50 mg capsules for oral administration. The blinding codes 
were not broken during the entire study. Compliance and the use of rescue medication 
(acetaminophen) were recorded. 
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Figure 1. Schematic diagram of study. 
 
Legend to figure 1: This is the schematic design of the study. After the screening, eligible patients were 
randomized. After that, the titration period of 3 weeks was followed by a treatment period of 8 weeks and ended 
by a tapering period of 2 weeks. After a washout period of at least 2 weeks, the same study periods took place 
with the different treatment. In addition to the visits at every new study period, there were regular telephone 
calls and patients filled in a daily pain diary from the first day of the study until the end.  
 
Procedures 
Figure 1 provides the study algorithm.24 In essence, each study part consisted of a titration 
period of three weeks, followed by a treatment period of eight weeks, and a tapering period 
of two weeks. After a washout period of at least two weeks, the same schedule was repeated 
for the other arm. Four weeks after the last tapering period the study ended. During the three-
week titration period, patients received an increasing dose of lacosamide or placebo, starting 
with 50mg BID in the first week, 100mg BID in the second week, and 150mg BID in the third 
week. Doses of 200mg BID were then administered for eight weeks. This part of the trial 
concluded with a two-week tapering period, in which patients received 100mg BID in the 12th 
week and 50mg BID in the 13th week. At the beginning of each period (for example the titration 
period or treatment period), patients visited our center. The unused study medication of the 
previous period was returned and the study medication for the next period was provided. 
Additionally, questionnaires were taken, blood tests and an electrocardiogram (ECG) were 
performed. In between the visits, there were standardized check-up telephone calls scheduled.  
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Outcome 
The daily pain intensity numerical rating scale (PI-NRS) was used as the primary outcome 
measure according to the provided guidelines in painful neuropathic studies.28 The PI-NRS 
consists of an 11-point numerical scale ranging from 0 to 10, where 0 represents no pain and 
10 the worst pain possible. Subjects were asked to complete the PI-NRS twice daily, in the 
morning and evening at fixed time points. In addition to the PI-NRS, the daily sleep interference 
scale (DSIS) was completed every day on awakening. The DSIS consists of an 11-point numerical 
scale ranging from 0 (pain does not interfere with sleep) to 10 (pain completely interferes with 
sleep). Additional questionnaires were completed at each visit that included the neuropathic 
pain scale (NPS), small fiber neuropathy symptom inventory questionnaire (SFN-SIQ), patients’ 
global impression of change (PGIC), and the generic short-form SF-36 health survey (SF-36). 
The primary efficacy outcome was at least a 1-point improvement (thus, reduction in score) on 
the PI-NRS compared to baseline, which is considered the minimum clinically important 
difference (MCID), according to unified rule of ½ x standard deviation (SD) and the guidelines.28 
Secondary outcomes were the proportion of patients having ≥ 2 points average pain 
improvement compared to their baseline PI-NRS scores, changes in the mean and maximum 
pain score on the PI-NRS, the NPS, DSIS, PGIC, SFN-SIQ, SF-36, adverse events, laboratory safety 
tests, blood pressure, pulse rate, and ECG. Sensitivity analyses included the 1-point and 2-point 
improvement from a less restricted baseline. 
 
Statistical analyses 
The sample size of 25 subjects was calculated with a response rate of 20% in the placebo- group 
and 60% in the lacosamide-group, a two-sided alpha of 5%, and an 80% power between the 
two groups (chi-square test), including the assumption of a dropout rate of 10%. An 
independent statistician was consulted and analyzed the results after making some 
adjustments to the previously published statistical protocol.24 
The Full Analysis Set (FAS) consisted of all subjects who were randomized to receive study 
medication, regardless of whether or not they subsequently completed the study or deviated 
from the protocol. However, at least one measurement after taking the study medication 
should have been recorded. Subjects were analyzed for efficacy according to randomized 
treatment. The FAS was used for all analyses of efficacy endpoints.  
For all questionnaires, the difference between the baseline and treatment period was 
analyzed. To determine the baseline of period 1, the last 14 days prior to randomization were 
taken. The interval for determining the period 2 baseline was the last 7 days of the washout 
period prior to commencing titration of the period 2 study medication. The comparator interval 
for the endpoint was the last 28 days of the respective treatment maintenance period.  
For the primary efficacy endpoint (PI-NRS), each subject produced a baseline mean pain 
average and an on-treatment mean pain average. The average of non-missing day pain and 
night pain scores was derived. This was termed pain average. For example, if a night pain score 
was missing then the pain average equaled the day pain score. The difference between the 
average pain at baseline and after treatment was computed for each subject for each period. 
If for a given subject the change in mean pain average from on-treatment to period baseline 
was ≤ -1, then the subject was defined as a responder for that period. Any subject with missing 
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change was defined as a non-responder for that period conditional upon that subject having 
commenced study treatment for that period. Otherwise their responder status was set to 
missing. In one of the secondary efficacy endpoints, a responder was defined as a subject 
whose pain was reduced by 2 or more points. Other secondary endpoints, the mean day and 
night pain, the maximum day and night pain and the maximum average pain were analyzed, 
using these as a continuous variable. In the sensitivity analyses the 1-point and 2-point 
improvement were analyzed with a less restricted baseline too include more information in 
the analyses. 
Period 1 baseline was only calculated if the subject has recorded a pain score for at least 10 
days of the 14 day baseline period.  Period 2 baseline was only calculated if the subject has 
recorded a pain score for at least 5 days of the 7 day baseline period. A weekly pain score was 
only calculated if the subject has recorded a pain score for at least 4 days for that week. If the 
subject failed to meet these criteria the pain score was set to missing. Averages and maxima 
were calculated over available data.  No data was imputed for missing observations.  
The DSIS outcome was derived for PI-NRS, where the changes from baseline were analyzed as 
a continuous variable without dichotomization. The measurements at baseline and the last 28 
days of the maintenance treatment period were compared. 
For the other non-diary efficacy endpoints: NPS, PGIC, SFN-SIQ, and the SF-36, the period 
baselines were those assessed before the titration period of period 1 and 2. The comparator 
assessment was taken at the end of the 8-week maintenance course of treatment. Changes 
from period baseline were derived. The 10 NPS subscales were calculated separately. For the 
PGIC, for each period a subject was coded to ‘responder’ if their response was either, 
“minimally improved”, "much improved", or "very much improved". Missing values were coded 
to 'non-responders'. The SFN-SIQ sumscore was calculated. For the SF-36, absolute scores and 
changes from baseline for the different dimensions were analyzed. 
The Safety Set (SAF) included all subjects in the FAS who received at least one dose of 
comparative study medication and had one measurement after taking medication. Subjects 
were analyzed according to treatment received. The SAF was used for all analyses of safety 
endpoints.  
The binary data for whether or not a subject was a responder was analyzed using Generalized 
Estimating Equations (GEE) with treatment, period, period baseline, subject baseline, the 
stratification factors and interaction between treatment and period in the model. Subject was 
a random factor. The formal test of the primary hypothesis was conducted at the two-sided 
5% level of significance. For continuous outcome variables, a mixed effect model was used to 
investigate the treatment effect upon the change in scores between baseline and after 
treatment, fitting treatment, period, interaction between treatment and period, subject 
baseline, period baseline, and the stratification factors as fixed effects. Subject was fitted as a 
random effect. Least squares (LS) means for the change from baseline with standard errors 
were calculated for each treatment, and the LS mean difference between the treatment groups 
was presented together with the 95% CI. The PGIC was analyzed with a McNemar’s test instead 
of the planned repeated measures analyses, because with the stricter definition, the placebo 
response was too sparse. All analyses and summaries were produced using SAS® version 9.2 
(or higher). There was no imputation of missing data. 
Chapter 6 
108 
Role of the funding source 
The Prinses Beatrix Spierfonds funded the study (W.OR12-01). The foundation had no role in 
the study design, data collection, data analysis, data interpretation, or writing of the report. 
The corresponding author had full access to all data of the study and had final responsibility 
for the decision to submit for publication. 
 
Results 
Twenty nine patients were screened for the study between November 2014 and July 2016 
(figure 2). Four of these patients were excluded, because of prohibited co-medication (n=2), 
ECG abnormalities (n=1), and non-compliance of scheduled appointments (n=1). A total of 25 
patients were randomized, with one patient dropping out directly after randomization but 
before treatment due to an accidental fall. This patient was excluded from further analyses 
because no post-baseline measurements were recorded. An additional patient dropped out 
during the washout period after the first treatment period, due to conflicting personal 
commitments, not related to the study medication. This patient was included in the analyses 
for the first period. Thus, 24 patients received lacosamide and 23 patients received placebo.  
 
Figure 2. Trial profile. 
 
Legend to figure 2: In total 29 patients were screened for the study. Four were excluded, because of using 
medication that acts on sodium channels (n=2), because of ECG abnormalities (n=1), and non-compliance of 
appointments (n=1). In total 25 patients were randomized, of which one patient dropped out directly after 
randomization due to an accidental fall. The patient was excluded from further analyses because no post-baseline 
measurements were recorded. An additional patient dropped out during the washout period after the first 
treatment period, due to personal circumstances, not related to the study medication. This patient was included 
in the analyses for the first period. In total 24 patients received lacosamide and 23 patients received placebo. 
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Baseline characteristics are shown in table 1. Because of the trial design, the analyses of the 
primary and secondary outcomes were based on the whole group (n=24). Therefore, 
differences between the groups based on baseline characteristics were not analyzed.
Figure 3 shows the average pain scores for each individual before and after treatment for the 
lacosamide and the placebo period. Figures 3A and 3B show that average pain decreased more 
during the lacosamide period compared to the placebo period. The individual change in 
average pain scores before and after treatment for the two periods shows a larger significant 
decrease in patients using lacosamide compared to placebo. Figure 4 shows the weekly mean 
average pain for both groups in both treatment periods. The mean average pain of the patients 
that were using lacosamide was lower compared to the scores of the patients that used 
placebo during that time, which was the case in both treatment periods. 
Figure 3. Average pain before and after treatment.
A
B
Legend to figure 3:
A: Change in average pain scores and in pain scores for each individual patient with the use of lacosamide. 
B: Change in average pain scores and in pain scores for each individual patient with the use of placebo. 
In figure 3A and 3B the average pain scores are shown before and after treatment for respectively lacosamide 
and placebo (in red lines). The mean change of the average pain is larger for the lacosamide period compared to 
the placebo period. Also the change per subject before and after treatment is shown. More subjects have a 
decline, or a larger decline, during the use of lacosamide compared to placebo. 
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Table 1. Baseline characteristics. 
 Lacosamide : Placebo (n=12) Placebo : Lacosamide 
(n=12) 
Total (n=24) 
Age (years) 
  Mean (SD) 
  Median (range) 
 
48.3 (14.87) 
50.5 (24-70) 
 
59.8 (12.92) 
61.5 (27-78) 
 
54 (14.84) 
57.5 (24-78) 
Sex 
  Male 
  Female 
 
7 (58.3%) 
5 (41.7%) 
 
3 (25.0%) 
9 (75.0%) 
 
10 (41.7%) 
14 (58.3%) 
Race 
  Caucasian 
  Turkish 
  South-American 
  African 
  Asian 
 
11 (91.7%) 
0  
0 
1 (8.3%) 
0 
 
9 (75.0%) 
1 (8.3%) 
1 (8.3%) 
0 
1 (8.3%) 
 
20 (83.3%) 
1 (4.2%) 
1 (4.2%) 
1 (4.2%) 
1 (4.2%) 
Diagnosis 
  Abnormal TTT 
  Abnormal TTT and skin biopsy 
  Abnormal skin biopsy 
 
12 (100%) 
0 
0 
 
 
7 (58.3%) 
4 (33.3%) 
1 (8.3%) 
 
19 (79.2%) 
4 (16.7%) 
1 (4.2%) 
 
SCN9A-variant 
  Only genetically confirmed 
  Functionally and genetically  
  confirmed 
 
6 (50.0%) 
6 (50.0%) 
 
9 (75.0%) 
3 (25.0%) 
 
15 (62.5%) 
9 (37.5%) 
PI-NRS, median (range) 
  Mean day pain  
  Mean night pain 
  Mean average pain 
Max day pain 
Max night pain 
 
6.4 (4-9) 
5.7 (1-9) 
6.2 (3-9) 
7.6 (6-9) 
6.7 (1-10) 
 
6.6 (4-8) 
5.5 (1-8) 
6.1 (2-8) 
7.4 (5-10) 
7.0 (1-9) 
 
6.5 (4-9) 
5.6 (1-9) 
6.1 (2-9) 
7.5 (5-10) 
6.8 (1-10) 
DSIS 4.8 (0-10) 5.9 (5-8) 5.6 (0-10) 
SFN-SIQ 34.5 (24-43) 28.0 (18-45) 31.5 (18-45) 
NPS 
  Intense  
  Sharp 
  Hot 
  Dull 
  Cold 
  Sensitive 
  Itchy 
  Unpleasant 
  Intense deep 
  Intense surface 
 
6.5 (3-9) 
7.5 (0-10) 
7.5 (0-10) 
5.5 (0-9) 
3.0 (0-10) 
6.0 (0-9) 
4.5 (0-8) 
8.0 (4-10) 
7.0 (5-10) 
7.0 (2-9) 
 
7.0 (5-8) 
7.5 (0-9) 
7.0 (0-10) 
7.0 (0-9) 
3.5 (0-10) 
6.0 (0-10) 
2.5 (0-8) 
7.0 (4-8) 
7.0 (0-10) 
6.0 (5-9) 
 
7.0 (3-9) 
7.5 (0-10) 
7.0 (0-10) 
6.0 (0-9) 
3.0 (0-10) 
6.0 (0-10) 
3.5 (0-8) 
7.0 (4-10) 
7.0 (0-10) 
6.5 (2-9) 
SF-36 
  Physical Functioning 
  Role – Physical 
  Bodily Pain 
  Social Functioning 
  Mental Health 
  Role-Emotional 
  Vitality 
  General Health 
 
30.6 (10-67) 
12.5 (0-75) 
20.5 (0-61) 
62.5 (0-100) 
65.0 (10-100) 
70.8 (8-100) 
37.5 (0-75) 
42.5 (10-60) 
 
37.5 (28-90) 
18.8 (0-100) 
31.0 (0-61) 
75.0 (25-100) 
80.0 (25-95) 
75.0 (17-100) 
50.0 (6-69) 
35 (20-82) 
 
33.3 (10-90) 
12.5 (0-100) 
31.0 (0-61) 
62.5 (0-100) 
65.0 (10-100) 
75.0 (8-100) 
40.6 (0-75) 
37.5 (10-82) 
Legend to table 1: Data are mean (SD), median (range) or n (%). SD: standard deviation, TTT: temperature 
threshold testing. DSIS; daily sleep interference scale, NPS; neuropathic pain scale, PI-NRS; pain intensity 
numerical rating scale, SF-36; generic short-form SF-36 health survey, SFN-SIQ; small fiber neuropathy symptom 
inventory questionnaire. 
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Figure 4. Weekly mean acverage pain during both treatment periods.
Legend to figure 4: The weekly mean average pain is shown for both groups in both treatment periods. The mean 
average pain of the patients that were using lacosamide was lower compared to the scores of the patients that 
used placebo during that time, which was the case in both treatment periods. BL: baseline, SD: standard deviation, 
W: week number.
Table 2. Primary outcome.
Full analyses set Sensitivity analyses set
Lacosamide vs
placebo
p-value OR (95% CI) Lacosamide vs
placebo
p-value OR (95% CI)
≥ 1-point decrease in
average pain
50.0% vs 21.7% 0.0213* 4.45 (1.38;14.36) 58.3% vs 21.7% 0.0045* 5.65 (1.83;17.41)
≥ 2-point decrease in
average pain
25.0% vs 8.7% 0.0637 7.94 (1.20;52.79) 33.3% vs 8.7% 0.0244* 10.58 (1.63;68.63)
Legend to table 2: CI; confidence interval, OR; odds ratio, vs; versus. * p-value below 0.05. There was a significant 
effect of lacosamide on average pain compared to placebo.
The proportion of responders for lacosamide and placebo was calculated from these data, and 
as the primary outcome shown in table 2. There was a significant effect of lacosamide on 
average pain compared to placebo. In the full analyses set there was a significant effect of 
lacosamide in a ≥ 1-point decrease of the mean average pain (50.0% responder with
lacosamide versus 21.7% placebo) with a p-value of 0.0231 and odds ratio (OR) of 4.45 (95% 
CI 1.38;14.36) and a trend towards an effect on a ≥ 2-point decrease of the average pain with 
a p-value of 0.0637 (25% responder with lacosamide versus 8.7% responder with placebo). In 
the sensitivity analyses both effects were significant; for ≥ 1-point decrease 58.3% responded 
with lacosamide versus 21.7% with placebo (p-value 0.0045, OR 5.65 (1.83;17.41)) and for ≥ 2-
point decrease 33.3% responded with lacosamide versus 8.7% with placebo (p-value 0.0244, 
OR 10.58 (1.63;68.63)). Additionally, in the lacosamide period 10 out of 24 patients (41.67%) 
had a 30% reduction of the average pain from baseline, compared to 3 out of 23 patients 
(13.04%) in the placebo period. In total 4 out of 24 patients (16.67%) had a 50% reduction of 
the average pain, compared to 1 out of 23 patients (4.35%) in the placebo group. 
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A pathogenic gain-of-function mutation was found in 13 out of the 24 patients, while the other 
patients carried a variant that was not yet functionally confirmed. In the lacosamide period 6 
out of the 13 patients with a gain-of-function mutation (46.2%) had a ≥ 1-point decrease of the 
mean average pain and 4 patients (30.8%) had a ≥ 2-point decrease of the average pain 
(compared to 8 out of 11 (72.7%) and 4 out of 11 (36.4%) respectively for the patients with the 
other variants). In the placebo period, 3 out of 13 patients with a gain-of-function mutation 
(23.1%) had a ≥ 1-point decrease and 1 out of 13 (7.7%) had a ≥ 2-point decrease of the mean 
average (compared to 2 out of 10 (20.0%) and 1 out of 10 (10.0%) respectively for the patients 
with the other variants). 
The secondary outcomes, table 3, showed similar results for the sensitivity analyses for the 
mean day pain, the mean night pain, the maximal night pain, and the mean average pain (as a 
continuous outcome). Only the maximal day pain showed no significant difference between 
lacosamide and placebo. There was also a significant decrease of the influence of pain on sleep 
quality, with a median value of the DSIS of 5.3 for the lacosamide period and a 5.7 for the 
placebo period (least square (LS) mean of -1.32 for lacosamide compared to LS mean of -0.62 
for placebo, with a LS mean difference of -0.70). Also, the PGIC showed significant differences 
between the two groups, 33.3% of patients felt better during the use of lacosamide compared 
to 4.3% during the use of placebo (p-value of 0.0156). The NPS showed a significant effect of 
lacosamide on the intense surface pain (item 10b) (LS mean of -1.27 for lacosamide compared 
to LS mean of 0.03 for placebo, with a LS mean difference of -0.70) but there was also a 
significant effect of placebo on the itchy feeling of pain (LS mean of -0.24 for lacosamide 
compared to LS mean of -1.00 for placebo, with a LS mean difference of -0.76) compared to 
lacosamide. No significant differences were found for the SFN-SIQ sumscore and the SF-36. 
 
Regarding safety, in total six serious adverse events (SAE) were reported (which were classified 
as serious because they required hospitalization), of which two occurred in the lacosamide 
period and four in the placebo period. The six SAE’s were diplopia, vomiting, chest pain, 
conversion disorder, dyspnea, and a bladder operation (which was requested by the patient 
because of complaints present prior to the start of the study). The adverse events that 
occurred in at least 5% in one of the two treatment groups are presented in table 4. The most 
frequent AEs in the lacosamide period were dizziness, headache, and nausea, which were 
comparable to the most frequent AEs in the placebo period. 
 
During the study, eight of the 24 patients changed neuropathic pain medication, as shown in 
table 5. Three patients changed medication during the placebo period. One patient decreased 
the medication during the lacosamide period, because of side effects, and increased them 
again during the placebo period, because of the return of pain. This patient was a responder 
during the lacosamide period, but not during the placebo period. One patient started 
medication during the lacosamide period and also during the placebo period, but was a non-
responder in both periods. The other three patients started or increased their medication in 
the lacosamide period, 2 of them were responders for this period. 
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Table 4: Adverse events 
 Lacosamide (n=24) Placebo (n=23) 
 Total    Total    
Patients with at 
least one adverse 
event 
21 (87.5%)    19 (82.6%)    
All serious adverse 
events 
       
Diplopia 
Vomiting 
Chest pain 
Conversion 
disorder  
Dyspnea 
Bladder operation 
1 (4.2%) 
1 (4.2%) 
0 
0 
 
0 
0 
   0 
0 
1 (4.3%) 
1 (4.3%) 
 
1 (4.3%) 
1 (4.3%) 
   
Most common 
adverse events* 
Total Mild Moderate Severe Total Mild Moderate Severe 
Dizziness 
Nausea 
Headache 
Fatigue 
Tremor 
Somnolence 
Epigastric 
discomfort 
Memory 
impairment 
Pruritus 
Vomiting 
Balance disorder 
Constipation 
Flushing 
Disturbance in 
attention 
Feeling drunk 
Rash 
Vision blurred 
Dyskinesia 
Diarrhoea 
Influenza 
Back pain 
Dyspnoea 
Parasthesia 
Upper respiratory 
tract infection 
Viral upper 
respiratory tract 
infection 
Visual impairment 
10 (41.7%) 
6   (25.0%) 
6   (25.0%) 
5   (20.8%) 
5   (20.8%) 
4   (16.7%) 
4   (16.7%) 
 
3   (12.5%) 
 
3   (12.5%) 
2   (8.3%) 
2   (8.3%) 
2   (8.3%) 
2   (8.3%) 
2   (8.3%) 
 
2   (8.3%) 
2   (8.3%) 
2   (8.3%) 
2   (8.3%) 
1   (4.2%) 
1   (4.2%) 
1   (4.2%) 
1   (4.2%) 
0 
0 
 
0 
 
 
0 
6   (25.0%) 
3   (12.5%) 
4   (16.7%) 
2   (8.3%) 
3   (12.5%) 
1   (4.2%) 
3   (12.5%) 
 
0 
 
3   (12.5%) 
1   (4.2%) 
0 
0 
0 
1   (4.2%) 
 
1   (4.2%) 
1   (4.2%) 
1   (4.2%) 
2   (8.3%) 
0 
0 
1   (4.2%) 
1   (4.2%) 
0 
0 
 
0 
 
 
0 
4 (16.7%) 
3   (12.5%) 
2   (8.3%) 
3   (12.5%) 
2   (8.3%) 
3   (12.5%) 
1   (4.2%) 
 
3   (12.5%) 
 
0 
0 
2   (8.3%) 
2   (8.3%) 
2   (8.3%) 
1   (4.2%) 
 
1   (4.2%) 
1   (4.2%) 
1   (4.2%) 
0 
1   (4.2%) 
1   (4.2%) 
0 
0 
0 
0 
 
0 
 
 
0 
0 
0 
0 
0 
0 
0 
0 
 
0 
 
0 
1   (4.2%) 
0 
0 
0 
0 
 
0 
0 
0 
0 
0 
0 
0 
0 
0 
0 
 
0 
 
 
0 
4 (17.4%) 
4 (17.4%) 
4 (17.4%) 
0 
0 
0 
1 (4.3%) 
 
0 
 
1 (4.3%) 
0 
1 (4.3%) 
0 
0 
0 
 
1 (4.3%) 
1 (4.3%) 
0 
0 
2 (8.7%) 
3 (13.0%) 
2 (8.7%) 
3 (13.0%) 
3 (13.0%) 
2 (8.7%) 
 
2 (8.7%) 
 
 
2 (8.7%) 
1 (4.3%) 
2 (8.7%) 
2 (8.7%) 
0 
0 
0 
0 
 
0 
 
0 
0 
0 
0 
0 
0 
 
0 
1 (4.3%) 
0 
0 
2 (8.7%) 
2 (8.7%) 
1 (4.3%) 
0 
2 (8.7%) 
0 
 
0 
 
 
2 (8.7%) 
3 (13.0%) 
2 (8.7%) 
2 (8.7%) 
0 
0 
0 
1 (4.3%) 
 
0 
 
1 (4.3%) 
0 
1 (4.3%) 
0 
0 
0 
 
1 (4.3%) 
0 
0 
0 
0 
1 (4.3%) 
1 (4.3%) 
3 (13.0%) 
1 (4.3%) 
2 (8.7%) 
 
2 (8.7%) 
 
 
0 
0 
0 
0 
0 
0 
0 
0 
 
0 
 
0 
0 
0 
0 
0 
0 
 
0 
0 
0 
0 
0 
0 
0 
0 
0 
0 
 
0 
 
 
0 
Legend to table 4: * Only those reported by at least 5% of participants in one of the groups are shown. 
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Discussion 
This is the first study that investigated the efficacy of lacosamide in patients with SFN. The 
results show that lacosamide significantly decreased pain and had a positive effect on sleep 
quality compared to placebo in patients with Nav1.7-related SFN. Specifically, the surface pain 
intensity (item 10b of the NPS) was positively influenced. In addition, more than 33.3% of 
patients felt better (as reflected by the PGIC questionnaire) when using lacosamide. Compared 
with placebo, lacosamide appeared to be safe to use and well-tolerated in this cohort of 
patients with SFN.  
The results are similar or even more positive compared to studies investigating the effect of 
lacosamide on neuropathic pain in painful diabetic neuropathy.20-23 In contrast to those 
studies, however, the crossover design used in our study was chosen to provide reliable results 
despite small patient numbers. A recent study showed an effect of another Nav blocker, 
BIIB0074 on the pain attacks in patients with trigeminal neuralgia.29 
Lacosamide appears to be as effective as currently available neuropathic pain treatment, with 
a response rate of 50-60%, which is at least comparable to the 50% of patients that have a 
reduction in pain intensity when treated with currently available therapeutics.6,7 The factors 
underlying the variance in response to lacosamide are not known, but the variability in 
response possibly could be due to the different gene variants or epigenetic differences 
between patients. In this study, lacosamide showed a significant effect on the intensity of 
surface pain (item 10b on the NPS), which might suggest that lacosamide reduces the allodynic 
symptoms. At the moment, no accurate objective tools are available to test allodynia in the 
clinic; however this would be of interest to test in future trials with lacosamide. 
Our study did not show an effect of lacosamide on quality of life. The treatment period of eight 
weeks was long enough to observe differences in pain intensity, but the duration of pain 
reduction might have been too short to result in a positive effect on quality of life. Another 
explanation for the absence of a significant change in quality of life could be that, in addition 
to neuropathic pain, other factors such as autonomic dysfunction might influence the quality 
of life of these patients.  
Nav1.7 is expressed in both DRG neurons and sympathetic ganglion neurons, which explains 
the combination of neuropathic pain and dysautonomia in most patients with Nav1.7-
mutations.14 Based on this, lacosamide also might be expected to have a positive effect on 
autonomic complaints. However, it is known that mutated sodium channels can have a 
different effect on excitability, depending on the cell background, with some mutations having 
dramatically different effects on excitability of peripheral sensory versus sympathetic ganglion 
neurons.30,31 The effect of lacosamide on Nav1.7 within different subtypes of neurons, and its 
effect on excitability in different cell types of neurons, have not thus far been studied.  
 
In this study, we did not see any changes in the SFN-SIQ, a questionnaire that also includes 
autonomic functions. A confounding factor could be the side effects that lacosamide can cause 
(like dizziness, dry eyes, or intestinal problems). It is not clear if these side effects are the result 
of central autonomic dysregulation, or due to a direct effect of lacosamide on the peripheral 
sympathetic neurons.  
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In the placebo-group a significant positive effect on the itchy feeling of pain was demonstrated. 
This is in line with previous research that showed a substantial placebo-effect on itch in various 
dermatological conditions.32 
The attenuation of pain that we observed is consistent with the mechanism of action of 
lacosamide. Lacosamide is thought to bind to preferentially to Nav channels in the inactivated 
state.16,17 Our previous studies have demonstrated spontaneous firing in DRG neurons 
expressing SFN-related Nav1.7 mutations.15,33,34 As a result of spontaneous activity in these 
neurons, which appears to contribute to pain, lacosamide would be expected to have a 
preferential effect on DRG neurons in SFN. As with lacosamide and other sodium channel 
blockers (e.g. phenytoin and carbamazepine) in epilepsy, the mechanistic bases for non-
responsiveness of some patients are not fully understood. 
The strength of the crossover-design in our study was that fewer patients were required to 
obtain reliable results than in a parallel design, because each patient served as his/her own 
matched control. The crossover-design is justifiable because lacosamide was not being 
evaluated as a cure or a disease modifying agent, but only a therapy for alleviating pain 
symptoms. It has been shown earlier that this design is useful for screening compounds for 
efficacy in proof-of-concept studies with neuropathic pain.35 The dosage used in this study 
(200mg BID) was based on previous studies.36,37 At this dosage, a significant effect was reached. 
In practice, for patients who did not respond on 200mg BID, an increase of dosage to 300mg 
BID might be considered, although the expected incidence of side effects increases with higher 
doses. Conversely, the dosage of lacosamide can be lowered to 100mg or 150mg BID when 
patients experience bothersome side effects. 
This study has some potential limitations. First, as a result of the chosen study design a 
carryover effect could have occurred. This might confound direct treatment effects, because 
these effects cannot be estimated separately. This is minimized, however, because we 
implemented a washout period that was longer than the advised five (or more) half-life time 
lengths of the drug concentration in the blood (half-life of approximately 13 hours). In the 
mixed effects model analyses, no significant interaction was found between the treatment 
effect and the period effect, suggesting that there was no carry-over effect. This is confirmed 
by data in figure 4, which show that the average pain scores return to the baseline in the 
washout period after the lacosamide arm. Thus, although the design is potentially open to 
carry-over effects, we found no evidence for such effects.  
Second, the cohort that was been investigated was relatively small and limited to patients 
carrying specific Nav1.7 variants. SFN is rare and an SCN9A-variant can be found in around 9%.38 
We chose this well-defined cohort, because our aim was to demonstrate proof of concept, 
which can be used for future studies involving larger groups of patients diagnosed with SFN. 
Since VGSCs also play a role in pathological neuropathic pain states even in the absence of 
mutations,8 a positive effect of lacosamide on pain in non-VGSC-mutation-related SFN is 
expected. After this study was started, the SFN-specific Rasch-built overall disability scale (SFN-
RODS) was developed.39 Besides the effect on neuropathic pain, this outcome measure can be 
of great value in future SFN studies to investigate the effect of lacosamide and other 
treatments on daily activity.39 
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Third, the study was powered to find a difference between 60% response rate in the treatment 
period and 20% in the placebo period. However, the observed proportions were 58.3% and 
21.7%, which was a little lower than expected. The results of this proof-of-concept study 
support further studies on lacosamide in patients with SFN. 
Fourth, during this study, patients were allowed to continue using their current medications, 
when the dosage was stable for 30 days prior to screening and they did not inhibit sodium 
channels. Our data show that lacosamide can be prescribed as an effective add-on therapy. 
However, the quantities and types of concomitant medications differed between patients. 
Although we attempted to keep the use of concomitant medication as constant as possible, 
change was unavoidable in some cases, for example when patients suffered from side effects 
or severe pain. Therefore, no statements about interactions between lacosamide and other 
neuropathic painkillers can be made. In epilepsy it is known that lacosamide is more effective 
as a first add-on drug compared to a later add-on treatment.40 This might suggest that the 
effect of lacosamide might be even greater as a monotherapy or a first add-on treatment.  
Finally, multiple Nav1.7-variants were included in this study. Almost one-half of the patients 
with a pathogenic gain-of-function mutation were responders, which is comparable to the 
overall effect. Further research will be needed to see whether patients with some specific 
variants are to be more likely to respond to lacosamide compared to other variants. This could 
lead to more insight into why some patients derive benefit from lacosamide and some do not, 
and could lead to patient-specific treatments in the future.  
In conclusion, this study provides evidence indicating that, in some patients with SFN, 
lacosamide can attenuate neuropathic pain. Specifically, our results show that lacosamide is 
well-tolerated and safe, and can reduce neuropathic pain in Nav1.7-related SFN. 
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Abstract 
Background: Small fiber neuropathy is the most common cause of neuropathic pain in 
peripheral neuropathies, with a minimum prevalence of 53/100,000. Patients experience 
excruciating pain and currently anti-neuropathic and other pain drugs do not relieve the pain 
substantially. Several open-labeled studies have suggested an immunological basis in small 
fiber neuropathy and have reported efficacy of treatment with intravenous immunoglobulin. 
Therefore, immunological mechanisms conceivably may play a role in small fiber neuropathy. 
To date no randomized controlled study with intravenous immunoglobulin in patients with 
small fiber neuropathy has been performed. 
Methods/Design: This study is a randomized, double-blind, placebo-controlled clinical trial in 
patients with idiopathic small fiber neuropathy. The primary objective is to investigate the 
efficacy of intravenous immunoglobulin versus placebo on pain alleviation. A 1-point change 
on the PI-NRS compared to baseline is considered the minimum clinically important difference. 
In the IVIg-treated group we assume a response rate of  approximately 60% based on the 
criteria composed by the IMMPACT group for measurement of pain. Based on this, a total 
sample size of 60 patients is needed. Eligible patients fulfilling the inclusion/exclusion criteria 
will be randomized to receive either intravenous immunoglobulin or placebo (0.9% saline). The 
treatment regimen will start with a loading dose of 2 g/kg body weight over 2-4 consecutive 
days, followed by a maintenance dose of 1 g/kg body weight over 1-2 consecutive days given 
3 times at 3 weeks interval. The primary endpoint is the comparison of the percentage of 
responder subjects between the two treatment groups from the first randomization during 12 
weeks treatment. A responder is defined as ≥ 1-point Pain Intensity Numerical Rating Scale 
improvement on the mean weekly peak pain relative to baseline. The secondary outcomes are 
pain intensity, pain qualities, other small fiber neuropathy-related complaints, daily and social 
functioning, as well as quality of life. In addition, safety assessments will be performed like 
adverse events, vital signs and laboratory values outside the normal range. Responders during 
the 12 weeks treatment period will be followed during a 3-month extension phase. 
Discussion: This is the first randomized, double-blind, placebo-controlled clinical trial with 
intravenous immunoglobulin in patients with idiopathic small fiber neuropathy. Positive 
findings will result in a new treatment option for small fiber neuropathy and support an 
immunological role in this condition.  
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Background 
Small fiber neuropathy (SFN) is a disorder of the thinly myelinated Aδ-fibers and the 
unmyelinated C-fibers, with a minimum prevalence of 53/100,000.1 Patients suffer from 
neuropathic pain, usually following a length-depending pattern.2 Besides, they report 
autonomic symptoms, like palpitations, gastrointestinal disturbances, and orthostatic 
dizziness.3, 4 SFN interferes with daily functioning and may lead to a decrement in quality of life 
expectations.5 The diagnosis is based on SFN related symptoms, without signs of large-fiber 
involvement, in combination with an abnormal intra-epidermal nerve fiber density (IENFD) in 
skin biopsy and/or an abnormal temperature threshold levels in quantitative sensory testing.3, 
4 Despite intensive search for underlying causes such as diabetes mellitus, impaired glucose 
tolerance, Fabry’s disease, hereditary disorders, celiac disease, sarcoidosis, HIV and other 
systemic illnesses which may be potentially treatable,3, 4 the proportion of patients with 
idiopathic SFN (I-SFN) remains substantial, ranging in different series from 24% up to 93%.1, 6-8 
It is conceivable that immunological mechanisms may play a role in patients with I-SFN, since 
several immune-mediated diseases, such as sarcoidosis, Sjogren’s disease and systemic lupus 
erythematosus are associated with SFN.8-11 Auto-antibodies have also been reported in 
patients with SFN.12-14 Moreover, inflammatory changes in nerves have been found.15, 16 
Elevated pro-inflammatory cytokines have been suggested to be involved in the 
pathophysiology of pain in SFN.17 In other immune-mediated neuropathies, such as chronic 
inflammatory demyelinating polyneuropathy, treatment with intravenous immunoglobulin 
(IVIg) has proven to be efficacious.18, 19 Moreover, some immunomodulation therapies have 
shown efficacy in some open-labelled case studies in patients with SFN with chronic pain.20-24 
Similar findings have been reported in erythromelalgia, a condition that is associated with 
SFN.25, 26 Pain reduction with IVIg treatment has been summarized recently.23 
IVIg is a blood product with high doses of pooled IgG molecules, which are derived from 
thousands of donors. IgG antibodies are the primary mediators of protective humoral 
immunity against pathogens, but can also be pathogenic.27 IVIg may be used either to boost 
the patients’ immunological capabilities or, conversely, to blunt an immune response directed 
toward the patients’ own tissues.28 This dual IVIg-mediated effect on the immune system 
makes IVIg suitable for the treatment of several different diseases. When administered in high 
concentrations, IVIg has anti-inflammatory properties. How this anti-inflammatory effect is 
mediated has not been fully elucidated yet. Several mechanisms have been proposed, 
including toxin inactivation, stimulation of the leukocyte and serum bactericidal action, 
modulation of cytokine effect, and the modulation of the complement system.28 
In SFN, current neuropathic pain treatment options are generally insufficient to relief the pain 
substantially.29, 30 Therefore, a better treatment is warranted. IVIg appears to be a potential 
therapeutic option for pain alleviation in SFN. The aim of the current pilot study is to investigate 
the efficacy and safety of IVIg in patients with I-SFN in a randomized, double-blind, placebo-
controlled, clinical trial. 
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Methods/Design 
Objectives 
The primary objective of the study is to evaluate the efficacy of IVIg treatment compared to 
placebo in patients with skin biopsy proven I-SFN on pain alleviation.  
Secondary objectives are to assess the effect of IVIg on pain intensity, pain qualities, and other 
small fiber neuropathy-related complaints, daily and social functioning, as well as quality of 
life. In addition, safety features of IVIg therapy in SFN will be evaluated. 
 
Study design 
The study has a randomized, double-blind, parallel group, placebo-controlled prospective 
design, shown in Figure 1.  This design has been partly applied and published previously.18, 31 
This design has been partly applied and published previously in the ICE-trial, in which the effect 
of IVIg for the treatment of chronic inflammatory demyelinating polyradiculopathy has been 
studied.18 In that study a screening period up to 10 days was chosen, thereafter patients were 
divided to one of the two parallel groups with IVIg or placebo. Patients received a baseline-
loading dose of 2g/kg over 2-4 days, followed by a maintenance infusion of 1g/kg over 1-2 days 
every 3 weeks. For the current trial this part of the study design has been adopted. 
In brief, after a screening period of ≤ 10 days, eligible subjects are randomized to receive either 
IVIg at a uploading dose of 2 g/kg body weight (bw) ideally over 2-4 (consecutive) days or 
matching placebo. Thereafter, a study drug infusion is administered every 3 weeks at a dose of 
1 g/kg bw, given over 1-2 (consecutive) days for a total of 3 additional infusions following 
baseline.  Subjects’ pain is measured using Pain Intensity Numerical Rating Scale (PI-NRS) at 
baseline and at each study visit scheduled every 3 weeks for 12 weeks.  Pain is also assessed 
twice a day (daytime and nocturnal pain, through PI-NRS) on two days per week (Monday and 
Friday). A responder is defined as ≥ 1-point improvement on the mean weakly peak pain using 
the PI-NRS relative to baseline. Patients who showed an improvement and completed the 12 
weeks of study treatment will be followed during a 3-month extension phase to determine the 
long-term effect on pain alleviation of therapy received. 
The study is placebo-controlled, because previously in analgesic trials a placebo effect of 7-
37% has been shown.32 To make sure IVIg has a factual effect on pain reduction, a placebo-
controlled design is necessary to exclude the placebo-effect of this treatment on the patients. 
In addition, patients are allowed to use pain medication that not has been changed in the 30 
days prior to randomization. As a result, in case the patient receives a placebo, the treatment 
does not differ from the situation before participating the study.  
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Figure 1. Schematic diagram representing overall study design and study visits.  
 
Legend to Figure 1: IVIg = intravenous immunoglobulin, red triangles represent the treatment visits. The first 
treatment visit is spread out over 2-4 consecutive days, treatment visit 2-4 will consist of 1-2 consecutive days.  
 
Setting and duration 
The study is conducted at the department of Neurology of the Maastricht University Medical 
Center+ (Maastricht UMC+), Maastricht, the Netherlands. For logistic reasons, all subjects are 
residents of the Netherlands. The duration of the study is 6 months per subject. Examination 
will be performed by neuromuscular experts and/or highly trained fellows in neurology. We 
are aiming to conduct the study in a 2-year period. 
 
Participants 
A total of 60 patients, 30 per treatment arm, will be included in the study. These are patients 
with newly or previously diagnosed skin-biopsy proven idiopathic (predominantly) SFN. 
Subjects are recruited at the Maastricht UMC+, the Netherlands. Informed consent will be 
obtained from all participants, before study start. 
 
Inclusion criteria 
Subjects must meet all of the following inclusion criteria to be eligible for enrollment into the 
study:  
1. 18 years or older.  
2. Skin-biopsy proven idiopathic SFN or idiopathic painful neuropathy with 
predominantly SFN pattern. 
3. Pain intensity rated ≥ 5 on the PI-NRS (maximum pain) or on the neuropathic pain 
scale (NPS),33, 34 question number 1 for at least 12 weeks before the study as 
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declared by each patient to the best of their knowledge; if available, medical 
records of each patient will be consulted on the reported pain intensity. 
4. Each subject will receive an information leaflet and an informed consent form. 
Subjects must give written informed consent prior to study entry. 
5. Eligible patients must be willing to complete all study-related activities and 
examination required by the protocol. 
 
Exclusion criteria: 
Subjects presenting with any of the following will not be included in the study:  
1. Predominant clinical picture of large nerve fiber involvement (i.e., weakness, loss 
of vibration sense, hypo-/areflexia). 
2. Treatment with IVIg or any other immunomodulatory/immunosuppressive agents 
(e.g., steroids) within the last 12 weeks prior to the date of informed consent. 
3. An underlying cause of SFN (diabetes, SCN9A/SCN10A/SCN11A mutations, 
hypothyroidism, renal failure, vitamin B12 deficiency, monoclonal gammopathy, 
alcohol abuse (more than 5 IU/day), malignancies, drugs that cause neuropathy 
(e.g. chemotherapy, amiodarone, propafenone)). 
4. History of anaphylaxis or severe systemic response to immunoglobulin or with a 
blood product. 
5. Cardiac insufficiency (NYHA III/IV), cardiomyopathy, significant cardiac dysrhythmia 
requiring treatment, unstable or advanced ischemic heart disease, or history of 
congestive heart failure, severe hypertension (diastolic blood pressure >120 mmHg 
or systolic >170 mmHg). 
6. Known hyperviscosity, history of renal insufficiency or high serum creatinine levels 
(MDRD<30), selective IgA deficiency, or hypercoagulable state.  
7. Conditions whose symptoms and effects could alter protein catabolism and/or IgG 
utilization (e.g. protein-losing enteropathies, nephrotic syndrome). 
8. Females who are pregnant, breast-feeding, or, if of childbearing potential, unwilling 
to practice adequate contraception throughout the study. 
9. Mentally challenged adult subjects unable to give independent informed consent. 
10. Patients using pain medication that has changed in the 30 days prior to 
randomization. Unchanged pain medication is allowed, provided dosages stay equal 
during the study. 
 
Study medication 
Gamunex© 10%, 100 mg/ml, solution for infusion is a Human normal immunoglobulin that is 
currently available commercially in a number of countries for the treatment of primary 
immunodeficiency, idiopathic thrombocytopenic purpura, and chronic inflammatory 
demyelinating polyneuropathy as well as other indications in some countries. Placebo is 
supplied as 0.9% saline. 
The dose of IVIg chosen for this study has been considered to be potentially the most effective 
in other immune-mediated polyneuropathies, specifically 2.0 g/kg of IVIg as loading dose 
followed by 1 g/kg bw for maintenance at intervals of 3 weeks.18 
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The maximum dose is 80 g IVIg per infusion day, even for subjects whose body weight exceed 
80 kg.  Maximum dose is 160 g IVIg for a 2 g/kg bw application and 80 g for 1 g/kg/bw 
application.  
The calculated dose is administered over a 2-4 days period at baseline, dividing the total dose 
equally among the amount of infusion days. The infusion will be prepared on the day of infusion 
and administered on that same day. The 3 additional infusions, given at subsequent study visits, 
are each administered as a single infusion on 1 day but may be given over 2 consecutive days 
for reasons of tolerability. 
On the first two days of the treatment (day 1 and day 2), the initial infusion rate will be 0.05 
mL/kg/hour for the first 20 min. If there is no evidence of a hypersensitivity reaction, the 
infusion rate will be increased to 1.0 mL/kg/hour for the next 20 min. After that, the infusion 
rate will be increased to 3.0 mL/kg/hour. If this is tolerated well, the infusion rate will start at 
1 mL/kg/hour for additional treatments and will be increased to 3 mL/kg/hour and 5 
mL/kg/hour over 20 minutes up to a maximum allowable rate of 7 mL/kg/hour. This infusion 
scheme is according to the protocol of the hospital. Each infusion will take approximately 3-4 
h. Vital signs will be documented during the infusion. The subject will be monitored during the 
infusion for any adverse events. 
 
Compliance 
Volume of the study drug administered will be documented in the medical record and the 
electronic case report file (eCRF). When less than 100% of the calculated study drug volume is 
given, the reasons for deviation will be recorded in medical record and eCRF. 
 
Randomization and blinding 
All eligible subjects participating in the study will receive a subject number consecutively 
beginning with the abbreviation of the study (IVIG) followed by 01, 02, 03, etc. A computer will 
randomize the subjects to one of the two treatment groups. An automatic message with this 
allocation will be send to the unblinded pharmacist and will be kept confidential.  
The study will be subject- and investigator blinded during the treatment periods, from visit 2 
until the end of the study. Blinding codes will only be broken in emergency situations for 
reasons of subject safety.  
Blinding of different study groups will be guaranteed by ensuring all subjects receiving the 
same total volume per kg body weight of trial medication with no visible difference in the 
external aspect between IVIg and placebo, by using nontransparent infusion lines and bags. An 
unblinded pharmacist or designee will prepare study medication. This individual, responsible 
for dispensing the drug, will also be responsible for the blinding procedure. 
 
Outcome measurements 
Primary outcome 
The primary outcome measure will be based on pain assessment, since pain is considered the 
most important feature of SFN.2-4, 35, 36 Pain intensity will be evaluated using the 11-point Pain 
Intensity Numeric Rating Scale (PI-NRS; 0: no pain to 10: worst imaginable pain).33, 37  In 
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particular, a difference in mean weakly peak pain intensity will be considered as the primary 
outcome parameter. A responder is defined as ≥ 1-point improvement on the PI-NRS during 
12 weeks treatment relative to baseline. The rationale for choosing the primary outcome 
measure was based on recommendations regarding the clinical importance of treatment 
outcomes in chronic pain clinical trials as postulated by the IMMPACT (Initiative on Methods, 
Measurements and Pain Assessment in Clinical Trials) study group.38, 39 
 
Secondary outcomes 
Secondary outcome measures include changes in daily pain intensity, nocturnal pain intensity, 
and the average of these two obtained from the PI-NRS, change in Patients’ Global Impression 
of Change (PGIC),38, 39 the Rash-transformed 13 items SFN-Symptoms Inventory Questionnaire 
(RT-SFN-SIQ),40 the amount of pain medication, the use of non-medical rescue activities, the 
amount of pain relief (using a 5-point Likert-scale), the NPS,34 Daily Sleep Interference Scale 
(DSIS), the Short Form 36 Health Survey (SF-36),41, 42 and the Rasch-built Overall Disability 
Outcome Scale (SFN-RODS).40 
Safety evaluation features will include the following additional tests: adverse events, 
laboratory test (e.g. hematology, clinical chemistry, as shown in table 2), and vital signs. 
 
Data management 
An eCRF is used for each patient to collect all data. To host the eCRF, MACRO electronic data 
capture is used, powered by InferMed Ltd, London. It has been designed to support compliance 
with the requirements of relevant regulatory bodies including ICH Good Clinical Practice 
(www.infermed.com). Assessments start at the screening visit and are subsequently 
performed according to the scheme presented in Figure 1, Table 1 and Table 2, and include a 
standardized interview to determine patient’s clinical condition and well-being, assessment of 
various questionnaires, and laboratory assessment. During each visit, adverse events and 
concomitant medication are discussed. At each visit, the diary and residual medications are 
collected.  
Privacy of the patients is guaranteed; stored data and materials are only identifiable to the 
person by a sequential assigned subject number. The handling of personal data complies with 
the Dutch Personal Data Protection Act (De Wet Bescherming Persoonsgegevens, WBP). The 
figure for this study protocol is shown in supporting information 1. 
 
Adverse events 
Adverse events will be recorded and monitored. The principal investigator will be informed 
immediately in case of any serious adverse event (SAE) is occurring. Every SAE will be reported 
to the Ethics Committee.     
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Supporting information 1. Figure of content for the schedule of enrolment, interventions, and assessments. 
 STUDY PERIOD 
 Enrolment Allocation Post-allocation End of 
treatment 
Follow-up 
TIMEPOINT** -t1 0 v1 v2 v3 v4-6 v7 v8-10 
ENROLMENT:         
Eligibility screen X        
Informed consent  X        
Medical history X        
Physical examination X        
Nerve conduction 
studies 
X        
Skin biopsy and QST X        
Allocation  X       
INTERVENTIONS:         
Intravenous 
Immunoglobulin 
        
Placebo         
ASSESSMENTS:         
Laboratory 
assessments 
X  X X X X X  
PI-NRS X     X X X 
PGIC      X X X 
SFN-SIQ X     X X X 
NPS X     X X X 
SFN-RODS X     X X X 
Pain relief      X X X 
Sleep quality X     X X X 
SF-36 X     X X X 
Study medication 
infusion 
  X   X   
Vital signs   X   X X  
Concomitant 
medication 
X X X X X X X X 
Adverse events X X X X X X X X 
Legend to supporting information 1: In this table, the schedule for enrolment, interventions and assessments are 
shown. 
v1 = Week 0 baseline / day 1 
v2 = Completion of baseline infusion  
v3 = 3-6 days after completion of baseline infusion 
v4 = week 3 (second treatment) 
v5 = week 6 (third treatment) 
v6 = week 9 (fourth treatment) 
v7 = week 12 (end of treatment) 
v8 = month 4 (follow-up) 
v9 = month 5 (follow-up) 
v10 = month 6 (follow-up)  
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Table 1. Study flow chart (except laboratory assessments) 
 Screening Treatment phase End of 
Treatment 
Follow-
up5 
Assessment/ 
Evaluation 
- 10 days 
(Day -10 
to Day 0) 
Week 0 
Baseline/ 
Day 1 
Completion 
of baseline 
infusion 
(Day 2, 3 or 
4)3 
3-6 Days 
after 
completion 
of baseline 
infusion4 
Week 
3,6,9 
(± 3 
days) 
Week 
12 
(± 3 
days) 
Month 4, 
5, 6 
Informed Consent X       
Medical 
History/physical 
examination  
X       
Nerve Conduction 
Studies  
X       
Skin biopsy and QST X       
Laboratory 
Assessments  
(see Table 2) 
X X X X X X  
PI-NRS X    X X X 
PGIC     X X X 
SFN-SIQ X    X X X 
NPS X    X X X 
SFN-RODS X    X X X 
Pain relief     X X X 
Sleep quality X    X X X 
SF-36 X    X X X 
Study Medication 
Infusion1 
 X   X   
Vital Signs2  X   X X  
Concomitant 
Medication 
X X X X X X X 
Adverse Events X X X X X X X 
Legend to table 1:  
1. Medications given over 2 consecutive days at baseline and over 1 day every 3 weeks thereafter. 
Treatment is allowed to be prolonged up to 4 or 2 days respectively for reasons of tolerability. 
2. Vital signs (blood pressure and heart rate) to be taken right before infusion, 30 minutes after starting 
infusion, and immediately after infusion completed. 
3. Visit to be conducted after completion of entire baseline infusion (Day 2, 3, or 4 depending on 
duration of baseline infusion). 
4. Visit to be conducted 3-6 days after completion of the baseline infusion, not 3-5 days after 
baseline/Day 1 infusion began. 
5. The follow-up period will be performed by standardized telephone call interviews. 
QST = quantitative sensory testing, PI-NRS = pain intensity numerical rating scale, PGIC = patients’ global 
impression of change,  RT-SFN-SIQ = Rasch-transformed small fiber neuropathy symptoms inventory 
questionnaire, NPS = neuropathic pain scale, SFN-RODS = small fiber neuropathy Rasch-built overall disability 
outcome scale, SF-36 = short form 36 health survey. 
 
Statistical analysis 
Sample size 
One point change on the PI-NRS compared to baseline is considered as the minimum clinically 
important difference (MCID), according to unified rule of ½ x SD and recommendations given 
by the IMMPACT group.38, 43 In the placebo group we assume a response rate of approximately 
25% in the placebo treated group, based on a meta-analysis of the placebo effect in pain 
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studies in which the effect varied from 7-37%, and where 16% of the patients had a pain 
reduction of 50%.32 In the IVIg treated group we assume a response rate of approximately 60% 
based on the IMMPACT criteria.38 
 
Table 2. Study flow chart – laboratory assessments 
 Screening Treatment phase End of 
Treatment 
Follow-
up5 
Lab assessment - 10 days 
(Day -10 
to Day 0) 
Week 0 
Baseline/ 
Day 1 
Completion 
of baseline 
infusion 
(Day 2 or 3 
or 4) 
3-6 Days 
after 
completion 
of baseline 
infusion 
Week 
3,6,9 
(± 3 
days) 
Week 
12 (± 3 
days)  
Month  
4, 5, 6 
Immunofixation  X       
Pregnancy Test (Serum 
β HCG) 
X       
TSH1 / regular T4 X       
Fasting blood glucose, 
vitamin B122 
X       
Serum Retain3 X     X  
Urinalysis X   X    
IgG4  X X4 X X X  
Hematology/CBC 
(hematocrit, 
hemoglobin, WBC, RBC, 
platelets) 
X X  X X X  
Creatinine, Blood urea 
nitrogen  
X X  X X X  
AST/ALT, LDH, 
potassium, bilirubin, CK 
 X X4  X X  
Gamma-GT  X X4 X  X  
Legend to table 2: 
1. TSH to be conducted at screening if results not available since SFN diagnosis. Regular T4 
automatically run by LabCorp if TSH determined to be above the upper limits of normal. 
2. To be conducted at screening if results not available since SFN diagnosis. 
3. 2 aliquots required at screening (one for viral retain and one for possible future antibody testing); 1 
aliquot required at both Week 12 (for possible future antibody testing). 
4. Samples to be obtained immediately after completion of entire baseline infusion. If the entire 
baseline infusion is completed in 2 days, then samples are to be collected post-infusion on Day 2. If 
the entire baseline infusion is completed in 3 or 4 days, then samples are to be collected post-
infusion on Day 3 or 4 respectively. 
5. The follow-up period will be performed by standardized telephone call interviews. 
 
Fixing a one-sided alpha at 5%, a sample size of 24 patients per treatment group would be 
required to show efficacy with 80% power and an effect size of 60% between the two groups 
(Chi-squared test). Accounting for a dropout rate of approximately 20% (six patients), a total 
of 30 subjects per treatment group will be included in this study. 
 
Type of analysis 
The primary efficacy comparison is the comparison of the proportion of responders in the per-
protocol-population where a responder is defined as ≥ 1 point improvement in the mean 
weekly peak pain measured with the PI-NRS (maximum pain) during the 12 weeks treatment 
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period after first study drug infusion compared to baseline, using Kaplan-Meier curves (log rank 
test). The following sensitivity analyses will be performed. The primary efficacy analysis will be 
repeated in the per-protocol population using a more strict definition of a responder:  a 
‘responder of ≥ 2 points’ is defined as ≥ 2 points improvement in the PI-NRS at the last 
evaluation following the first study drug infusion during the blinded 12 weeks treatment period 
compared to baseline.  
In the intention to treat (ITT) population the following additional sensitivity analyses will be 
performed: Any subject who drops out with at least the week 6 PI-NRS assessment with their 
last mean weakly peak pain on the PI-NRS will be carried forward. A subject dropping out 
before the week 6 PI-NRS assessment or any subject with no baseline PI-NRS will be counted 
as non-responder independent of the last PI-NRS. Furthermore, in the ITT population the 
following sensitivity analyses will be performed. The analysis will be repeated using a more 
strict definition of a responder: a ‘responder of ≥ 2 points’ is defined as ≥ 2 points improvement 
in the PI-NRS at the last evaluation following the first study drug infusion during the blinded 12 
weeks treatment period compared to baseline. Subjects with no baseline or no post baseline 
PI-NRS assessment will be counted as non-responder in this analysis.  
When there are missing values, we will use multiple imputation based on a regression method, 
using SPSS (IBM Corp. Released 2015. IBM SPSS Statistics for Macintosh, Version 22.0. Armonk, 
NY: IBM Corp) or Stata (StataCorp. 2013. Stata Statistical Software: Release 13. College Station, 
TX: StataCorp LP). 
The differences between the per-protocol-analyses and the ITT-analyses will give a good 
impression of the bias that might occur in the study. Comparing these two methods, we can 
make a clear picture of the two populations and can investigate the true effect of IVIg in the 
most reliable way. 
The secondary efficacy variables will be tested for treatment group differences by analyses of 
covariance (ANCOVAs) with baseline measurement as covariate and the difference of the last 
post-baseline measurement in the treatment period relative to baseline as an independent 
variable (treatment group as fixed factor). In case no post-baseline measurement is 
documented, the baseline measurement will be used as the last post-baseline measurement. 
This analysis is an endpoint analysis using the ‘last observation carried forward’ (LOCF) 
approach.  
 
Discussion 
In this study, the efficacy and safety of IVIg is evaluated in patients with skin-biopsy proven 
idiopathic SFN. This will be the first randomized, placebo-controlled, double-blind clinical trial 
with IVIg versus placebo in patients with SFN.  
In previous case studies with patients diagnosed with SFN and an underlying autoimmune 
disease (such as sarcoidosis, Sjögren’s syndrome and celiac disease), IVIg has shown to be 
effective on chronic pain.20, 21, 24 Besides, in chronic refractory pain in general, pain reduction 
after IVIg treatment has been described,23 suggesting immunological mechanisms may play a 
role in the development or maintenance of pain, even if no clear immunological disorders are 
present.  
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One of the limitations of the study is that the specific mechanism of action of IVIg is not known, 
making it hard to predict which patients will have benefit of the treatment. A second limitation 
might be that the treatment period of three months is too short to obtain effect.  Third, 
patients will be kept stable on their current pain treatment, which could be of influence. 
However, stopping current pain medication would be ethically difficult.  
In SFN, a better treatment is warranted, since currently available (neuropathic) pain 
medication does not relief pain substantially and often have a lot of side effects.44 For IVIg both 
a complementary and diminishing acting on the immune system have been described.45 In SFN, 
probably an activated immune system is causing inflammatory responses to the small nerve 
fibers, which can be diminished by IVIg.  
Positive findings of IVIg treatment in SFN will result in a new treatment option and may support 
an immunological role in this condition. 
 
Trial status 
Participant recruitment will start at the half of 2016. 
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Neuropathic pain in patients with small fiber neuropathy (SFN) is difficult to control. To provide 
more specific treatments, with higher efficacy and fewer side effects, more knowledge is 
needed regarding the underlying pathophysiological mechanisms and conditions related to 
SFN. This thesis provides insight in the incidence of underlying SFN conditions in a large cohort 
of patients and presents data on potential mechanisms related to SFN, which is reflected in 
some studies investigating possible targeted therapeutic approaches in this debilitating 
condition. In the following, a summary of the chapters in this thesis will be provided, followed 
by future perspectives highlighting some caveats and unsolved needs in SFN. 
 
Summary and general discussion. 
Chapter 1 is an introduction in which general information about SFN is presented. The anatomy 
and function of the peripheral nerves is briefly described. Subsequently, the symptoms and 
diagnosis of SFN are clarified. In literature, various diseases have been suggested being related 
to SFN. These conditions and, specifically, the role of voltage-gated sodium channels are 
discussed. Finally, the current approach, from diagnostic to therapeutic management of 
neuropathic pain is addressed. The aims and outline of the thesis are presented in this chapter 
as well. 
 
Associated conditions in SFN and pathophysiological mechanisms 
SFN is a condition that reflects the complaints related to small nerve fiber damage. It is a 
“horrible condition that drives some patients crazy due to the excruciating continuously 
ongoing pain”, as pointed out by a patient and agreed upon by many others suffering from 
SFN.  Key questions are why specifically these nerve fibers get damaged and what the possible 
underlying pathophysiological mechanism would be. Various articles have been written 
regarding the possible underlying causes potentially related to SFN. Numerous diseases have 
been mentioned to be causal to SFN, however, most of these being based on cohort studies or 
case studies without providing any pathophysiologic evidence to develop SFN. For most of the 
diseases mentioned in literature potential treatments are available, justifying the need to test 
patients with SFN for the presence of such potentially related conditions. However, extensive 
diagnostic testing in SFN is not always the solution, and physicians should examine the burden 
to patients and related costs on the one hand, versus the benefits of an elaborative diagnostic 
approach on the other hand. 
 
Chapter 2 illustrates elegantly the disadvantages of standard execution of additional tests 
having little if any benefit at all. Fabry disease is a metabolic disease that results in an 
accumulation of globotriaosylceramide (lyso-GB3) in different cell types, including the heart, 
kidneys, skin, and also neurons.1,2 Some patients with Fabry disease suffer from burning or 
shooting pains in hands and feet. Therefore, it was thought that SFN could be the first symptom 
of Fabry disease as has been previously reported.1-5 In a large cohort of patients (n=725) with 
pure SFN, we investigated the presence of Fabry disease and found no patients with this 
concomitant illness.6 This finding suggests that pure SFN is unlikely to be the first expression 
of Fabry disease in adult patients, which contradicted literature on the presence of Fabry in 
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pure SFN.7,8 Screening for Fabry disease in patients with SFN leads to high health care costs 
and may even provide confusing test results within a patient when one of the diagnostic tests 
turn out to be inconclusive, while the others are negative. Hence, we conclude that in patients 
with pure SFN, without other signs or symptoms of Fabry disease (like cardiac involvement, 
kidney involvement, or skin abnormalities), the screening for Fabry disease can be left out. 
However, this should always be chosen with great care, since this illness is treatable. It is 
suggested to re-evaluate those patients with additional involvement of other organs during 
evaluation over time and reconsider this testing if needed.  
 
Patients that were referred to our center with the suspicion of SFN, have not only been tested 
for Fabry disease, but also for many other potentially related conditions based on literature 
review as presented in Table 1.8-18  
The absence of Fabry disease in our cohort of patients with SFN triggered the thought of 
investigating the prevalence of other conditions too, which is presented in Chapter 3. In the 
SFN cohort (n=921), the most prevalent conditions were: autoimmune diseases (including 
abnormal immunological laboratory findings) in 19% of the patients, sodium channel gene 
variants (including variants with uncertain clinical significance, possibly pathogenic, probably 
pathogenic or pathogen variants)19 in 16.7%, diabetes mellitus in 7.7%, impaired glucose 
tolerance in 9.7%, and vitamin B12 deficiencies in 4.7%. All of these conditions were more 
prevalent than reported in the general Dutch population. Besides, even though some patients 
already had a known condition related to SFN before screening, additional underlying 
conditions related to SFN were found in 26.7% of these patients.20  
 
These findings are considered the first step in investigating the relationship between SFN and 
most prevalent underlying conditions found. More research is suggested to investigate and 
provide knowledge on the pathophysiology and mechanisms behind this relationship. This 
might eventually lead to more targeted treatments, as are discussed in chapters 5-7. Even 
though there are a lot of conditions present in patients with SFN, in the cohort of the study no 
underlying condition could be found in 53% of the patients, which is congruent with reported 
literature.14,21-23 The findings also tell us that even though someone may have an illness that 
might contribute to SFN (e.g. diabetes mellitus) one should still examine the patient for other 
additional conditions that may co-contribute to its existence.  
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Table 1. Underlying conditions of SFN mentioned in literature. 
 
Metabolic 
Diabetes mellitus 
Impaired glucose tolerance 
Rapid glycaemic control 
Hyperlipidaemia 
Hypo-/hyperthyroidism 
Chronic kidney disease 
Vitamin B12 deficiency 
 
 
 
 
 
 
Infectious 
Human immunodeficiency virus 
(HIV) 
Hepatitis B/C 
Leprosy 
Lyme disease 
Epstein-Barr virus 
Influenza 
Critical illness or severe sepsis 
Herpes simplex infection 
Mycoplasma pneumonia 
Rubella 
Antecedent viral infection 
Syphilis 
Rabies vaccination 
Varicella 
Diphtheria 
Chagas disease 
Botulism 
 
Hereditary 
Sodium channel gene mutations 
Primary erythermalgia 
Fabry disease 
Haemochromatosis 
Familial amyloidosis 
Hereditary sensory autonomic 
neuropathies 
Autosomal recessive hereditary 
neuropathy 
Pompe disease 
Ross syndrome 
Tangier disease 
Friedreich ataxia 
Cerebrotendinous 
xanthomatosis 
Familial burning feet syndrome 
Spinocerebellar Ataxia 3 
Charcot-Marie-Tooth 
Mitochondrial disease 
Acute intermittent porphyria 
Generalized anhidrosis 
 
 
Immune-mediated 
Sarcoidosis 
Sjögren syndrome 
Celiac disease 
Inflammatory bowel disease 
Monoclonal gammopathies 
Systemic lupus erythematosus 
Paraneoplastic neuropathy 
Rheumatoid or psoriatic arthritis 
(Primary) Amyloidosis 
Chronic inflammatory 
demyelinating 
polyradiculoneuropathy (CIDP) 
Vasculitis 
Guillain-Barré syndrome 
Autoimmune autonomic 
ganglionopathy 
Scleroderma 
Behcet disease 
Churg-Strauss syndrome 
Anti-sulfatide antibodies 
Anti-trisulfated heparin 
disaccharide antibodies 
 
Neurotoxic exposure 
Alcohol abuse 
Chemotherapeutic agents  
Antiretroviral agents 
Pyridoxine (vitamin B6) 
intoxication 
Statins 
Antiarrhythmic drugs 
(flecainide, amiodarone) 
Antibiotics (metronidazole, 
nitrofurantoin, linezolid, 
ciprofloxacin) 
Industrial, environmental, and 
marine toxins (including heavy 
metals like thallium and lead)  
Ingestion of Clostridium 
botulinum toxin 
Tumour necrosis factor α 
inhibitors 
 
 
Idiopathic 
Idiopathic small fiber 
neuropathy 
Burning mouth syndrome 
Fecal urgency and rectal 
hypersensitivity 
Complex regional pain 
syndrome 
 
 
 
Other 
Fibromyalgia 
Parkinson disease 
Postural orthostatic tachycardia 
syndrome 
Restless legs syndrome 
 
Legend to table 1. This tables summarizes all the different conditions that are mentioned in the literature to be 
associated with SFN. 
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For some of the above-mentioned conditions, data have been provided regarding a 
pathophysiological mechanism leading to small nerve fibers damage. Some of these conditions 
are briefly discussed in the following:  
- Diabetes mellitus (DM) is one of the best-known underlying diseases of painful 
neuropathies. It is believed that hyperglycemia-mediated superoxide overproduction may 
lead to micro vascular complications via various pathways.24 But also other mechanisms of 
action are described, like an increase in inflammatory markers in the dorsal root ganglia 
(DRG).25 However, even though these mechanisms might explain how the small nerve 
fibers are damaged, it still leaves us with some questions. Part of the patients with diabetes 
mellitus will develop a painful neuropathy as a complication of the disease, while others 
develop a non-painful neuropathy, and another subset does not develop a neuropathy at 
all. Moreover, next to neuropathic pain, also nociceptive pain occurs in DM.26 Nociceptive 
pain is a result of injury of tissues, for example because of ischemia damaging the blood 
vessels and tissues. Which factors contribute to the susceptibility for developing a painful 
neuropathy are largely unknown. This also illustrates that a condition may be related to 
SFN, but may not directly cause SFN.27 
- Sodium channels play an important role in neuropathic pain. The SCN9A-, SCN10A-, and 
SCN11A-gene are encoding for Nav1.7, Nav1.8, and Nav1.9 respectively, which are 
preferentially expressed in the peripheral nerves and the DRG neurons. Gain-of-function 
mutations in these genes are found in around 15% of the patients with SFN20,28 and can 
cause increased firing frequency and spontaneous firing of the neurons of the DRG.29-34 
These changes may lead to a decreased neurite length, but no DRG neuron death occurs.29 
 
Even though the screening of underlying conditions in patients with SFN is very comprehensive, 
in half of the patients, no conditions can be found and these patients are still idiopathic after 
an extensive diagnostic work up.20-22 This might suggest that there are still unknown 
internal/external mechanisms that cause damage to the small nerve fibers, such as other gene 
mutations leading to hyperexcitable neurons or intracellular deficits leading to a disturbed 
axonal transport.  
 
Treatment of neuropathic pain in SFN 
About 5-10% of the general population is suffering from neuropathic pain,35 which is caused 
by a disease or lesion that affects the somatosensory nervous system.36 Patients with SFN are 
suffering from excruciating neuropathic pain, having a negative impact on their quality of life.37 
Therefore adequate treatment is desirable. There are different types of drugs that are used to 
reduce the symptoms of SFN, i.e. anticonvulsants, antidepressants, opioids, and topical agents. 
In chapter 4, the different therapeutic possibilities are mentioned with their known 
pathophysiological aspects, side effects and precautions. Especially in the elderly, a large 
proportion of patients with SFN (19% begins at the age of 65 years or older), the treatment is 
more challenging because of frequent comorbidity and the use of co-medication.38 Therefore, 
other first-line treatments or another regimen of use of neuropathic agents might be 
considered compared to younger patients.  
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Even though several drugs are available for the treatment of neuropathic pain, and practical 
treatment algorithms are available, still only 50% of the patients have demonstrated a 50% 
reduction of their pain experience, often with disturbing side effects.38,39 One of the crucial 
things is that all these medications are not very specific and are only used to reduce the 
symptoms, but not heal the patients or the small nerve fibers’ damage. Therefore, we are in 
desperate need for new and more targeted treatment options.  
 
Lacosamide is an anticonvulsant that selectively acts on the sodium channel Nav1.3, Nav1.7, 
and Nav1.8. Next to this selectivity in sodium channels, lacosamide spares the channels with a 
normal activity and only inhibits the currents of hyperexcitable neurons. Thereby, it binds to 
the channels with a slow- or fast-inactivated state.40-46 Lacosamide has not been tested before 
in patients with SFN. In studies with painful diabetic neuropathy however, a reduction in 
neuropathic pain was found, although not robust.47-50 In chapter 5, the rationale and the design 
of the Lacosamide-Efficacy-‘N’-Safety in SFN (LENSS-study) is explained in detail.  
The LENSS-study was a randomized, double-blinded, placebo-controlled crossover trial. The 
primary objective of this study was to evaluate the efficacy of lacosamide versus placebo in 
subjects with SCN9A-associated SFN. The primary efficacy endpoint was defined as at least a 
1-point decrease on the daily pain intensity numerical rating scale (PI-NRS) and the secondary 
efficacy endpoint at least a 2-point decrease. These efficacy outcomes were chosen as such 
based on the IMMPACT recommendations.51 Other secondary objectives were the evaluation 
of the safety and tolerability of lacosamide, and the effect of lacosamide versus placebo on 
autonomic symptoms, daily sleep interference, and quality of life.  
To assure that the study results could be interpreted with sufficient power and because SCN9A-
associated SFN is relatively rare, a crossover trial design was chosen. Another advantage of the 
crossover design was that the influence of confounders (e.g. age, gender distribution) could be 
reduced, since every patient will be his/her own control, an extremely important entity in a 
heterogeneous condition like SFN. Patients were given a dose of 200mg BID of lacosamide (and 
placebo in the other treatment period). This dose was selected based on previous studies, 
where it was shown that 200mg BID was effective and the side effects were acceptable, in 
contrast to a dose of 100mg BID which had few side effects but was less effective and 300mg 
BID which was effective however caused a lot of side effects.52 The treatment period for both 
lacosamide and placebo had duration of eight weeks. This was chosen because of the 
knowledge that the analgesic effect of the pain medication may take several weeks to occur.53  
 
In Chapter 6 the results of the LENSS-study are described.54 In total 24 patients received 
lacosamide and 23 of them placebo. In 58.3% the average pain decreased with at least 1 point 
on the PI-NRS during the lacosamide period, compared to 21.7% during the placebo period (p-
value = 0.0045, with an odds ratio of 5.65 and a 95% confidence interval of 1.83-17.41). A 
decrease of at least 2 point on the PI-NRS was found in 33.3% in the lacosamide period and in 
8.7% in the placebo period (p-value = 0.0244, with an odds ratio of 10.58 and a 95% confidence 
interval of 1.63-68.63). Additionally, in the lacosamide group, 33.3% reported that their 
general condition improved, versus 4.3% in the placebo group (p-value = 0.0156), captured 
with the Patients’ Global Impression of Change (PGIC) questionnaire. Other secondary 
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outcomes showed that there was a significant positive effect on the daily sleep interference 
and there was a significant decrease in surface pain. In contrast, there was no significant 
improvement on quality of life or autonomic symptoms. The most common side effects of 
lacosamide were dizziness (41.7%), nausea (25.0%), and headache (25.0%), which is in 
agreement with the known adverse event profile reported, although these were addressed as 
being mild.52 However, these complaints were also the most frequent adverse event during 
the placebo period (17.4% for all three complaints). Furthermore lacosamide was safe to use.  
The results of this study are in line with the clinical experience that the current treatment 
possibilities cause a 50% reduction of the complaints in 50% of the patients.39,55 Based on the 
theoretical background of the working mechanism of lacosamide on this specific group of 
patients, a larger effect could be expected. Even though the effect was similar than in other 
drugs, in our study patients were allowed to continue most of their pain medication, and 
therefore the treatment effect may even be bigger in drug-naïve patients. Whether lacosamide 
is also beneficial in SFN patients without SCN9A mutations, remains to be investigated. 
One can also question if the right outcome measure has been used to investigate the efficacy 
of the medicine. For this study, the primary efficacy endpoint was at least 1-point decrease on 
the PI-NRS, based on guidelines for painful neuropathic studies.51 There are a lot of different 
outcome measures regarding measuring the effect on pain, the 1-point or 2-point decrease on 
the PI-NRS can be used, but also a 30% or 50% reduction from baseline on the PI-NRS is 
mentioned.51 Perhaps we should not look at these numbers since these are simple ordinal 
metrics with no numerical value, but we have to start listening to our patients and take their 
response’s addressing voices into account. A patient score going from 8 to 7, does not per se 
mean anything, since the patient may still feel terrible. Or what if a patient’s pain goes from 6 
to 5, but they feel much better? Therefore, we should focus more on patients’ response 
questionnaires like the Patients’ Global Impression of Change (PGIC) addressing the clinical 
meaningfulness of their personal experience rather than looking at these insignificant numbers 
or multidimensional scales.56 57 
In the LENSS study, no significant effect of lacosamide on the autonomic symptoms was found. 
An explanation could be that the side effects that are caused by using lacosamide mask the 
effect of lacosamide on the autonomic symptoms, because they are comparable; for example, 
dizziness is an autonomic symptom, but also a side effect of lacosamide. So the questionnaire 
to register autonomic symptoms might be influenced by the presence of similar side effects.  
The influence of small fiber neuropathy on the quality of life of these patients has been 
investigated earlier.37 The biggest declines were found in the domains of physical role of 
functioning and body pain.37 By decreasing the intensity of pain in these patients with 
lacosamide, it could be expected that the quality of life would increase because the role of 
body pain would decrease. However, in this study this was not found, not even in the pain 
domain, which could be explained by a study period that was too short (8 weeks) to notice a 
significant reduction in quality of life. 
To conclude, the study showed that lacosamide is an effective, safe and tolerable treatment 
for SCN9A-associated SFN. However, the study has to be confirmed in a larger cohort and in 
patients without an SCN9A-variant before proposing the therapeutic use of this drug.  
Chapter 8 
150 
The LENSS-study is an example of a study that investigates a drug that is more targeted than 
other current available treatment possibilities for SFN. However, a targeted approach is only 
possible when the target is known. As mentioned earlier, in a large proportion of patients with 
SFN no underlying conditions have been found. However, the question is what to do if there is 
no defined underlying condition? In patients with SFN, a role of the immune system is 
suggested in those with associated diseases, such as sarcoidosis, Sjogren disease, and celiac 
disease.23,58,59 Also the presence of inflammatory changes,60 autoantibodies,61,62 and elevated 
cytokines63 provide some support for the hypotheses that in SFN the immune system plays an 
important role, even in absence of immune-mediated diseases. Without knowing the specific 
disturbance in the immune system, there are treatment possibilities based on this hypothesis. 
Based on literature review, some open-labelled studies in patients with painful neuropathies 
treated with intravenous immunoglobulin (IVIg) have shown substantial relief, justifying the 
exploration of IVIg as a new treatment modality in SFN in a more extensive manner.64,65 
 
Chapter 7 describes a randomized, double-blinded, placebo-controlled, parallel study 
evaluating the efficacy and safety of IVIg in patients with predominant SFN complaints.66 The 
study design has been adopted from the landmark paper of IVIg in the treatment of patients 
with chronic inflammatory demyelinating polyradiculoneuropathy (ICE trial),67 starting with a 
loading dose of IVIg of 2g/kg body weight given over 2-5 days. After that, patients will be 
receiving a maintenance dose of 1g/kg body weight IVIg every three weeks for three months, 
with an extension period after the randomization period of three months to determine the 
long-term effect of IVIg on pain. This is the first randomized clinical trial that will be 
investigating the efficacy, safety, and tolerability of IVIg in patients with idiopathic SFN. Patients 
randomized to placebo, will get the same treatment regimen. The study is currently running 
and aims to include 60 patients. The primary outcome will be a 1-point decrease change in the 
PI-NRS from baseline. Secondary outcomes will be 2-point decrease change in the PI-NRS from 
baseline, the influence of IVIg on autonomic symptoms, daily sleep interference, and quality of 
life. Because all of these outcome measures are based on questionnaires, also an objective 
outcome measure has been included, namely the cornea confocal microscopy.68 This is a 
technique that can detect nerve fiber loss but also nerve fiber regeneration, investigated 
thoroughly in patients with diabetes mellitus.69,70 In this sub-study, only patients with an 
abnormal skin biopsy and no underlying conditions (idiopathic SFN) will be examined. If IVIg is 
proven to be effective, more insight could be obtained to examine the underlying 
pathophysiology in patients with idiopathic SFN. 
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Future perspectives 
In this thesis, more insight is provided regarding the underlying conditions that are prevalent 
in patients with SFN. In addition, new treatments are investigated, not only to give more 
possibilities for patients to reduce their complaints, but also to gain more insight into the 
pathophysiology of SFN. So all studies that are described in this thesis contribute to the 
knowledge on SFN, but also generate more research questions, which can be investigated in 
the future. 
 
Diagnostics and clinical outcome measures 
The complaints of SFN are mostly subjective feelings, which are difficult to measure objectively. 
At the moment, skin biopsy and temperature threshold testing are used to confirm the 
diagnosis of SFN.9,18 However, the intensity of pain, different pain sensations, quality of life, 
and autonomic symptoms should all be evaluated by questionnaires because of the lack of an 
objective measurement. This could lead to biased results, as mentioned above in the LENSS 
study, where the influence of lacosamide on autonomic symptoms might be influenced by the 
occurrence of side effects, which are not differentiated through the questionnaire. Future 
studies should aim to develop a tool that can measure the autonomic function.  
In addition to objectifying more symptoms of SFN, it would be very worthwhile to have a 
diagnostic tool, which can be used in clinical trials.  
Skin biopsy is used at the moment as the golden standard to diagnose SFN, together with the 
temperature threshold testing. However, the sensitivity of the skin biopsy is moderate. When 
the intraepidermal nerve fiber density (IENFD) is normal in patients with possible SFN, it could 
suggest that there is no SFN, but it is also possible that there is a pre-degenerative functional 
impairment of the small nerve fibers, which cannot be detected with the current skin biopsy 
method. It is known that the IENFD decreases with increasing age71 and the IENFD is stable 
within a 3-week period and for right and left side.72 The decreasing IENFD in aging might be 
due to the aging of the central nervous system.73 
A small study investigated the longitudinal trend of the IENFD in patients with idiopathic SFN 
(n=25), found no different degree of decrease in IENFD compared to patients with SFN and 
diabetes mellitus or glucose intolerance.74 It would be of interest to compare the decrease in 
IENFD in patients with (complaints of) SFN and healthy subjects. Besides, the proximal/distal 
IENFD ratio can give more insight and be of value for diagnosing SFN.75 Currently, the distal 
IENFD is used for diagnosing SFN. The ratio between the proximal and distal IENFD is 
investigated sparsely. One study showed that there was a greater reduction in the IENFD of 
the distal leg compared with the thigh, resulting in an elevated proximal/distal IENFD ratio, 
compared to healthy controls.76,77 The use of the longitudinal course of the distal IENFD and/or 
the use of the proximal/distal IENFD ratio, in addition to the current one-time distal IENFD 
might be an enrichment for the diagnostic workup for SFN.  
Skin biopsy is an invasive, time-consuming and expensive method for diagnosing SFN. In the 
Bowman’s membrane of the cornea, the nerve endings of the unmyelinated C-fibers from the 
trigeminal nerve can be seen.78 Corneal confocal microscopy (CCM) is a non-invasive method 
that detects these nerve fibers and nerve fiber loss in the cornea, with a high repeatability.79 
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This method has been primarily applied in patients with diabetes mellitus.80 In two small 
studies, a decrease in the corneal nerve fiber density was found in patients with SFN.69,81 
Subsequently, it was also shown that CCM was not only useful to prove nerve fiber loss, but 
also nerve fiber regeneration after pancreas and kidney transplantation in patients with 
diabetes mellitus.70 Therefore, CCM might be useful as a diagnostic tool to diagnose (non-
length-dependent) SFN, and perhaps also as an objective outcome measure in clinical trials. 
Because of this, the CCM was included in the IVIG in SFN study. 
All of the above-mentioned methods are based on the peripheral mechanisms that are known 
in SFN. However, this focus should be widened to also understand other potential 
pathophysiological mechanisms of pain in these patients like the (central) processing of pain 
stimuli. This entity is thought to be very complex, including different regions of the brain, like 
the cortex, subcortical structures and the midbrain.82 In addition, chronic pain may lead to 
structural changes in the brain.83 The pattern of these changes may differ among different pain 
syndromes and may be reversible.84 Functional imaging of the brain has shown specific brain 
activity patterns in patients with pain.85,86 To date, there is no objective tool to measure pain, 
but only questionnaires are available like the neuropathic pain scale (NPS), Pain Intensity 
Numeric Rating scale (PI-NRS), or the Visual Analogue Pain Scale (VAS). Functional MRI (fMRI) 
data can provide more insight into the specific pathways of neuropathic pain in SFN. 
Additionally, the fMRI can possibly be used in the future as a biomarker for evaluation in clinical 
trials. This technique may also elucidate differences that might reflect the heterogeneity of 
SFN, as has been demonstrated in patients with migraine.87   
The finding of new biomarkers could be very helpful in conditions like SFN.88 With the finding 
and presence of biomarkers, patients can be stratified in different groups, new treatment 
targets arise, and more personalized treatments can be given.89 Besides, specific biomarkers 
can create an opportunity to grade disease severity, which is not possible at current stage.  
In the literature some biomarkers are linked to neuropathic pain. Post-transcriptional regulator 
molecules, microRNAs, are reported to be dysregulated in patients with pain.90 MicroRNAs are 
crucial micro-modulators of normal cellular homeostasis, and dysregulation has been 
associated with different conditions such as cancer,91 cardiovascular diseases,92 and 
neurodegenerative disorders.93 In animal pain models, microRNA modulation is present in 
different levels, like the sciatic nerve, DRG, spinal dorsal horn and the brain.90 Additionally, it 
has been found that microRNAs control sodium channel expression.94 Besides the finding that 
microRNAs have a potential of being a specific biomarker for neuropathic pain, it could possibly 
also create new therapeutic possibilities, as shown in animal models.95,96 Because microRNAs 
are present in all biofluids, it can be searched for in patients with SFN in the blood or in the 
cerebrospinal fluid as is done in other pain conditions.97,98  
Also cytokine-related biomarkers have been found in neuropathic pain, for example anti-tumor 
necrosis factor (TNF)-α. Upregulated TNF-α is believed to play a role in the development, 
facilitation, and maintenance of neuropathic pain.99-103 Thereby, it is shown that agents that 
antagonize TNF-α can reduce pain-behavior in animal models.104,105  
A totally different biomarker that is mentioned in literature, is objectifying the hyperexcitability 
of the small nerve fibers, for example with microneurography. The finding that in patients with 
neuropathic pain due to peripheral neuropathy a large proportion of the nociceptors had a 
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significant ongoing activity, led to the hypothesis that microneurography could be a biomarker 
for pain.106 Microneurography can record the peripheral C-nociceptors in humans and 
aminals,107 which make it an interesting method to be used in clinical trials. 
A targeted approach can be used to search for the above-mentioned biomarkers in SFN. An 
untargeted approach can also be considered, although this has some advantages and 
disadvantages. This cohort of patients is probably very heterogeneous, which might make it 
very difficult to find a specific biomarker, compared with subgroups (for example idiopathic 
SFN patients with abnormal skin biopsy). However, this group is very suitable because of the 
large sample size for modern statistical techniques, like machine learning with which 
biomarkers can be identified out of large datasets.108,109 
To find these biomarkers, different methods are described, for example metabolomics or 
proteomics. Metabolomics is the profiling of metabolites, with nuclear magnetic resonance 
spectroscopy,110 mass spectrometry,111 gas chromatography,112 or liquid 
chromatography.113,114 The analysis can be targeted (quantitative analyses of a substrate or 
product metabolites of a target protein), untargeted (overview of whole-cell metabolic 
patterns), or metabolic profiling can be performed (quantitative analyses of a set of pre-
defined metabolites). Proteomics is the quantitative analyses of the composition of proteins in 
a cell, tissue, or organism. 
A recent study investigated metabolomics and proteomics in sciatic nerves in diabetic and 
healthy control rats. Alterations in the metabolic lipids were found, which were more present 
distal than proximal. In addition, increased proteins were found in the sural nerve and not more 
proximal.115 These findings gave more insight in the consequences of diabetes mellitus and the 
influence on the nerve fibers. This is one example of how metabolomics or proteomics can 
provide more insights in underlying pathophysiological mechanisms, but may also reveal 
specific biomarkers.  
In many diseases, the correlation between subjective and objective measures is weak.116 
Thereby, subjective measurements are highly variable and therefore only really useful when 
the effect of an intervention is large. The invention of objective tools to measure the function 
of the nerve fibers or autonomic symptoms or the discovery of biomarkers is therefore an 
important step. However, we should also focus on the opinion of the patients and listen to 
what they have to say. What does improvement of a biomarker following treatment mean if 
the patient is still having the same complaints? Do we conclude that our treatment is effective 
or not? Therefore, we should, besides objective measurements, include the opinion of the 
patient (like the PGIC). Or maybe the disability and functionality of patients should be taken 
more into consideration, with for example the small fiber neuropathy Rasch-built overall 
disability (SFN-RODS) as an option.117 Moreover, the opinion of the patient should also be used 
in designing studies, making decisions, and evaluating treatments. With this we can shift our 
focus from statistical significance to clinical relevance.118 Shared-decision making is defined as 
an approach where patients and clinicians share the best available evidence in order to make 
a decision, where patients are supported to consider different options and point out their 
preference.119,120  
Lately, shared-decision making is more and more used in clinical practice. However, it has been 
known for a long time that patients prefer to have experts perform the problem-solving tasks, 
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but wish to take an active role in decision making.121 Shared-decision making was first proven 
to be effective in serious or life-threatening conditions, when different therapies exist with 
different benefits and risks.122,123 Shared decision-making is also useful in situations where 
outcomes are uncertain. For neuropathic pain, current treatment possibilities are not 
satisfactory at the moment, as discussed earlier. Therefore, when patients with SFN start using 
one of these therapies, the result is uncertain (trial and error approach). It is shown that the 
implementation of shared-decision making in pain management will increase the satisfaction 
of patients.124,125 Because pain is a multidimensional entity, shared-decision making could lead 
to a more bearable experience of their complaints. 
In studies, quantitative data is often used without the presence of qualitative data. 
Quantitative data consists of close-ended information, such as rating scales and other 
questionnaires. On the other hand, qualitative data consists of open-ended information that is 
gathered for example by interviews and focus groups. The addition of qualitative data can be 
used to elaborate, clarify, or build on findings from other methods, but also for looking at a 
research question from different angels, for example from a patients perspective or other 
caregivers. With this we can evaluate why patients think their quality of life is diminished, or 
which other things they experience because of SFN. Or focus groups with clinical experts from 
different disciplines can be organized, to develop new ideas, insights or theories. So for some 
research questions a single research method might not be enough.126 Mixed methods analyses 
are used to combine these two types of data by triangulation.127 The combination provides 
strengths that can neutralize the weaknesses of both quantitative (weak knowledge of context) 
and qualitative (biased interpretations) research. 
Mixed methods analyses and shared-decision making are two examples in which patients and 
physicians are ‘forced’ to talk and listen to each other. However, also the communication 
between patients themselves should be stimulated. Patient can give advice or share 
experiences with each other. It would be beneficial to create a platform in which patients can 
be in contact with each other, but also caregivers and physicians should be a part of this. 
Working together can on the one hand improve the patient care, but on the other hand also 
gain new ideas or insights. In epilepsy, for example, it is shown that an online platform benefits 
in finding other patients experiencing the same symptoms and learning more about the 
symptoms and treatments.128 
In line with this, one could also think about making a mobile application wherein patients can 
monitor their complaints, for example with questionnaires or diaries. 
 
Associated conditions and pathophysiology 
To confirm if some underlying conditions, which are found in patients with SFN, are really a 
cause of the disease, more studies should be conducted. In diabetes mellitus, a lot of animal 
studies are already performed.129-131 This should also be executed (more) for other conditions 
like vitamin B12 deficiencies and autoimmune disorders. When knowing the exact underlying 
pathophysiology of these conditions, this could lead to possible treatment options. The 
advantage of interfering with these pathways with for example targeted drugs, is that the 
disease could possibly be solved and the nerve fibers can be regenerated, instead of symptom 
reduction as we do with our current practice. 
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When potential underlying mechanisms are hypothesized, animal models can give evidence 
for this. For example, mouse models can be used, in which some mice are exposed to the 
hypothesized underlying mechanism, and the others don’t. After that, differences can be 
visualized, like pain, anxiety, and distress.132 It would also be interesting to investigate if all 
animals exposed to that mechanism develop the same complaints. Animal models can also be 
used to see the effect of different levels of biomarkers, again to prove their causality.133 In 
models for sodium channel gene mutations, often zebra fish are being used.134 In these, 
transfected lines can be created, with the mutation of interest, and compared to the wild types. 
On the one hand, these animal models can be used to search and prove underlying 
mechanisms. On the other hand, they are of importance for testing different treatment 
possibilities. 
The finding of mutations in the sodium channels Nav1.7,32 Nav1.8,33 and Nav1.9,34 was a large 
breakthrough in SFN, and has led to more insight in the pathophysiology, and to new treatment 
possibilities, for example with pharmacogenomics.135 In addition, this has led to the idea that 
maybe other sodium channels or other mechanisms might also be responsible for neuropathic 
pain in SFN. In DRG, sodium channels Nav1.3 and Nav1.6 are also present and seem to have a 
role in pain as well.28,136-140 
However, sodium channels are working together with other channels and have some 
corresponding characteristics. Potassium and calcium channelopathies have also been 
associated with pain.141 
To investigate which other gene mutations are present in patients with chronic neuropathic 
pain, next generation sequencing (NGS) like whole exome sequencing (WES) or whole genome 
sequencing (WGS) can be used as an untargeted approach, while the analysis of candidate 
genes can be a useful targeted method. The PROPANE study group aimed to identify why 
patients with a common associated condition can have different phenotypes, for example a 
painful or painless neuropathy in patients with DM. The findings of this study will be published 
soon, hopefully providing us more insights into the genetic background.34,142 The advantage of 
WES analyses is that not only preselected variants can be found, so it is an example of an 
unbiased molecular-genetic approach.143 With this, new insights can be gained and a possible 
explanation for the 50% of idiopathic patients can be found. However, WES analyses also have 
disadvantages. With this technique, various variants will be found in even only one person. 
When searching for common variants in a cohort, even more different results will arise. For 
this, again machine learning or clustered data analyses can solve this, to search for correlations 
even between different variants in relation to patient’s personal determinants like age, gender, 
educational level, habits, occupation, etc. 
Although sodium channel gene mutations have been proven to be responsible for the clinical 
picture in a proportion of patients suffering from SFN, it is remarkable that there is a marked 
clinical heterogeneity between these patients, even when the same mutation is found.144 
Furthermore, in some patients a trigger (like a viral infection, trauma, operation, severe 
exercise, pregnancy of vaccination) precedes the clinical symptoms. Since all these factors 
demand a lot of energy of the body, dysfunction of mitochondria might be an explanation. In 
case the energy supply or reserves are not sufficient, this may lead to nerve damage. Both in 
the central and in the peripheral nervous system neurons have a high-energy demand, which 
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is reflected by the high number of mitochondria in these cells.145 Especially unmyelinated 
neurons and the nerve endings contain mitochondria.146,147 Dysfunctional mitochondria or a 
disturbed migration of healthy mitochondria to the nerve endings can result in a disturbance 
of different steps in the oxidative phosphorylation. Peripheral neuropathic pain has been 
shown to be a result of ATP-depletion, an elevation of free radicals or inadequate calcium 
buffering in the cell.146 When the ATP-production is too low this might lead to a dysfunctional 
Na+/K+-pump, leading to abnormal firing of the neurons.147 A combination of a high sodium 
influx in sodium channel gene mutations and dysfunctioning mitochondria, will lead to a 
reverse-mode Na+/Ca2+ exchange because of the increased intracellular sodium level, resulting 
in import of calcium into the cell, rising to toxic levels and causing cell death.148-150 
But also defects in the mitochondrial dynamics might contribute to the origin of SFN. Since 
most patients show a length-dependent pattern, disturbances in the axonal transport or 
mitochondrial fusion or fission could be responsible for the nerve endings damage.150-152 
Already, in other hereditary neuropathies of the Charcot-Marie-Tooth spectrum these 
mechanisms have been shown to be pathogenic.151 Both DNA-analysis of mtDNA or nuclear 
DNA responsible for the mitochondrial dynamics genes might be of interest in SFN. 
Also epigenetic mechanisms might play a role in the pathophysiology of SFN.153 These 
mechanisms can enhance or suppress gene expressions, without altering the primary DNA 
sequence.154 This may explain why some people are carrying for example an SCN9A-gene 
mutation, without having complaints, while a different person with the same variant does have 
complaints of SFN. It may also provide the explanation for the development of SFN symptoms 
later in life in patients carrying a sodium channel gene mutation. Epigenetics may therefore be 
an important link between acquired and hereditary causes.  
 
Treatment  
There is high demand for new treatment possibilities. The current available medications are 
not effective in all patients and have side effects that can be very bothersome. 
At this time, more targeted treatments are being investigated. Lacosamide is a sodium channel 
blocker that is selectively blocking sodium channels Nav1.3, Nav1.7, and Nav1.8.42 At present, 
sodium channel blockers with a high selectivity for Nav1.7 are being investigated. Such a 
selective sodium channel blocker was studied in trigeminal neuralgia.155 Even though this was 
a Nav1.7-selective and state-dependent sodium channel blocker, the response in pain 
reduction was again similar as the current medications, a 50% reduction in paroxysms in 60% 
of the patients with the use of the selective sodium channel blocker, compared to 21% in the 
placebo group. In addition to the comparable pain effect, additionally side effects occurred 
similar to the side effect profile of current available medications, e.g. headache and dizziness. 
So it might be a utopia to expect that a selective and targeted approach always will lead to 
better efficacy and fewer side effects. This might be explained by the idea that some underlying 
conditions of SFN are not causative alone, and thereby other pathways play a role at the same 
time.  A more recent study investigated a different Nav1.7 blocker in a randomized, placebo-
controlled, double-blinded study.156 However, this agent showed no statistically significant 
decrease in the average pain score. Besides, the effect was even lower than seen in pregabalin 
study. The past years, a lot of patents are treated with sodium channel blockers.157 The future 
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will show if this is the right direction and the solution for patients with SFN. One could also 
speculate whether studies combining different agents could provide via different action 
mechanisms more relief to the experience of pain.  
Until now, it is still unclear why some patients respond to treatment and others don’t. For this, 
it would be very useful to have some patient-specific factors known that influence the drug 
response. A recent study started to search for associations between underlying conditions and 
the response on neuropathic pain medication. They found that diabetes mellitus had an impact 
on the effect of anticonvulsants and the duration of pain had an impact on the effect of 
antidepressants on neuropathic pain.158  
The genetic and functional findings in SFN may lead to the development of new targeted 
treatments. This can also be supported by pharmacogenomics. As mentioned earlier, not all 
patients with SFN respond to the current available treatments in the same way and even the 
side effects differ between patients. Pharmacogenomics may be an additional tool to predict 
the variability in treatment efficacy and side effects.159 A few experiments already showed that 
with pharmacogenomics, it could be predicted if the hyperexcitability of nerve fibers due to a 
specific SCN9A mutation is reduced by a specific treatment, or not.160,161 With these results, 
eventually prediction models can be developed to be used in daily clinical practice. In the long 
term, this may lead to higher satisfaction of the patients and lower health care costs. However, 
when it is predicted that a specific treatment should work in specific patients, naturally this 
should still be proven in practice, as for example is done in patients with erythromelalgia.162 
Targeting the sodium channels may be of interest in patients having mutated channels (about 
15% of the patients), though other patients may also benefit from sodium channel blockers. In 
over 50% of the SFN patients no underlying condition can be found. However, for new 
treatment possibilities for these idiopathic patients, we should think about possibilities that 
are beyond the current knowledge of the pathophysiology. One of these new ideas is the use 
of intravenous immunoglobulins in SFN. The results of the IVIg in SFN study will become 
available in 2019. If positive, a lot of new research questions will arise, to figure out how this 
treatment works in these patients, which patients would benefit, and what treatment regime 
should be used and for how long. To ensure health insurance coverage and registration of IVIg 
as a treatment option for patient with SFN, clear evidence of the efficacy should be available, 
and probably future confirmation studies should also investigate the cost-effectiveness of this 
treatment. In extension to this study, the benefit of other immunomodulating therapies in SFN 
may also be hypothesized  
Corticosteroids are working via various mechanisms, for example inhibition of the T-cell-
dependent immunity and interfering with cytokines of which TNF-α is an example.163 As 
mentioned earlier, there are suggestions that TNF-α is a biomarker in neuropathic pain, so 
corticosteroids might be effective. An example from current practice is the use of prednisone 
in patients with post-herpetic pain,164 as well as reduction of the pain resulting from a vasculitic 
neuropathy in HIV.165 There are also studies that investigate the role of biologicals as an 
alternative for chemical substances in chronic pain. Monoclonal antibodies (mAbs) are very 
specific and have a high affinity.166 However, the mAbs should attack the right targets to be 
effective. There are mAbs that inhibit TNF-α, interleukin-1 or interleukin-6, in immune-
mediated conditions as rheumatoid arthritis. Therefore, it should be investigated if these are 
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still effective in diminishing non-inflammatory pain.167 Biologicals can provide more specific 
and therefore safer alternatives in the future, though the high costs of these therapies are a 
limit to wide-spread use. 
To take it one step further, maybe not only chemical or biological agents should be investigated 
more in the future, but it would be of interest to look more in depth into interventional 
methods, or combinations of these. Spinal cord stimulation could lead to a reduction of pain 
in chronic pain patients, based on the gate control theory and general principles of segmental 
pain inhibition.168-170 Or, should we even move more upwards, to the brain, for new 
interventions? It is hypothesized that abnormal synchronization between brain networks in 
chronic pain can be disrupted by deep brain stimulation DBS.171 Finally, repetitive transcranial 
magnetic stimulation is a noninvasive neuromodulation technique, which can possibly improve 
the efficacy of conventional medical treatments in chronic pain patients.172  
Besides trying to treat SFN or diminish the symptoms, attention should be given to the 
consequences of the symptoms on patients’ wellbeing. As described earlier, patients with SFN 
have a decreased quality of life,37 but also affective disorders like anxiety or depression have a 
high prevalence.173 High levels of depression and anxiety may worsen pain and pain-related 
disability.174 Therefore, trials regarding the effect of interventions focused on mood disorders 
or coping with pain are of great interest. Mindfulness therapy has been described to improve 
pain, as well as depression symptoms and quality of life.175 Furthermore, several trials have 
been performed with graded exposure or graded activity therapy in chronic pain, for example 
in chronic back pain.176,177 There is some evidence that both of them may be effective, 
however, these therapies are not tested yet in patients with SFN.  
The oldest known non-pharmacological method for relieving pain is music.178 Pain can be 
diminished by passive music listening, called music-induced analgesia. Thereby, music can also 
diminish stress, depression and distress.179 Even a 70% greater probability of reporting a pain 
decrease of at least 50% and a reduction in opioid medication as a result of music listening is 
reported.179 In addition, changes on functional MRI are found.178 
In patients with chronic neuropathic spinal cord injury pain, it is found that multidisciplinary 
cognitive behavioral programs improved pain intensity, pain-related disability, anxiety and 
participation.180 So finally, why use only one method, when combining therapeutic strategies 
(figure 1) might be even better?181 
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Figure 1. Multimodal treatment possibilies and shared-decision making.
Legend to figure 1. This figure represents the mulitmodal treatment possibilities and shared-decision making in 
SFN.
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Conclusions 
SFN is a condition resulting in a heterogeneous cohort of patients. Not only the complaints can 
differ between patients, there is also a variety of underlying conditions that can possibly cause 
damage to the small nerve fibers. However, in a substantial part of the patients no underlying 
potential cause can be demonstrated. The knowledge that some conditions are more prevalent 
in patients with SFN compared to healthy subjects, like diabetes mellitus (including impaired 
glucose tolerance), autoimmune diseases (including abnormal immunological laboratory 
findings), sodium channel gene mutations, and vitamin B12 deficiencies, could lead to more 
specific research in the future. Unraveling the exact pathophysiological pathways behind these 
conditions leading to SFN perhaps may lead to better treatment options. As an example, the 
finding of sodium channel gene mutations, led to a more selective treatment with lacosamide, 
which can be used possibly in the future as a treatment option for a broader group of patients 
with SFN after confirmative studies have been performed. More specific treatments might 
result in better pain relief with fewer side effects. However, new insights may also lead to the 
finding that SFN might not be caused by one mechanism on its own, but it is a more complex 
process. In all cases, other multimodal new therapeutic strategies should be considered in the 
approach of SFN, as it is a debilitating disorder. 
As already mentioned in the introduction of this thesis, our aim is to work from the perspective 
of the patients, searching for associated conditions and biomarkers, revealing the 
pathophysiological mechanisms behind this, which may lead to new treatment possibilities; 
the entire process should be evaluated with the patients, and this cycle can then be repeated. 
From bench to bedside and back again: translational research is of great importance to finally 
rule out SFN. 
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Dunnevezelneuropathie (DVN) is een aandoening waarbij pijn op de voorgrond staat. Dit is het 
gevolg van een beschadiging van de aller dunste zenuwvezels (dun-gemyeliniseerde Aδ-vezels 
en ongemyeliniseerde C-vezels), die normaal gesproken voor de registratie van pijn en 
temperatuur zorgen. Bij DVN ervaren patiënten neuropathische pijn, die meestal in de voeten 
begint. Daarnaast kan DVN ook autonome klachten veroorzaken, zoals duizeligheid, droge 
ogen, maag- en darmklachten en hartkloppingen. De combinatie van deze klachten leidt vaak 
tot een sterke verminderde kwaliteit van leven.  
De diagnose DVN wordt gesteld op basis van typische klachten, in combinatie met een 
verlaagde intra-epidermale zenuwvezeldichtheid in het huidbiopt en/of een afwijkend 
temperatuurdrempelonderzoek. De behandeling is meestal symptomatisch, waarbij het vaak 
lastig is de neuropathische pijn onder controle te krijgen. Om meer specifieke behandelingen 
aan te kunnen bieden, met een hogere werkzaamheid en minder bijwerkingen, is meer kennis 
nodig omtrent de onderliggende pathofysiologische mechanismen en aandoeningen die 
geassocieerd zijn met DVN. Dit proefschrift geeft inzicht in de incidentie van onderliggende 
aandoeningen bij DVN in een grote groep patiënten met daarbij de mogelijke onderliggende 
mechanismen. Op basis hiervan zijn twee studies opgezet om een meer gerichte behandeling 
voor deze invaliderende aandoening te onderzoeken.  
 
Hoofdstuk 1 is een introductie waarin algemene informatie over DVN wordt gegeven. De 
anatomie en functie van de perifere zenuwen wordt kort beschreven. Vervolgens worden de 
symptomen en de diagnose van DVN uitgelegd, zoals ook kort hierboven besproken is. In de 
literatuur worden verschillende aandoeningen in verband gebracht met DVN. Deze 
aandoeningen en in het bijzonder de rol van spanningsafhankelijke natriumkanalen worden 
besproken. Ten slotte wordt de huidige aanpak beschreven van diagnose tot de behandeling 
van neuropathische pijn. 
 
Geassocieerde aandoeningen bij DVN en pathofysiologische mechanismen 
DVN is een aandoening waarbij klachten ontstaan door beschadiging van de dunne 
zenuwvezels. Een patiënt beschreef het als: "vreselijke aandoening die sommige patiënten gek 
maakt vanwege de ondraaglijke, voortdurend aanhoudende pijn", waar vele anderen die lijden 
aan DVN zich in  herkennen. De vraag is waarom specifiek deze dunne zenuwvezels beschadigd 
raken en wat het mogelijke onderliggende pathofysiologische mechanisme zou kunnen zijn. Er 
zijn diverse artikelen geschreven over onderliggende aandoeningen die gerelateerd zouden 
kunnen zijn aan DVN. Verschillende ziekten zijn genoemd als oorzaak van DVN, maar dit is 
meestal gebaseerd op kleine cohortstudies of casestudies zonder dat pathofysiologisch bewijs 
is geleverd over hoe dit leidt tot DVN. Voor een aantal aandoeningen die in de literatuur 
worden genoemd, zijn mogelijke behandelingen beschikbaar, wat het rechtvaardigt om 
patiënten met DVN op de aanwezigheid van deze aandoeningen te testen. Voor diagnostische 
testen moeten de lasten voor de patiënten en de bijbehorende kosten afwegen tegen de 
voordelen van een uitgebreide diagnostische aanpak. 
 
Hoofdstuk 2 toont de nadelen van het standaard uitvoeren van aanvullende testen die weinig 
of geen toegevoegde waarde hebben. De ziekte van Fabry is een metabole ziekte die resulteert 
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in een opeenstapeling van globotriaosylceramide (lyso-GB3) in verschillende cellen, waaronder 
cellen van het hart, de nieren, de huid en ook de zenuwen. Sommige patiënten met de ziekte 
van Fabry lijden aan brandende of schietende pijn in handen en voeten. In de literatuur wordt 
beschreven dat DVN een eerste symptoom van de ziekte van Fabry kan zijn. Aangezien de 
aandoening behandelbaar is, zou testen voor deze aandoening van belang kunnen zijn. In een 
groot cohort van patiënten (n = 725) met pure DVN (zonder beschadiging van de dikke 
zenuwvezels), hebben we bij niemand de ziekte van Fabry aan kunnen tonen. Deze bevinding 
suggereert dat pure DVN waarschijnlijk niet de eerste uiting van de ziekte van Fabry bij 
volwassen patiënten is, in tegenstelling tot wat er eerder in de literatuur werd vermeld. 
Screening op de ziekte van Fabry bij patiënten met DVN leidt tot hoge kosten voor de 
gezondheidszorg en kan zelfs verwarrende testresultaten opleveren bij een patiënt, wanneer 
bijvoorbeeld één van de diagnostische testen een twijfelachtige uitslag geeft en de rest goed 
is. Daarom concluderen we dat bij patiënten met pure DVN, zonder andere tekenen of 
symptomen van de ziekte van Fabry (zoals betrokkenheid van het hart, nieren of 
huidafwijkingen), de screening op de ziekte van Fabry kan worden weggelaten. Dit moet echter 
altijd met de grootste zorg worden besloten, aangezien het een behandelbare ziekte betreft. 
Het voorstel is om de patiënten die in de loop der tijd betrokkenheid van andere organen 
ontwikkelen opnieuw te evalueren en eventueel dan alsnog te testen. 
 
Patiënten die naar ons centrum worden verwezen met het vermoeden van DVN, worden niet 
alleen getest op de ziekte van Fabry, maar ook op vele andere potentieel gerelateerde 
aandoeningen op basis van literatuuronderzoek (hoofdstuk 3). In het DVN-cohort (n = 921) 
waren de meest voorkomende aandoeningen: auto-immuunziekten (inclusief afwijkende 
immunologische laboratoriumuitslagen) bij 19% van de patiënten, natriumkanaalmutaties 
(inclusief varianten met onzekere klinische betekenis, mogelijk pathogene, waarschijnlijk 
pathogene of pathogene varianten) bij 16,7%, diabetes mellitus bij 7,7%, gestoorde 
glucosetolerantie bij 9,7% en vitamine B12-tekort bij 4,7%. Al deze aandoeningen kwamen 
meer voor dan beschreven in de algemene Nederlandse bevolking. Hoewel bij sommige 
patiënten al voorafgaand aan de screening een aandoening aanwezig was die gerelateerd is 
aan DVN, werd alsnog bij 26,7% van deze patiënten een andere onderliggende aandoening 
aangetroffen. 
 
Bovenstaande bevindingen zijn de eerste stap in het onderzoek naar de relatie tussen DVN en 
de meest voorkomende onderliggende aandoeningen. Meer onderzoek is nodig om kennis te 
verkrijgen over de mogelijke onderliggende pathofysiologische mechanismen. Dit kan 
uiteindelijk leiden tot meer gerichtere behandelingen, zoals besproken in hoofdstuk 5-7. 
Hoewel verschillende aandoeningen bij patiënten met DVN voorkomen, kon in het cohort van 
de studie bij 53% van de patiënten geen onderliggende aandoening worden gevonden, wat 
overeenkomt met eerder gerapporteerde studies. De bevindingen van de studie laten ook zien 
dat, hoewel iemand misschien een ziekte heeft die kan bijdragen aan DVN (bijv. diabetes 
mellitus), een patiënt nog steeds moet worden onderzocht op andere onderliggende 
aandoeningen. 
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Voor sommige van de bovengenoemde aandoeningen is al wat bekend over het 
pathofysiologisch mechanisme dat leidt tot beschadiging van dunne zenuwvezels.  
- Diabetes mellitus (DM) is een van de bekendste onderliggende aandoeningen bij 
pijnlijke neuropathieën. Er wordt verondersteld dat hyperglycemie-gemedieerde 
superoxide-overproductie op verschillende manieren kan leiden tot microvasculaire 
complicaties. Maar ook andere werkingsmechanismen worden beschreven, zoals een 
toename van inflammatoire markers in de dorsale ganglia (DRG). Hoewel deze 
mechanismen kunnen verklaren hoe de dunne zenuwvezels beschadigd raken, het laat 
nog steeds enkele vragen onbeantwoord. Slechts een deel van de patiënten met DM 
ontwikkelt een pijnlijke neuropathie als een complicatie van de ziekte, terwijl anderen 
een niet-pijnlijke neuropathie ontwikkelen, en een ander deel helemaal geen 
neuropathie ontwikkelt. Bovendien treedt, naast neuropathische pijn, ook nociceptieve 
pijn op bij DM. Nociceptieve pijn is een gevolg van een beschadiging van weefsels, 
bijvoorbeeld vanwege een verminderde doorbloeding die de bloedvaten en weefsels 
beschadigt. Welke factoren zorgen voor de ontwikkeling van een pijnlijke neuropathie 
zijn grotendeels onbekend. Dit laat ook zien dat een aandoening mogelijk gerelateerd 
is aan DVN, maar dat het DVN mogelijk niet direct veroorzaakt. 
- Natriumkanalen spelen een belangrijke rol bij neuropathische pijn. Het SCN9A-, 
SCN10A- en SCN11A-gen coderen respectievelijk voor de natriumkanalen Nav1.7, 
Nav1.8 en Nav1.9, die voornamelijk tot uiting komen in de perifere zenuwen en de 
dorsale ganglioncellen. Gain-of-function-mutaties in deze genen werden gevonden bij 
ongeveer 15% in een DVN cohort en kunnen leiden tot een verhoogde frequentie van 
vuren en spontaan afvuren van de neuronen van de DRG. Deze veranderingen kunnen 
leiden tot een afname van de lengte van de zenuwen. 
Hoewel de screening naar onderliggende aandoeningen bij patiënten met DVN zeer uitgebreid 
is, wordt bij de helft van de patiënten geen onderliggende aandoening gevonden. Bij deze 
patiënten is de oorzaak ondanks uitgebreid diagnostisch onderzoek nog steeds onbekend, wat 
idiopathische DVN genoemd wordt. Waarschijnlijk spelen bij deze groep patiënten voor nu nog 
onbekende interne en/of externe mechanismen een rol bij het ontstaan van schade aan de 
dunne zenuwvezels. Hierbij kan gedacht worden aan mutaties in andere genen of verstoringen 
in het axonaal transport. 
 
Behandeling van neuropathische pijn bij DVN 
Ongeveer 5-10% van de algemene bevolking lijdt aan neuropathische pijn, die wordt 
veroorzaakt door een ziekte of beschadiging die het somatosensorische zenuwstelsel aantast. 
Patiënten met DVN lijden aan ondraaglijke neuropathische pijn, welke een negatieve invloed 
heeft op hun kwaliteit van leven. Daarom is een betere behandeling erg gewenst. Er zijn 
verschillende soorten medicijnen die worden gebruikt om de symptomen van DVN te 
verminderen, waaronder anticonvulsiva, antidepressiva, opioïden en lokale behandelingen. In 
hoofdstuk 4 worden de verschillende behandelingsmogelijkheden benoemd met hun bekende 
werkingsmechanismen, bijwerkingen en voorzorgsmaatregelen. Bij 19% van de patiënten met 
DVN beginnen de klachten op een leeftijd van 65 jaar of ouder. Vooral bij ouderen is de 
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behandeling van DVN uitdagender vanwege vaker voorkomende comorbiditeit en het gebruik 
van co-medicatie.  
Hoewel verschillende medicijnen beschikbaar zijn voor de behandeling van neuropathische 
pijn heeft slechts 50% van de patiënten een pijnreductie van 50%, waarbij daarnaast vaak 
vervelende bijwerkingen aanwezig zijn. Een van de redenen voor deze teleurstellende 
resultaten is dat de huidige medicijnen niet erg specifiek zijn en alleen worden gebruikt om de 
symptomen te verminderen, maar niet om de patiënten of de beschadiging van de dunne 
zenuwvezels te genezen. Daarom is er dringend behoefte aan nieuwe en meer gerichte 
behandelingsmogelijkheden. 
 
Lacosamide is een medicijn dat wordt gebruikt bij de behandeling van epilepsie. Lacosamide 
werkt specifiek op het natriumkanaal Nav1.3, Nav1.7 en Nav1.8. Naast de werking op deze 
specifieke natriumkanalen, bespaart lacosamide de kanalen met een normale activiteit en remt 
het alleen de overactieve zenuwen. Het bindt aan de kanalen met een langzame of snel-
geïnactiveerde toestand. Lacosamide is nog niet eerder getest bij patiënten met DVN. In 
studies met pijnlijke diabetische neuropathie werd een vermindering van neuropathische pijn 
gevonden, hoewel deze resultaten niet heel overtuigend waren. In hoofdstuk 5, wordt de 
motivering en het ontwerp van de Lacosamide-Efficacy-‘N’-Safety in SFN (LENSS-studie) in 
detail uitgelegd. 
De LENSS-studie was een gerandomiseerde, dubbel-geblindeerde, placebo-gecontroleerde 
cross-over studie. Het primaire doel van deze studie was om de werkzaamheid van lacosamide 
versus placebo te evalueren bij patiënten met SCN9A-geassocieerde DVN. Het primaire 
eindpunt om de werkzaamheid te testen, werd gedefinieerd als een daling van ten minste één 
punt op de numerieke beoordelingsschaal voor de dagelijkse pijnintensiteit (PI-NRS) ten 
opzichte van baseline. Het secundaire eindpunt om de werkzaamheid van lacosamide te 
testen, was een afname van ten minste 2 punten. Deze uitkomstmaten voor de werkzaamheid 
werden als zodanig gekozen op basis van de IMMPACT-aanbevelingen. Andere secundaire 
doelstellingen waren de beoordeling van de veiligheid en verdraagbaarheid van lacosamide en 
het effect van lacosamide versus placebo op autonome klachten, dagelijkse invloed van pijn op 
het slapen en de kwaliteit van leven. 
Omdat SCN9A-geassocieerde DVN zeldzaam is, werd gekozen voor een cross-over design. Een 
ander voordeel van het cross-over design was dat de invloed van andere bijdragende factoren 
(bijvoorbeeld leeftijd en geslacht) kon worden verminderd, omdat elke patiënt zijn/haar eigen 
controle was. Dit is belangrijk omdat DVN een heterogene aandoening is. In de studie kregen 
patiënten tweemaal daags een dosering van 200 mg lacosamide (en placebo in de andere 
behandelingsperiode). Deze dosering werd gekozen op basis van eerdere onderzoeken, 
waarbij werd aangetoond dat tweemaal daags 200 mg lacosamide effectief was en de 
bijwerkingen aanvaardbaar waren. Daarentegen bleek dat een dosering van 100 mg tweemaal 
daags minder effectief te zijn met weinig bijwerkingen en dat een dosering van 300 mg 
tweemaal daags effectief was maar veel bijwerkingen veroorzaakte. De behandelingsperiode 
voor zowel lacosamide als placebo was acht weken. Dit werd gekozen vanwege het feit dat het 
pijnstillende effect van de medicatie enkele weken kan duren. 
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In Hoofdstuk 6 worden de resultaten van de LENSS-studie beschreven. In totaal kregen 24 
patiënten lacosamide en 23 van hen placebo. Bij 58,3% nam de gemiddelde pijn af met 
tenminste 1 punt op de PI-NRS tijdens de lacosamide-periode, vergeleken met 21,7% tijdens 
de placebo-periode. Een afname van de gemiddelde pijn van ten minste 2 punten op de PI-NRS 
werd gevonden bij 33,3% van de patiënten in de lacosamide-periode en bij 8,7% in de placebo-
periode. Bovendien rapporteerde 33,3% in de lacosamidegroep dat hun algemene toestand 
verbeterde, versus 4,3% in de placebogroep, gemeten met de Patients’ Global Impression of 
Change (PGIC). Andere secundaire uitkomsten toonden aan dat er een significant positief 
effect was van lacosamide op de dagelijkse invloed van pijn op slaap en dat er een aanzienlijke 
afname van de oppervlakkige pijn was. Er was geen significante verbetering van de kwaliteit 
van leven of autonome symptomen. De meest voorkomende bijwerkingen van lacosamide 
waren duizeligheid (41,7%), misselijkheid (25,0%) en hoofdpijn (25,0%), wat overeenkomt met 
de bekende gerapporteerde bijwerkingen van het medicijn; deze bijwerkingen werden als mild 
beschouwd. Deze bijwerkingen waren ook de meest frequente tijdens de placebo-periode 
(17,4% voor alle drie de klachten). Bovendien was lacosamide veilig om te gebruiken. 
De resultaten van deze studie zijn in overeenstemming met de klinische ervaring dat de huidige 
behandelingsmogelijkheden een 50% vermindering van de klachten geven bij 50% van de 
patiënten. Een groter effect werd verwacht, op basis van de theoretische achtergrond van het 
werkingsmechanisme van lacosamide op deze specifieke groep van patiënten. In onze studie 
konden patiënten voor het grootste deel hun eigen pijnmedicatie blijven gebruiken. Daarom 
zou het behandelingseffect van lacosamide misschien zelfs groter kunnen zijn bij patiënten die 
(nog) geen medicatie gebruiken. Of lacosamide ook effectief is bij DVN-patiënten zonder 
SCN9A-mutaties moet nog worden onderzocht. 
Een vraag is of de juiste uitkomstmaat is gebruikt om de werkzaamheid van het medicijn te 
onderzoeken. Voor deze studie was het primaire eindpunt om de werkzaamheid te meten ten 
minste 1 punt afname van de gemiddelde pijn op de PI-NRS, gebaseerd op richtlijnen voor 
studies naar pijnlijke neuropathieën. Er zijn veel verschillende uitkomstmaten voor het meten 
van het effect op pijn, de 1-punts of 2-punts afname van pijn op de PI-NRS kan worden gebruikt, 
maar ook een vermindering van 30% of 50% ten opzichte van de baseline op de PI-NRS wordt 
vermeld. Deze schalen hebben als nadeel dat het ordinale maten zijn; de getallen die worden 
gegeven hebben dus geen numerieke waarde. Dat maakt rekenen met dergelijke getallen niet 
goed mogelijk. Bovendien weten we niet goed wat een klinisch relevant verschil is. Wanneer 
een pijnscore van een patiënt van een 8 naar een 7 gaat, betekent dat op zichzelf niets, omdat 
de patiënt zich nog steeds verschrikkelijk kan voelen. Of wat als de pijn van patiënten van 6 
naar 5 gaat, maar ze voelen zich veel beter? Daarom moeten we ons meer richten op de 
klinische betekenis van de persoonlijk ervaring van patiënten, zoals gemeten met de PGIC, in 
plaats van onbelangrijke getallen of multidimensionele vragenlijsten te gebruiken. 
In de LENSS-studie werd geen significant effect van lacosamide op de autonome symptomen 
gevonden. Een verklaring zou kunnen zijn dat de bijwerkingen die worden veroorzaakt door 
het gebruik van lacosamide het effect van lacosamide op de autonome symptomen maskeren, 
omdat ze vergelijkbaar zijn. Zo is duizeligheid bijvoorbeeld een autonome klacht, maar ook een 
bijwerking van lacosamide. De vragenlijst om autonome symptomen te registreren kan 
daarmee zijn beïnvloed door de aanwezigheid van vergelijkbare bijwerkingen. 
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De invloed van dunnevezelneuropathie op de kwaliteit van leven van deze patiënten is eerder 
onderzocht. De sterkste verminderingen van de kwaliteit werden gevonden in de domeinen 
van fysieke rol van functioneren en lichaamspijn. Door de pijnintensiteit met lacosamide te 
verlagen, zou het te verwachten zijn dat de kwaliteit van leven toeneemt omdat de invloed van 
lichaamspijn op de kwaliteit van leven zou afnemen. In deze studie werd dit echter niet 
gevonden, zelfs niet in het pijndomein. Dit kon mogelijk verklaard kon worden doordat de 
studieperiode van 8 weken te kort was om een significante vermindering van de kwaliteit van 
leven op te merken. 
 
Tot slot toonde de studie aan dat lacosamide een effectieve, veilige en goed te verdragen 
behandeling is voor SCN9A-geassocieerde DVN. Het onderzoek moet echter worden bevestigd 
in een groter cohort en bij patiënten zonder een SCN9A-variant voordat het gebruik van dit 
medicijn kan worden aanbevolen als algemene behandeling bij DVN. 
De LENSS-studie is een voorbeeld van een onderzoek dat een geneesmiddel onderzoekt dat 
specifieker gericht is dan andere momenteel beschikbare behandelingsmogelijkheden voor 
DVN. Een gerichte aanpak is echter alleen mogelijk als het doelwit ook bekend is. Zoals eerder 
vermeld, worden bij een groot deel van de patiënten met DVN geen onderliggende 
aandoeningen gevonden. De vraag is echter: wat wat als er geen onderliggende aandoening 
wordt gevonden? Bij patiënten met DVN wordt een rol van het immuunsysteem gesuggereerd 
bij patiënten met geassocieerde aandoeningen zoals sarcoïdose, de ziekte van Sjögren en 
coeliakie. Ook de aanwezigheid van inflammatoire veranderingen, auto-antilichamen, en 
verhoogde cytokines, bieden ondersteuning voor de hypothese dat het immuunsysteem bij 
DVN een belangrijke rol speelt, zelfs bij afwezigheid van immuun-gemedieerde ziekten. Een 
aantal open-label studies, waarbij pijnlijke neuropathieën werden behandeld met  
intraveneuze immunoglobulinen (IVIg), tonen een aanzienlijke verlichting van de pijn. Dit heeft 
geleid tot het idee om IVIg als nieuwe behandelingsmethode bij DVN verder te onderzoeken. 
 
Hoofdstuk 7 beschrijft de opzet van een gerandomiseerde, dubbel-geblindeerde, placebo-
gecontroleerde, parallel studie waarin de werkzaamheid en veiligheid van intraveneuze 
immunoglobulinen (IVIg) wordt geëvalueerd bij patiënten met DVN. Het onderzoeksdesign is 
hetzelfde als van een belangrijke studie van IVIg bij de behandeling van patiënten met 
chronische inflammatoire demyeliniserende polyradiculoneuropathie (de ICE trial). In de 
studie wordt gestart met een oplaaddosering van IVIg van 2g/kg lichaamsgewicht gedurende 
2-5 aaneengesloten dagen. Daarna krijgen patiënten elke drie weken een infuus met een 
onderhoudsdosering van 1g/kg lichaamsgewicht IVIg gedurende drie maanden. Daarna 
worden patiënten gedurende drie maanden gevolgd om het lange-termijneffect van IVIg op 
pijn te bepalen. Dit is de eerste gerandomiseerde klinische studie die de werkzaamheid, 
veiligheid en verdraagbaarheid van IVIg bij patiënten met idiopathische DVN zal onderzoeken. 
Patiënten die gerandomiseerd zijn voor placebo, krijgen hetzelfde behandelingsschema. Het 
onderzoek loopt momenteel en heeft als doel 60 patiënten te includeren. De primaire 
uitkomstmaat zal een 1-puntsdaling op de PI-NRS ten opzichte van baseline zijn. Secundaire 
uitkomsten zijn 2-puntsdalingen op de PI-NRS ten opzichte van baseline, de invloed van IVIg op 
autonome symptomen, dagelijkse invloed van pijn op slaap en kwaliteit van leven. Omdat al 
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deze uitkomstmaten gebaseerd zijn op vragenlijsten, is ook een objectieve uitkomstmaat 
meegenomen, namelijk de cornea confocale microscopie. Dit is een techniek die het verlies 
van dunne zenuwvezels en de regeneratie van zenuwen in het hoornvlies kan meten. Deze 
techniek is uitvoerig onderzocht bij patiënten met diabetes mellitus. In deze studie zullen 
alleen patiënten met een afwijkend huidbiopt en zonder onderliggende aandoeningen 
(idiopathische DVN) worden onderzocht. Als aangetoond kan worden dat IVIg effectief is bij 
DVN, kan mogelijk ook meer inzicht worden verkregen om de onderliggende pathofysiologie 
te onderzoeken bij patiënten met idiopathische DVN. 
 
In hoofdstuk 8 worden de resultaten van dit proefschrift ter discussie gesteld en aanbevelingen 
gedaan voor toekomstig onderzoek. 
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Valorization is the utilization of the scientific knowledge in practice and the act of making 
research results appropriate and useful in order to enhance opportunities for others to use 
them.1 It is a process with the aim to create societal impact in any way. This thesis provided 
more knowledge about the underlying conditions and possible treatments for patients with 
small fiber neuropathy (SFN). In this chapter I will discuss the clinical and societal relevance of 
these findings.  
 
Small fiber neuropathy 
Patients with SFN suffer from excruciating neuropathic pain and autonomic symptoms. The 
combination of complaints leads to a severe decrease in quality of life.2 Between 2006 and 
2011, the overall minimum incidence was calculated to be 12 cases /100,000 inhabitants/year 
and the overall minimum prevalence of SFN was 53 cases/100,000.3 The last years, SFN has 
received more attention and recognition, possibly leading to higher incidence and prevalence 
numbers. Because many general practitioners and physicians still do not recognize the 
disorder, patients often visit multiple specialists to search for answers, and it usually takes a 
long time before the diagnosis is confirmed. SFN leads to substantial direct and indirect costs.4,5 
For example, current available treatments only diminish the pain of 50% of the patients, with 
many side effects. This may lead to a long search for the right treatment per patient. Patients 
may be interested in the prognostic information that testing provides, even if it is not used to 
guide treatment.6 Establishing a diagnosis as explanation for unexplained pain may result in 
reassurance, acceptance, understanding, and more insight in their future perspectives.6 In 
contrast, not performing diagnostic testing may lead to a continued search for an explanation, 
with increased medical consumption, resulting in higher costs on the longer term (both medical 
and non-medical, e.g. absenteeism). An adequate diagnosis may also be relevant to patients in 
terms of self-management and positive health.7 
 
Associated conditions in SFN 
There are several studies reporting many different conditions to be associated with SFN. 
However, most of these studies lack evidence for the underlying pathophysiological 
mechanisms. The endless list of associated conditions mentioned in literature leads to a large 
number of diagnostic tests, often with low yield. A proper guideline is needed describing the 
tests that should be performed to cover the conditions that are associated with SFN. For such 
a guideline, knowledge about the prevalence of these diseases in SFN patients is needed. This 
thesis describes the negative and positive consequences of testing different conditions 
mentioned in literature. In some studies, it is claimed that SFN could be a first sign of Fabry 
disease. However, in a large cohort of patients with SFN, no patients were diagnosed with Fabry 
disease. The diagnostics for this condition included three different tests, which led to cases in 
which one of the test had a doubtful result, but the other two tests were negative. These 
results may lead to confusion within and between physicians, but even more to confusion and 
uncertainty for the patient. The costs of these diagnostic tests were high. On the other hand, 
Fabry disease is a treatable disease, which brings up an ethical dilemma when deciding not to 
test patients for this condition. As a follow-up to this study, we investigated the prevalence of 
other conditions based on a literature study in a large cohort of patients with SFN. With these 
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results, we were able to generate recommendations for other physicians regarding additional 
testing in patients with SFN, like diabetes mellitus, glucose intolerance, vitamin B12 deficiency, 
immunological abnormalities, and sodium channel gene mutations. With this information, a 
physician can make a more evidence-based decision on required additional testing.  
There is a growing interest in the hypothesis that early treatment might lead to less 
chronification of pain.8,9 Additionally, screening might lead to early detection of an underlying 
condition, and the possibility to prevent further damage to the nerve fibers. If so, proper and 
early diagnostics are crucial. However, screening tests are only justified when benefits 
outweigh drawbacks.10 A physician should always make a decision based on the benefits for 
the patients on the one hand and the burden (physical and mental) and costs on the other 
hand.  
 
New treatment possibilities for SFN 
The results about the prevalence of underlying conditions in SFN also lead to new research 
questions. The underlying pathophysiological mechanisms are still largely unknown. Better 
understanding of the mechanisms may provide new targets for treatment, with a greater 
probability of pain reduction and less side effects, finally resulting in a better quality of life. This 
would also have a positive effect on reduction of health-related costs.4 
Both the lacosamide (LENSS) study and the IVIg in SFN study are examples of studies that 
investigate the efficacy and safety of specific therapies in SFN, based on the mechanisms of 
action. Although already registered for the treatment of other conditions, both of these agents 
were never tested before in this specific group of patients. 
The LENSS-study provided evidence for lacosamide being an effective treatment option for 
patients with SCN9A-associated SFN. Besides patients with SCN9A-associated SFN (in 8.5% of 
all SFN patients), it is thought that also other patients, without a mutation, may benefit from 
sodium channel blockers, like lacosamide, because sodium channels play an important role in 
the generation and conduction of pain signals in the small nerve fibers. This hypothesis needs 
to be confirmed in a larger cohort of SFN patients without sodium channel gene mutation. At 
the moment, more selective sodium channel blockers are being tested in clinical studies.    
The LENSS-study is an example of targeted treatment that is studied because of the discovery 
of the sodium channel gene mutations in SFN.11-13 However, in around 50% of the patients with 
SFN, no underlying condition can be found at screening, as presented in this thesis. In these 
cases, no targets for treatment are available. In the IVIg in SFN study, we treat idiopathic SFN 
patients with IVIg based on supposed immunological mechanism that might play a role in the 
development of SFN in general. In case the study proves that IVIg is effective in these patients, 
this may lead both to a new treatment possibility and a new mechanisms of action in SFN.  
 
Conclusion 
This thesis provides more knowledge about the underlying conditions associated with SFN. 
These results have led to recommendations for which underlying condition to test. This thesis 
also presents two treatment options with lacosamide and IVIg, also enabling us to gain further 
knowledge about the underlying mechanisms, and possibly leading to more targeted 
treatments in the near future.  
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Zoals Johan Cruijff ooit zei: “alleen kun je niets, je moet het samen doen”. Dit geldt zeker ook 
voor de totstandkoming van dit proefschrift. Niet alleen het onderzoeksteam en collega’s 
hebben ervoor gezorgd dat ik sta waar ik nu sta, maar ook de dierbaren om me heen. Graag 
wil ik in dit hoofdstuk een aantal mensen in het bijzonder bedanken. 
 
Allereerst gaat mijn dank uit naar het Prinses Beatrix Spierfonds en Spierziekten Nederland. 
Zonder de steun van het Prinses Beatrix Spierfonds had ik dit promotietraject niet kunnen doen 
en had de lacosamide studie niet uitgevoerd kunnen worden. Dank dat jullie, net als 
Spierziekten Nederland, zo voor de patiënten klaar staan en voor hun strijden om deze ziekte 
bekender te maken en onderzoeken te financieren. Ook jullie steun aan promovendi zelf is erg 
waardevol en het is erg bijzonder dat zelfs Koninklijke Hoogheid Prinses Beatrix ons persoonlijk 
een warm hart heeft toegedragen. Tevens gaat mijn dank uit naar de patiënten die hebben 
meegedaan aan de verschillende studies. Zonder jullie waren de resultaten van dit proefschrift 
er niet geweest. Dank voor jullie geduld, want helaas duurt onderzoek altijd net wat langer 
duren dan gepland. Ik hoop dat we in de toekomst nog meer vragen kunnen beantwoorden en 
betere behandelingsmogelijkheden hebben. 
 
Mijn allergrootste dank gaat uit naar mijn promotieteam: prof. dr. C.G. Faber, dr. I.S.J. Merkies 
en dr. J.G.J. Hoeijmakers. Jullie ambities, enthousiasme en harde werken is uitzonderlijk. 
Bedankt voor de kansen die jullie me geven en hebben gegeven en jullie geloof in mij. Jullie zijn 
me altijd blijven steunen en hebben me de vrijheid gegeven om aan mezelf te werken en mijn 
eigen ambities te ontdekken. Zonder deze vrijheid en jullie vertrouwen had ik hier nu niet zo 
gestaan. Ik hoop dan ook dat ik nog lang onderdeel mag uitmaken van dit bijzondere team. 
 
Beste Karin, jouw oneindige energie, vrolijkheid en optimisme is noemenswaardig. Daarnaast 
werkt het ook erg aanstekelijk. Toen ik na 3 maanden bij je binnen liep en mijn twijfels uitsprak 
over mijn toekomst als neuroloog, vertelde jij me dat ik op zoek moest naar hetgeen waar mijn 
hart lag. Een beter antwoord had je op dat moment niet kunnen geven. Ik wil je dan ook enorm 
bedanken voor het feit dat je me de ruimte hebt gegeven en me hebt geholpen mijn hart te 
volgen. Ik waardeer je openheid en de warmhartigheid die je uitstraalt naar iedereen om je 
heen. Ook dank voor alle borrels en heerlijke etentjes bij je thuis. 
 
Beste Ingemar, vanaf onze eerste ontmoeting gingen onze gesprekken al snel over 
onderwerpen in de statistiek. Ik denk dat jij als een van de eersten doorhad dat ik erg blij werd 
van discussies omtrent wiskundige berekeningen. Deze passie is alleen maar sterker geworden 
en inmiddels denk ik dat een aardig weerwoord kan leveren in deze gesprekken. Ook heb je 
me een aantal levenslessen bijgebracht in de afgelopen jaren, waaraan ik mezelf zo af en toe 
weer even moet helpen herinneren. Ik hoop dat we onze dromen snel kunnen gaan najagen 
en de (onderzoeks-)wereld kunnen veroveren met onze ideeën. 
 
Beste Janneke, wat was het een eer om jouw onderzoek te mogen voortzetten. Ik weet nog 
dat ik na een maand in dienst te zijn, ontzettend zenuwachtig was om bij jouw verdediging 
aanwezig te zijn. Dit moment zal ik niet meer vergeten. Vanaf toen wist ik dat ik een lange weg 
 190 
te gaan had, maar dat ik een ontzettend sterk en intelligent team om me heen had. Jij bent 
altijd een luisterend oor voor me, ook in periodes waarin ik me wat minder goed voelde. 
Hoewel sommigen vinden dat we samen veel te veel, te snel en van de hak op de tak springend 
praten, wij volgen elkaar perfect. Onze denkpatronen zijn soms angstaanjagend vergelijkbaar. 
Naast collega ben je ook een hele goede vriendin geworden bij wie ik mijn hart kan luchten. Ik 
hoop dat we nog lang samen mogen werken en we nog lang heel hard kunnen lachen om onze 
eigen grappen. 
 
Dear prof. S.G. Waxman, Dr. S.D. Dib-Hajj, and your team of Yale University, thank you for all 
the support in our studies. Although there are many miles in between us, you always respond 
directly to our questions and inspire us with fantastic ideas concerning the role of sodium 
channels in painful neuropathies. I would also like to thank dr. G. Lauria and his team of the 
Carlo Besta institute in Milan for the great collaboration. I am honored to be involved in the 
PROPANE-study and PAIN-Net project. 
 
Hartelijk dank aan de leden van de beoordelingscommissie, prof. dr. C.D. Dirksen, dr. M. 
Bakkers, prof. dr. W.H. Mess, dr. C. Verhamme en prof. dr. R.J. Vermeulen, voor jullie tijd en 
moeite om dit proefschrift te lezen en beoordelen. 
 
Naast mijn promotieteam zou ik heel graag de rest van het neuromusculaire team willen 
bedanken voor hun eindeloze steun en hulp in de patiëntenzorg en het onderzoek. 
 
Zonder Carla Gorissen-Brouwers zouden we nooit zoveel patiënten kunnen zien en konden we 
nooit al deze studies uitvoeren. Lieve Carla, als er iemand is bij wie het hart bij de patiënten 
ligt, ben jij het. Zowel bij dunnevezelneuropathie als myotone dystrofie zijn alle patiënten 
ontzettend blij met je, en terecht! Jij zal altijd alles aan de kant schuiven, inclusief jezelf, om 
nog ergens een patiënt tussen te plannen of te woord te staan. Maar niet alleen voor de patiënt 
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bijhouden van de database. Maar vooral heel veel dank voor alle kopjes thee en uren die we 
samen kletsend hebben doorgebracht.  
 
Na een lange zoektocht, was met name ík erg blij dat Maurice Sopacua zich bij ons team 
aansloot. Lieve Maurice, bedankt voor het overnemen van de PROPANE-studie en al het werk 
dat je hebt verricht. Dank voor het feit dat je altijd wilde inspringen als er iemand ziek was, ik 
met verlof ging of als we planningstechnisch niet uitkwamen. Het is bewonderenswaardig dat 
je alles deed zonder ook maar ooit geklaagd te hebben over de drukte.  
 
Gedurende mijn promotietraject kwam Margot Geerts bij ons team en heeft zij me erg veel 
geholpen tijdens de uitvoering van de medicatiestudies. Lieve Margot, bedankt voor je hulp bij 
alle studies, niet alleen in het zien van de patiënten maar ook in de planning en registratie. Ik 
kan nog veel leren van jouw organisatievermogen. Onze sterke eigen meningen hebben de 
kwaliteit van het onderzoek alleen maar verbeterd.  
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Natuurlijk wil ik ook alle anderen van het huidige onderzoeksteam bedanken. Mariëlle 
Pruppers, ik vond het een eer dat jij mijn eerste studente was, beter had ik het niet kunnen 
treffen en des te leuker dat je nog steeds in ons team bent. Brigitte Brouwer, dank voor je 
positiviteit en goede zorgen voor iedereen om je heen. Tim Draak, dank voor je rust en onze 
interessante brainstormen over Rasch-analyses en MCID. Isis Joosten, dank voor je 
enthousiasme en de inbreng van alle jonge plantjes in de kamer. Amir Far, een meer 
enthousiaste eerste promovendus om te begeleiden had ik me niet kunnen wensen. Karen 
Groot, Celine Goijen, Danielle Jeurissen-Bekkering en Romy Spee, dank voor jullie hulp bij alles 
en jullie gezelligheid in de kamer! 
 
Daarnaast zou ik graag alle medewerkers van de afdeling neurologie met aan het hoofd prof. 
dr. R.J. van Oostenbrugge, inclusief de neurodaycare (afdeling C5), willen bedanken. Alle poli-
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alle studiepatiënten. Ook dank aan het secretariaat van de neurologie, in het bijzonder 
Miranda Gerets, die alle telefoontjes heeft verwerkt en vragen omtrent studies bij de juiste 
persoon wist te krijgen. Speciaal mijn grote dank aan Charlotte van Hoegee en Edith Peeters 
die alle patiënten inplannen en zorgen dat alle onderzoeken gepland staan. Ook wanneer wij 
vragen of misschien nog één extra brief of vragenlijst bij de post kan, is dit nooit een probleem 
voor jullie. Ook dank aan de afdeling klinische neurofysiologie dat jullie zo flexibel zijn om alle 
onderzoeken op een dag te laten plaatsvinden. Tenslotte grote dank aan de afdeling 
pathologie, in het bijzonder Benoit Frere, Aline Kosten en Ilse Driesmans, voor het verwerken, 
kleuren en tellen van alle huidbiopten. 
 
Daarnaast wil ik de afdeling Clinical Genomics en klinische genetica bedanken voor hun 
bijdrage aan de studies. Daarbij wil ik graag prof. dr. H.J.M. Smeets en dr. M.M. Gerrits in het 
bijzonder bedanken. Monique, bedankt dat we je op elk moment mogen lastigvallen met 
vragen omtrent uitslagen of over eigenschappen van een specifieke variant. Dank voor je 
kritische blik en bijdrage bij het schrijven van een artikel of uitvoeren van een onderzoek. En 
natuurlijk ook onze gezellige momenten tijdens besprekingen of congressen niet te vergeten, 
zoals het noodzakelijke winkeluitstapje met Rowida al Momani in Canada. Tevens wil ik ook 
graag Arthur van den Wijngaard en Linda Meekels bedanken voor hun bijdrage aan de 
diagnostische testen voor de ziekte van Fabry.  
 
Beste collega’s van de apotheek en het interne dagcentrum, dank voor al jullie inspanningen 
om de patiënten van de studies te voorzien van de juiste medicatie. Bedankt voor jullie acuut 
inspringen en geduld wanneer het nodig was. Maar bovenal dank voor de prettige 
samenwerking en hulp die jullie ons hebben geboden. En natuurlijk ook mijn dank aan de MIT 
voor de hulp bij de zoektocht naar de mooie oranje infuuslijnen. 
 
Ook wil ik graag de collega’s van het CTCM bedanken. In het bijzonder wil ik Chantalle Moors 
bedanken voor je oprechte interesse en hulp, Mathieu van Adrichem, voor je altijd snelle hulp 
bij de database en Valery Hellwig, Nadine Severins en Davina Jorissen die urenlang alle data 
hebben gecontroleerd, dank voor jullie bijdrage, oplettendheid en gezellige dagen. 
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De afgelopen jaren voelde ik me ontzettend thuis bij de afdeling neurologie en bij het 
promotietraject wat ik aan het doen was. Echter kwam ik al snel tot de conclusie dat ik geen 
neuroloog wilde worden. Ik heb toen de vrijheid en mogelijkheid gekregen om mijn gevoel te 
volgen en een master in biostatistiek te gaan volgen naast mijn werk. Ik wil graag Prof. dr. C.D. 
Dirksen en Dr. S.M.J. van Kuijk bedanken. Beste Carmen en Sander, bedankt dat jullie mij een 
kans hebben gegeven om bij het KEMTA te komen werken ondanks mijn gebrek aan ervaring 
in de statistiek. Jullie en alle andere collega’s van het KEMTA hebben ervoor gezorgd dat ik in 
een warm bad terecht kwam en me meteen thuis voelde. Sander, bedankt dat ik met al mijn 
vragen en twijfels bij je binnen kan lopen en we gesprekken kunnen hebben over onze 
gedeelde frustraties die de statistiek ook soms met zich meebrengt. Ik hoop nog lang met jullie 
te blijven werken. 
 
De meeste uren heb ik tijdens mijn promotietraject doorgebracht op de onderzoekskamer. 
Lieve Debbie, Eleana, Ellen en Renske, dank voor jullie warme ontvangst en jullie hulp in de 
beginperiode van mijn promotietraject. Al snel bereidde het clubje zich uit, waarmee nog meer 
gezelligheid de kamer in kwam. Lieve Neuronols, Amir, Anne-France, Daniëlle, Danique, Eefje, 
Eleana, Eric, Fred, Irene, Isis, Judith, Mariëlle, Maurice, Renske, Robert-Jan, Sara, Sjors en 
Wouter, allen dank voor de leuke weekendjes weg, etentjes en afleiding van het werk (in 
positieve zin)! Ik zal de heerlijke tosti’s en vervelende pomodoro’s niet vergeten! Ook dank 
voor de interessante discussies, mede door jullie zal ik niet meer vergeten dat gapen een teken 
is van oververhitting van je hersenen maar je daarmee meteen kunt testen wie er van je houdt! 
Jullie hebben mijn promotietraject tot een onvergetelijke tijd gemaakt! 
 
Tijdens de verdediging van mijn proefschrift zullen Jordi van Laarhoven en Luca Lammers mij 
bijstaan als paranimfen. Lieve Jordi, urenlang hebben wij op straat met onze fiets in ons hand 
gesprekken gevoerd over alles en niets. Inmiddels vinden deze gesprekken plaats als we uren 
in de auto zitten van het werk naar huis. Je hebt me altijd goede adviezen gegeven. En hoewel 
ik daar niet altijd meteen naar luisterde, bleef je me altijd steunen. Natuurlijk wist ik stiekem 
dat je gelijk had en luisterde ik wel degelijk! Lieve Luca, al een paar dagen na onze kennismaking 
gaf jij me onderdak na een heftige periode samen (de ontgroening). Het was mooi om dit 
samen mee te maken en hieruit is een mooie vriendschap ontstaan. Ons clubje is de jaren 
daarna uitgebreid tot een hechte groep vrienden. Jullie beide bezitten dezelfde eigenschappen 
die ik enorm bewonder, namelijk jullie rust, humor, doorzettingsvermogen, intelligentie en 
perfectionisme. Ik vind het een grote eer dat jullie op deze speciale dag achter me staan en ik 
hoop dat onze bijzondere vriendschap nog lang voort zal duren. 
 
Lieve Mariska, Stephanie en Tessa, jullie mogen natuurlijk ook niet ontbreken! Dank voor alle 
heerlijke logeerpartijtjes waarbij we eindeloos spellen spelen, foute films kijken, genieten van 
lekker eten en elkaar bijpraten over alles wat we hebben meegemaakt. Ook al zien we elkaar 
niet vaak, de surprises, gedichten en met name de facebook-samenvattingen maken alles 
meteen weer vertrouwd. Dank voor jullie onvoorwaardelijke steun, ook in mindere tijden!  
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Dit dankwoord zou niet compleet zijn zonder nog een aantal belangrijke mannen uit mijn leven 
te bedanken. Lieve Alain, Bas, Dennis, Joep, Jordi, Mark en Steven, dank voor alle stapavonden 
en borrelavondjes sinds de middelbare school! Hoeveel tijd er soms ook tussen zit, niemand 
van jullie zal dit ooit veroordelen. Het is altijd even gezellig, hoewel het nóg gezelliger wordt 
wanneer de karaoke-set aangaat! Ook al vond ik het een eer om een hele tijd als enige vrouw 
in jullie midden te mogen zijn, ben ik erg blij met jullie lieve vriendinnen. Lieve Anne-Marie, 
Maud, Sanne, Sanne en Suzan, met jullie erbij zijn de gesprekken wat vrouwvriendelijker 
geworden en is er alleen nog maar meer gezelligheid bijgekomen!  
 
Lieve Kiki, dit boekje is voor jou. Er had hier een hele andere tekst moeten staan. Je was en 
blijft een groot voorbeeld voor me. Ik bewonderde je enthousiasme, vrolijkheid, assertiviteit, 
optimisme, doorzettingsvermogen en perfectionisme. Ik weet zeker dat jij net zo’n mooi 
boekje, maar waarschijnlijk een nog betere versie had gemaakt! Ik hoop zo dat je dit allemaal 
ziet en dat je trots bent. Ik zal onze reisjes, urenlange gesprekken, stapavonden en grappen 
echt nooit vergeten! Ik mis jou en Giuseppe nog elke dag en ik hoop, maar weet eigenlijk zeker, 
dat ik jullie voor altijd in mijn hart zal blijven voelen. Lieve Jos, Lian en Sjors, dit boekje is ook 
voor jullie. Ontzettend bedankt voor het contact en de band die we samen hebben, dit is een 
grote steun. Ik hoop jullie iets kleins terug te kunnen geven door jullie een onderdeel van mijn 
leven te maken. Ik bewonder jullie kracht en doorzettingsvermogen. Ik weet wel van wie Kiki 
dat had! Ik hoop dat we nog lang contact houden en jullie een beetje rust vinden. 
 
Lieve Anne, Luca, Karen en Tomas. Roerige jaren hebben we meegemaakt maar we slaan ons 
samen overal doorheen. De vriendschap begon natuurlijk in Maastricht, maar verplaatste zich 
al snel richting Brabant (en inmiddels nog iets noordelijker). Hoe groot het gemis van Kiki en 
Giuseppe ook is, des te sterker zijn wij naar elkaar toegetrokken en voelen we hoeveel we voor 
elkaar betekenen. Dank voor alle gezellige etentjes, spelletjesavonden en dagjes/weekendjes 
weg. Ik hoop dat onze vriendschap nog heel lang voort mag duren. 
 
Lieve pap en mam, zonder jullie steun en liefde was ik nooit gekomen waar ik nu ben. Jullie 
hebben me altijd meegegeven om te doen wat je hart je ingeeft, hoe eng of moeilijk dit soms 
ook is. Jullie staan altijd voor me klaar als ik weer eens een slaapplek na een feestje nodig heb, 
een bord eten of een oppas! Lieve Desirée en Robert, ook jullie wil ik bedanken voor jullie 
eindeloze steun. Ook al heb ik het jullie vroeger soms best lastig gemaakt, jullie staan altijd 
voor me klaar. Desirée, als ik persoonlijk advies nodig heb of een lunchgenoot of oppas zoek, 
weet ik dat je altijd mag bellen. Robert, als ik weer een langs de A2 sta, zijn jij en papa de eerste 
die ik bel om advies te vragen en daarna pas de ANWB. Het is een heel fijn maar ook bijzonder 
gevoel dat ik altijd op jullie kan rekenen. Lieve Niels en Salina, jullie hebben het maar getroffen 
met zo’n leuke partners, en wij met jullie! En hoe bijzonder dat de Roparun dit allemaal heeft 
veroorzaakt! Niels, jammer dat we nu niet meer kunnen winnen als we spelletjes spelen. Salina, 
dank voor je steun en goede invloed die je op mijn levensstijl hebt!  
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Natuurlijk kan ik ook de familie Bertens niet genoeg bedanken. Lieve Monique, Wim, Matthijs, 
Thom en Linda, dank dat jullie mij met open armen hebben ontvangen. Ook bij jullie weet ik 
dat ik op iedereen kan rekenen als we hulp nodig hebben. Ook dank voor alle leuke dagjes en 
weekendjes weg, die voor veel ontspanning en plezier hebben gezorgd tijdens mijn 
promotietraject. 
 
Lieve Nicky, wat ben jij een ongelofelijke steun voor me geweest de afgelopen jaren. Je maakt 
me altijd aan het lachen, ongeacht mijn humeur en altijd met dezelfde grap! Je bent de meest 
liefdevolle vader die ik me voor Sepp kan bedenken. ‘Some heroes don’t wear capes’ slaat 
zeker op jou! Dank dat je me onvoorwaardelijk steunt, me mijn hart laat volgen en je nooit zult 
klagen als ik ’s avonds nog héél even mijn laptop pak! Ik zou nooit zonder je kunnen! Ik hoop 
dat we nog lang onze dromen achterna kunnen gaan, prachtige bestemmingen mogen 
bezoeken en genieten van ons gezin! Ik hou van je, ‘to infinity and beyond’! 
 
Lieve Sepp, kleine boef, ook al was de zwangerschap niet mals, het cliché is helemaal waar, je 
krijgt er zoiets moois voor terug. Door jou heb ik leren ontspannen en ben ik gaan inzien wat 
nu echt belangrijk is in het leven! Ik had nooit kunnen voorstellen hoeveel ik van je houd en 
hoe blij je me maakt. Ik hoop dat je altijd die sprankel in je ogen houdt en de wereld vol 
bewondering zal blijven ontdekken. Maar wil je alsjeblieft niet te snel groot worden? 
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The cover of this thesis represents a map of Western Europe.  
The lines on this map reflect all kinds of routes that lead to Rome.  
“All roads lead to Rome” is an old proverb, as a metaphor for the  
infinite possibilities that exist to reach your goal.
This image is applicable to my thesis for different reasons. On the one 
hand because the roads on this map look very similar to the small 
nerve fibers that can be seen in a skin biopsy under a microscope.  
On the other hand, my dissertation describes that several disorders 
could lead to the development of one condition, namely small fiber 
neuropathy. Besides that, there are also several treatment options 
that can reduce the complaints associated with this condition.
In addition to the relationship with the content of my thesis, this  
image also represents a number of personal feelings. Personally, 
I have come to a point in my career, via a not entirely standard route, 
where I feel incredibly at home, happy, and enthusiastic. In my  
opinion, that is exactly what the proverb tries to say. Additionally,  
my partner and I have that same feeling about Italy (including Rome); 
ever since our first holiday together this country has felt like home 
and we will always keep coming back. Last but not least, there are 
two people who have a special place in my heart, with Italy also  
having a special place in their hearts. 
For all this, this cover has become a small tribute to Italy,  
with its Rome!
